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IABSTRACT
Background：Osteoarthritis (OA) is a highly prevalent joint degenerative disorder
among the older population. The main symptoms of OA are chronic pain, swelling
and stiffness of joint. OA histopathology is characterized by cartilage damage, syno-
vial inflammation and remodelling of subchondral bone. Resolvins are endogenous
lipid mediators produced from Ω-3 poly-unsaturated fatty acids (PUFAs) during reso-
lution of inflammation. The main biological functions of resolvins include anti-
inflammation and resolution of inflammation. Currently, the emerging anti-nociceptive
roles of some resolvins have been reported in various models of pain. However,
roles of resolvins and the resolvin receptor system on osteoarthritic pain are un-
known.
Objectives: This thesis assesses the therapeutic potential of a resolvin precursor on
OA pain and investigates the underlying mechanisms of action and resolvin receptor
system in OA.
Methods：Monosodium iodoacetate (MIA) and medial meniscus transection (MNX)
-induced joint damage was used as models of OA pain. 17(R)-HDoHE (300ng/300μl) 
or vehicle (1% ethanol in saline, 300μl) was acutely or chronically administered at 
day 14 post model induction and pain behaviour was measured to determine the an-
algesic effects of the drug in these models. Haematoxylin and eosin (H&E) staining
was used to assess joint histopathology. Gene expression of resolvin receptors, in-
flammatory cytokines and metabolic enzymes were measured by reverse transcrip-
tion quantitative polymerase chain reaction (RT-qPCR) in associated tissues from
the models and human OA samples.
Results: Pain behaviour and joint histopathology were established in both the MIA
and MNX models. Expression of chemokine-like receptor 1(ChemR23) was lower in
the synovia and higher in the spinal cord in the MIA model. 15-lipoxygenase (15-LOX)
was expressed at a lower level in both synovia and spinal cord in the MIA model.
Negative correlations were revealed between synovial ChemR23 expression and
pain behaviour at both day 14 and 35 in the MIA model. ChemR23 expression in the
spinal cord was positively correlated with pain behaviour at day 35 in the MIA model.
Expression of formyl peptide receptor 2 (ALX), some inflammatory cytokines and
metabolic enzymes was lower in the synovia in the MNX model but expression of 5-
lipoxygenase-activating protein (FLAP) was higher. Expression of ALX in the synovia
II
was positively correlated with tumor necrosis factor alfa (TNFα), interleukin 1 beta 
(IL1β) and cyclooxygenase 2(COX2) but negatively correlated with 5-LOX expres-
sion in the MIA model. Expression of ALX in the spinal cord was positively correlated
with pain behaviour at day 14 but then the converse was true at day 35. Expression
of ALX in the spinal cord was negatively correlated with IL6 in the MIA model.
17(R)HDoHE attenuated pain behaviour in both the MIA and MNX models following
acute, chronic and discontinuous administration. Effects of acute administration of
17(R)HDoHE on pain behaviour were associated with an up-regulation in the ex-
pression of IL6 and decreased 5-LOX expression in the synovia of MIA model. A
trend towards down-regulation of pro-inflammatory cytokines and associated en-
zymes by 17(R)HDoHE was observed in the acute study in the MIA model. Repeat-
ed administration of 17(R)HDoHE produced robust and sustained inhibitory effects
on pain behaviour, but no change in joint histopathology. Pain behaviour was atten-
uated when 17(R)HDoHE was administered but returned to levels seen in vehicle
treated rats after 7 days after drug cessation.
In human OA samples, expression of ChemR23 was significantly higher than ex-
pression of ALX in both synovia and medial tibial plateau. ChemR23 expression was
positively correlated with expression of 5-LOX in both synovia and medial tibial plat-
eau and negatively correlated with 15-LOX2 expression in the medial tibial plateau
from OA patients. There was a significantly positive correlation between ChemR23
expression and IL6 and 15-LOX1 expression in the medial tibial plateau. In addition,
there was a significantly positive correlation between ALX and IL6 and 15-LOX1 ex-
pression in both synovia and medial tibial plateau. Expression of ALX, TNFα, IL6, 
COX2 and 5-LOX in the medial tibial plateau from OA patients was lower, compared
to expression in bone from femoral heads obtained from trauma patients.
Conclusions: These findings support anti-nociceptive and anti-inflammatory roles
of resolvins and provide evidence that resolvins may be potential novel drugs to treat
OA pain.
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11 Introduction
1.1 Osteoarthritis
1.1.1Definition and classification
Osteoarthritis (OA) is a highly prevalent degenerative joint disease that involves loss
of cartilage, remodelling of subchondral bone and synovitis. OA can manifest in vari-
ous joints, such as hand, knee and hip (Hunter 2011) . The main symptoms of OA
are pain and stiffness of joints, which lead to disability (Goldring and Goldring 2007).
There is no agreed criteria for OA as it could be defined by radiographic assessment,
clinical symptoms or self-report.
The radiographic grading system established by Kellgren and Lawrence is widely
used for scoring the severity of OA into grades 0-4 (Kellgren and Lawrence 1957). In
1995, Osteoarthritis Research Society International (OARSI) published a radiograph-
ic atlas of OA and revised it in 2007 to include detailed scores for different joints of
OA (hand, hip and knee) (Altman and Gold 2007). The application of different imag-
ing approaches, such as magnetic resonance imaging (MRI), ultrasound and com-
puted tomography, for assessing the development of structural changes within the
joint, in particular the early stages of the disease, are improving. These approaches
should in the future provide three-dimensional and dynamic images of morphology of
joint that provide a stereo view of structures and help better understanding the dy-
namic progression of OA (Guermazi et al. 2013).
Symptomatic OA was described as a heterogeneous group of conditions that lead to
joint symptoms and signs which are associated with defective integrity of articular
cartilage, in addition to related changes in the underlying bone and at the joint mar-
gins by a subcommittee of the American Rheumatism Association in 1986. They sub-
classified primary and secondary OA and developed criteria for diagnosis. (Altman et
al. 1986). The details of criteria for diagnosis of OA will be discussed in 1.1.2.
Although people with OA experience pain, which can be chronic, this symptom is not
well correlated with the radiographic grading of the joint. A population survey of 2865
people showed that only 4.7% of subjects showed both radiographic OA and current
knee pain and no single clinical sign can predict radiographic OA well (Claessens et
2al. 1990). More recently, a systematic literature review revealed that 15-76% OA pa-
tients with knee pain have radiographic OA and 15-81% of patients with radiograph-
ic OA have pain (Bedson and Croft 2008). The prevailing current opinion is that OA
describes a range of disorders resulting in structural and symptomatic failure of syn-
ovial joints rather than a single disease or process to one component of the joint
(Brandt et al. 2006).
1.1.2Symptoms and Diagnosis
The major symptoms of OA are pain, joint stiffness, swelling of joint, joint crepitus
and limitation of motion (Haq et al. 2003). Joint pain is often associated with physical
activity, which then limits the amount of physical activity individuals undertake. Joint
instability limits the range of motion in activity and crepitus (grating or crunching
sound) is present at the later stages of OA (Felson 2006; Sinusas 2012).
The diagnosis of OA is based on clinical symptoms and radiography or MRI images.
The American College of Rheumatology (ACR) developed the clinical and radio-
graphic criteria of OA as joint pain, osteophytes and one of the following: age greater
than 50 years, morning stiffness less than 30 minutes, or crepitus which showed 91%
of sensitivity and 86% of specificity for clinical examination of idiopathic OA (Ta-
ble1.1) (Altman et al. 1986).
3Clinical and laboratory Clinical and radiographic Clinical
Knee pain+ Knee pain + Knee pain+
at least 5 of 9: at least 1 of 3: at least 3 of 6:
Age >50 year Age >50 years Age >50 year
Stiffness <30 min Stiffness <30 min Stiffness <30 min
Crepitus Crepitus+osteophytes Crepitus
Bony tenderness Bony tenderness
Bony enlargement Bony enlargement
No palpable warmth No palpable warmth
ESR* <40 mm/hour
RF <1:40
SF OA
92% sensitive 91% sensitive 95% sensitive
75% specific 86% specific 69% specific
OARSI used radiographic scoring of osteophytes, joint space narrowing, mal-
alignment, subchondral sclerosis and subchondral cyst as OA features (Altman and
Gold 2007). The European League Against Rheumatism (EULAR) recommends
combining clinical symptoms, risk factors, imaging and laboratory testing for the di-
agnosis of OA. Persistent pain, morning stiffness of joint, reduced function of joint,
crepitus, limitation of movement and bony enlargement are the predominant six fea-
tures used (Zhang et al. 2009).
Table 1.1 Criteria of diagnosis of OA is based on combination of clinical signs, radiographic fea-
tures and laboratory test. * ESR = erythrocyte sedimentation rate (Westergren); RF = rheumatoid
factor; SF OA = synovial fluid signs of OA (clear, viscous, or white blood cell count
<2,W/mm3). If the alternative criteria reach 4 of 6 in the clinical category, the sensitivity and
specificity of diagnosis will be 84% and 89% respective (Altman et al. 1986).
41.1.3 Incidence and prevalence
The prevalence of OA is increased with ageing, and is higher in females. It is esti-
mated that 9.6% of men and 18.0% of women aged at 60 or over have symptomatic
OA world-wide. Levels are higher when considering the US and Europe (14.1% of
men and 22.8% of women aged 45 years and over) (Woolf and Pfleger 2003). The
Framingham Study for 1041 people aged at 71-100 years reported 26.2% woman
and 13.4% man had symptomatic hand OA (Zhang 2002). A further 9-year follow-up
study of Framingham OA study showed age-standardised prevalence of symptomatic
OA was 15.9% for woman and 8.2% for man respectively (Haugen et al. 2011). The
age-standardised prevalence of hand OA was 44.2% for women and 37.7% for men
respectively (Haugen et al. 2011). Recently, OA in the hip and knee was ranked as
the 11th highest contributor to global disability (Cross et al. 2014). The appearance of
symptoms versus radiographic OA has been evaluated in the Johnston County Oste-
oarthritis Project of 2637 cases on hip symptoms, radiographic hip OA and sympto-
matic hip OA for African-Americans and Caucasians aged≥45 years; 36% of the
subjects had hip symptoms, 27.6% had radiographic hip OA and 9.7% had sympto-
matic OA. The prevalence of those categories was increased with age (45–54 years,
55–64 years, 65–74 years, and 75 years and older) (Jordan et al. 2009). In the UK, it
is estimated that over 8.75 million people have OA, 49% of woman and 42% of man
at 75 years old or over, and a third of people aged 45 or older have sought treatment
for OA) (Aruk 2013) . As people live longer and levels of obesity increase, it is pre-
dicted that the prevalence of OA will increase further. Obesity is a main risk factor for
the prevalence of OA as overload to the joint may result in cartilage damage. In addi-
tion, adipose tissue can release a number of adipocytokines such as TNFα, IL1β, lep-
tin and resistin which accelerate progression of OA (Pottie et al. 2006; Sowers and
Karvonen-Gutierrez 2010). A 10-year follow-up study has shown obesity was associ-
ated with hand OA and higher body mass index was associated with higher risk in
knee OA (Grotle et al. 2008). OA is becoming a major public health problem world-
wide that undermines the quality of life and represents a major economic burden on
countries with large population with OA.
51.1.4Aetiology and risk factors
The aetiology of OA is heterogeneous and multiple factors are involved in the patho-
genesis and progression of OA. Nevertheless, the susceptibility of OA has been as-
cribed to systemic and local biomechanical factors which exert mechanical stress on
joints and thus change microenvironment around the joints (Jordan et al. 2000; John-
son and Hunter 2014) (Fig 1.1).
Systemically, genetics (Cicuttini and Spector 1996), age and gender (Felson et al.
1987), bone density (Foss and Byers 1972) and nutritional factors such as diet and
obesity and vitamins (C,D and E) (Mcalindon and Felson 1997) are risk factors asso-
ciated with OA. Epidemiological studies of family history and family clustering
showed more than 50% of OA was heritable. Genetic factors affected 39-65% of ra-
diographic hand and knee OA in women, 60% of hip OA and 70% of spine OA
(Spector and Macgregor 2004). OA is more prevalent in old people as aging changes
musculoskeletal system (muscles and ligaments) and joint tissues such as cartilage
and meniscus (Shane Anderson and Loeser 2010). The Baltimore longitudinal co-
hort study reported an association of high bone mineral density with increased inci-
dence of knee OA (Hochberg et al. 2004), The Multi-centre Osteoarthritis Study
(MOST) of 1754 subjects also reported higher bone mineral density of femoral neck
and whole body increased the risk of OA (Nevitt et al. 2010).
6A number of factors including, obesity (Cicuttini et al. 1997), joint injury (Gelber et al. 2000) , muscle strength (Kathy D. Hall et al.
1993) and occupation (Rossignol et al. 2005) have been implicated in the initiation and progression of OA.
Fig 1.1 Susceptibility of OA with systemic factors and local biomechanical risk factors. Age, sex, obesi-
ty, genetic and instability of joints are involved in initiation and progression of OA. Figure was
adapted from Jordan et al (2000).
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71.1.5Pathophysiology
OA joints are characterized by articular cartilage degradation, meniscus damage,
subchondral bone remodelling and sclerosis, synovial hypertrophy, osteophytes for-
mation and mal-alignment of muscle and ligament (Hunter 2011). (Fig 1.2)
Fig 1.2 Comparison of an OA joint and normal joint. The OA joint shows degradation of
cartilage, meniscus damage, remodelling of subchondral bone, thickness of synovium,
osteophytes and mal-alignment of muscle and ligament compared to normal joint.
Figure was adapted from Hunter et al (2011).
8Under normal conditions, the turnover of cartilage in adult is very slow and the syn-
thesis and degradation of extra-cellular matrix component is regulated. Under oste-
oarthritic condition, however, this homeostasis is disrupted which leads to apoptosis
of chondrocytes, loss of articular cartilage and degeneration of joints (Sandell and
Aigner 2001; Goldring and Marcu 2009). In the early stage of OA, chondrocytes, the
only cell type producing proteoglycan, collagen and proteinases in cartilage, prolifer-
ate to compensate the loss of cartilage. However, as OA progresses, the balance is
disrupted. Chondrocytes cannot compensate the degradation of extra-cellular matrix
components and the anabolism shifts to catabolism which exacerbates the deteriora-
tion of joints (Stockwell 1991; Middleton and Tyler 1992; Lories and Luyten 2011).
During this process, a number of proteases, mediators and factors including matrix
metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs), bone
morphogenetic proteins (BMPs), inflammatory cytokines and growth factors promote
OA progression.
MMPs are a family of highly homologus endopeptidases that degrade most compo-
nents of the extracellular matrix (Birkedal-Hansen et al. 1993). Currently, 24 different
MMP genes have been identified and 23 members are present in man. These MMPs
belong to 6 different groups: collagenases (MMP1, 8, 13, and MMP18), gelatinases
(MMP2 and MMP9), stromelysins (MMP3, MMP10 and MMP11), matrilysins (MMP7
and MMP26), membrane-type MMPs (MMP14-17 and MMP24-25) and others
(MMP12,19-23,27-28) (Nagase et al. 2006). MMPs play multiple biological roles in
bone formation and remodelling, tissue morphogenesis, angiogenesis, inflammation,
wound healing, cell migration and proteolysis (Brewa; et al. 1999; Vu and Werb 2000;
Parks et al. 2004; Page-Mccaw et al. 2007). Physiologically, the activity of MMPs is
regulated by endogenous inhibitors and tissue inhibitors of metalloproteinases
(TIMPs) which have 4 homologous isomers (TIMP1-4). The balance of MMP-TIMP
has been shown to shift to MMPs under pathological conditions and loss regulation
of MMPs may contribute to a number of diseases such as arthritis, cancer and cardi-
ovascular diseases (Nagase and Woessner 1999; Visse and Nagase 2003).
Clinical studies have shown that concentrations of metalloproteinases, TIMPs and
proteoglycan fragments are significantly increased in synovial fluid of OA patients
compared to controls (Lohmander et al. 1993; Tchetverikov et al. 2005). MMPs,
membrane-type MMPs (MT-MMPs), ADAMs and a disintegrin and metalloproteinase
9with thrombospondin motifs (ADAMTS) including MMP1-3, MMP8-10, MMP12-14,
ADAMTS1, 4, 5,9,15, and ADAMTS 16 are produced by chondrocytes, osteoclasts
and synovial fibroblasts in OA (Murphy and Nagase 2008). These proteinases cleave
different types of collagen (I, II and III.), proteoglycan and aggrecan which are the
main extracellular components that lead to degradation of bone. (Martel-Pelletier et
al. 2001; Murphy et al. 2002; Murphy and Nagase 2008). Significant degradation of
type II collagen by MMP1 and MMP13 has been demonstrated in cartilage from OA
patients with total knee replacement. Furthermore, the synthesis of MMP13 was
modulated by TNFα and IL1β in a dose-dependent manner (Mitchell et al. 1996; Re-
boul et al. 1996). Imai showed expression of MT1-MMP (MMP14) in OA cartilage
and activated pro-MMP2 which can cause destruction of cartilage (Imai et al. 1997).
Increased MMP1 and MMP2 have been shown in co-cultured OA chondrocytes and
normal osteoblast taken from trauma patients (Prasadam et al. 2012).
Although cartilage has been the most heavily investigated of the structures exhibiting
pathological damage associated with OA, remodelling of subchondral bone, for-
mation of osteophytes and synovial inflammation are all associated with pathogene-
sis of OA. More recent studies have revealed that changes in subchondral bone pre-
cede cartilage damage (Carlson et al. 1994) and stiffness of subchondral bone can
cause deformity of cartilage and accelerate the fibrillation of cartilage (Radin and
Rose 1986; Carlson et al. 1994; Burr and Gallant 2012). Radiographic imaging of OA
has shown bone sclerosis, osteophytes and joint space narrowing in joints of hand,
knee and foot (Jacobson et al. 2008). Animal models of OA showed resorption of
subchondral bone at early stage but increased formation at late-stages of OA
(Hayami et al. 2006). Osteophytes are present in the femoral condyle and medial tib-
ial plateau of animal models of OA (Hayami et al. 2006). Inhibition of bone resorption
with alendrolate decreased resorption of subchondral bone and attenuated formation
of osteophytes in a dose-dependent manner in animal models of OA (Hayami et al.
2004). Previous work from our group demonstrated that pre-emptive treatment of os-
teoprotegerin-Fc (OPG-Fc) prevented ostephytes formation, decreased osteoclast
number and attenuated osteoarthritic pain in an animal model of OA (Sagar et al.
2014).
Although OA was traditionally considered a degenerative joint disorder induced by
‘wear and tear’ mechanical stress, more recently the role of inflammation in the
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pathogenesis of OA has been recognized (Berenbaum 2013). 31% of OA patients
have severe synovial inflammation and 62.5% of patients with mild or moderate syn-
ovial inflammation (Haywood et al. 2003). A longitudinal arthroscopic study has
shown 50% of patients have abnormal synovia with 21% having synovial inflamma-
tion (Ayral et al. 2005). OA patients with inflamed synovia (synovitis) have signifi-
cantly higher chondropathy compared to OA patients with normal synovia (Ayral et al.
2005) and synovitis is significantly associated with OA pain (Baker et al. 2010).
Numerous studies have investigated the inflammatory factors associated with OA.
Synovial tissue from early OA patients (arthroscopic manifestations of OA) showed
significantly increased infiltration of cluster of differentiation 4+ ( CD4+) T-cell,
CD68+ macrophage and formation of blood vessels compared to late OA patients
(knee joint arthroplasty) (Benito et al. 2005). Moreover, the immune cell numbers
which secreted TNFα and IL1β are also increased in early OA patients compared to 
late OA patients. The inflammation in early OA was associated with the increased
nuclear factors-κB (NF-kB), a nuclear transcription factor that controls transcription of
DNA, and COX2 (Benito et al. 2005). These findings may indicate a major role of in-
flammation in the initiation of OA. Nevertheless, whether inflammation, or degrada-
tion of cartilage, occurs first in OA remains to be determined. It has been proposed
that iinflammation may be initiated by fragments of cartilage degradation which acti-
vate the innate immune system via pattern-recognition receptors (PRRs) and dam-
age-associated molecular patterns (DAMPs) on chondrocytes in cartilage and syno-
viocytes (macrophage and fibroblast-like synoviocyte) in synovium (Berenbaum 2013;
Liu-Bryan 2013). Conversely, inflammatory mediators released by those cells acti-
vate more chondrocytes and synoviocytes, amplifying the activation of immune sys-
tem and accelerate loss of cartilage (Goldring and Otero 2011; Sokolove and Lepus
2013). Microarray gene expression profiling from OA patients has shown cytokines
(IL6, IL8 etc.), chemokines (chemokine (C-X-C motif) ligand (CXCL5), CXCL6, etc.),
FLAP, 5-LOX anabolic protein ( triggering receptor expressed on myeloid cells
1(TREM1), alarmin S100A9, etc.) and catabolic proteinases (MMP3, MMP9, cathep-
sin H etc.) were significantly up-regulated in inflamed synovia compared to normal
area of synovia from the same patient (Lambert et al. 2014). They further confirmed
activation of Wnt signalling pathway in inflammatory synovia (Lambert et al. 2014).
Cultured synovial cells from OA patients produced TNF-α, IL-1β and large amounts 
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of IL-6, IL-8, monocyte chemo-attractant protein-1(MCP-1), MMPs (1, 3, 9, and 13)
and TIMP1 (Bondeson et al. 2006; Bondeson et al. 2010). Wang et al. found signifi-
cantly higher expression of complement (C3 and C5), MMPs (MMP1, 3, 13),
ADAMTS4-5 and CCL2, 5 in synovial tissue in OA (Wang et al. 2011). Depletion of
C5 and C6 significantly reduced cartilage degeneration and C5 dramatically de-
creased levels of MMPs, ADAMTS and CCLs, which suggests an important contribu-
tion of inflammatory complements to the pathogenesis of osteoarthritis (Wang et al.
2011).
The complex mixture of inflammatory mediators and enzymes in joints indicate both
innate (PRRs, DAMPs and complement system) and adaptive immune system con-
tribute to pathophysiology of OA. The roles of inflammatory mediators are regulated
by various signalling pathways such toll-like receptors, receptor for advanced gly-
cation end-products (RAGE), NF-κB and Wnt (Haseeb and Haqqi 2013; Liu-Bryan
2013; Liu-Bryan and Terkeltaub 2014). A summary of the major features of OA path-
ophysiology and involvement of multiple inflammatory mediators and enzymes in
joint damage of OA is described in Fig1.3.
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Fig 1.3 Pathophysiology of normal joint and OA joint and mediators networks in the progression of
OA. Degradation products of cartilage activates macrophage and synovial fibroblast via the innate
immune system and these cells release a number of inflammatory mediators into the joint space
which degrade cartilage and exacerbate deterioration of the OA joint. The released mediators also
activate immune cells and induce adaptive immune system during progression of OA. Figures were
from Sallam and Berenbaum (2010) and Liu-Bryan and Terkeltaub (2014).
As described above, mechanical stress of the joint contributes to OA and is associ-
ated with risk factors such as obesity, trauma or joint instability (Guilak 2011; Heijink
et al. 2012; Buckwalter et al. 2013). Biomechanical loading of the joint may interact
with multiple biochemical factors, including Ca2+ signalling, cytokines, MMPs and
growth (Sanchez-Adams et al. 2014). However, the mechanism(s) by which mechan-
ical force could be transduced to biochemical signals and lead to pathogenesis of
OA is undefined. The roles of ion channels or integrins to mechanical stress re-
sponses of chondrocytes have been studied (Grandolfo et al. 1998; Millward-Sadler
et al. 1999; Mobasheri et al. 2012). Recently, Piezo1 and Piezo2 were identified as
essential components of mechanical activated channels for mechanotransduction
(Coste et al. 2010). Lee et al further confirmed mechanosensitivity of Piezo1 and Pi-
ezo2 in mechanotransduction of chondrocytes. Blocking the Piezo channels re-
duced chondrocyte death after mechanical injury in an explant cartilage injury model
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(Lee et al. 2014). Transient receptor potential V4 (TRPV4) is also involved in me-
chanical signal transduction in chondrocytes (O’conor et al. 2014).
Clearly, the pathophysiology and pathogenesis resulting in OA is complicated, in-
volving in a series of factors, mediators and signalling pathways at the cellular and
molecular levels. It is therefore not surprising that the specific mechanisms underly-
ing initiation and progression of OA remain elusive.
1.1.6Treatment
As a result of the heterogeneous aetiology and pathogenesis of OA, management of
OA is not achieved by a single therapy. The ACR recommends using non-
pharmacological and pharmacological therapy or surgery to treat OA according to
severity. The non-pharmacological management focuses on disease education,
weight loss and increasing activity. Analgesic treatments used are non-steroidal anti-
inflammatory drugs (NSAIDs), intra-articular steroid injection and opioids. The final
choice to treat OA is osteotomy or total joint replacement (Hochberg et al. 1995;
Hunter and Felson 2006; Hochberg et al. 2012). The OARSI recommendation for
treatment, based on systematic literature reviews and consensus of 16 experts, is 12
non-pharmacological modalities (self-management, loss weight, exercises, etc.), 8
pharmacological modalities including acetaminophen, COX2 non-selective and se-
lective NSAIDs, capsaicin, intra-articular injection of corticosteroids and hyaluronates
etc. for symptom relief and structure modification and 5 surgical modalities ( includ-
ing total joint replacement, osteotomy, arthroscopic debridement, etc.) to treat OA
(Zhang et al. 2007; Zhang et al. 2008). The EULAR used more than 20 experts from
various European countries and based on research evidence to make recommenda-
tion with Delphi consensus methods for management of knee OA, hip OA and hand
OA in 2003, 2005 and 2007 respectively. They also recommended the combination
of non-pharmacological and pharmacological therapy and surgery for treatment of
OA (Jordan et al. 2003; Zhang et al. 2005; Zhang et al. 2007). All these recommen-
dations are based on various treatment propositions for specific subgroups of OA
patients. Although conventional drugs are effective in relieving pain and other symp-
toms of OA, adverse effects, such as gastrointestinal bleeding, cardiovascular, he-
patic and renal injury limit their use (Vaile and Paul 1998; Sarzi-Puttini et al. 2005;
Shi and Klotz 2007).
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Currently, some of preclinical and clinical analgesic drugs such as anti-nerve growth
factor (NGF) drugs, bisphosphonate, duloxetine, poly-unsaturated fatty acids
(PUFAs) and stem cells are emerging and under investigation to find novel treatment
for OA and OA pain. The human soluble NGF receptor, tyrosine kinase Ad 5
(TrkAd5), was shown to inhibit pain behaviour in destabilisation of the medial menis-
cus (DMM) surgery model of OA via neutralizing NGF (Mcnamee et al. 2010). Tane-
zumab, an anti- NGF monoclonal antibody, reduced joint pain and improved joint
function in knee OA in a dose-dependent manner, compared to placebo. However, it
also showed some side effects such as headache, respiratory tract infection or par-
esthesia in OA patients (Lane et al. 2010). Subcutaneous injection of tiludronate, a
bisphosphonate, attenuated pain scoring, improved the joint histology and de-
creased synovitis in the anterior cruciate ligament (ACL) transection model of dog,
compared to placebo (Moreau et al. 2011). Bisphosphonate reduced scale pain
scores (numeric rating scale) in OA patients compared to OA patients without using
bisphosphonates at the first three years (Laslett et al. 2014). Duloxetine, a serotonin
and norepinephrine reuptake inhibitor, reduced pain score in knee OA compared to
placebo-control but also had some side effects (Chappell et al. 2009). In another 16-
week randomized placebo-control trial, duloxetine was shown to reduce pain scores
and improved physical function in OA patients, compared to placebo (Abou-Raya et
al. 2012). There is evidence to show PUFAs could down-regulate IL1α-induced 
ADAMTS-4, ADAMTS-5, COX2, MMP3, MMP13, TNFα and IL1β in bovine chondro-
cytes, which are essential enzymes and inflammatory cytokines in the initiation and
progression of OA (Zainal et al. 2009). Stem cells isolated from caprine (goat) bone
marrow have been shown to regenerate the medial meniscus and reduce degenera-
tion of cartilage, osteophytes and subchondral sclerosis after 6 weeks of intra-
articular injection in a combined (ACL) transection and medial meniscectomy goat
model of OA (Murphy et al. 2003). In a more recent 1 year follow-up study, mesen-
chymal stem cells from human bone marrow have been transplanted into four OA
patients and revealed that pain on visual analog scale (VAS) was improved
(Davatchi et al. 2011). Intra-articular injection of adipose-derived stem cells (ASCs)
attenuated synovial thickening and degradation of cartilage at early stage of OA (Ter
Huurne et al. 2012). Intra-articular injection of adipose tissue derived mesenchymal
stem cells (MSCs) demonstrated recovery of cartilage and reduction of cartilage de-
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fect in medial femoral and medial tibial condyle by histological MRI and arthroscopic
assessment (Jo et al. 2014).
Some disease modifying osteoarthritis drugs (DMOADs), for example, MMP inhibi-
tors, inhibitors to IL1, TNFα, inducible nitric oxide synthase ( iNOS),  bone morpho-
genetic protein 7 (BMP7), vitamin D, fibroblast grow factors, receptor activator of nu-
clear factor κB ligand (RANKL), calcitonin, cathepsin K and lubricin, are under inves-
tigation to modify progression of OA (Hunter 2011; Martel-Pelletier et al. 2012).
Traditional drugs such as steroids, NSAIDs and opioids are the mainstay of analge-
sic treatments until joint replacement, thus investigation of potential novel therapeutic
treatment for OA pain continues to be of clinical importance.
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1.2 Pain
1.2.1 Introduction to pain
Pain provides an early warning of tissue damage such as skin burning, finger prick-
ing and etc. This endogenous self-guarding system helps us to avoid external and
internal painful stimuli and congenital deficits in painful sensitivity can be life-
threatening (Scholz and Woolf 2002) . However, pain associated with disease can
also be maladaptive, serving little protection purpose and is difficult to treat (Scholz
and Woolf 2002). The sensation of pain not only refers to the detection of a painful
stimulus (nociception) but also the emotional component which gives rise to the un-
pleasant experience of pain, and the cognitive responses such as attention (Price
2000; Linton and Shaw 2011). Thus, pain is defined as ‘an unpleasant sensory and
emotional experience associated with actual or potential tissue damage, or de-
scribed in terms of such damage’ by International Association for the Study of Pain
(IASP) (IASP, 2012).
The importance of pain has been recognized for centuries from the initial thoughts of
ancient Aristotle (384–322 BC) to the advanced understanding in the past century
(Perl 2007). In 1906, Sherrington published the integrative action of the nervous
system which proposed that pain was normally produced from tissue injury and sig-
nalling of noxious events (nociception) (Burke 2007; Perl 2007). Understanding of
the mechanisms of pain was pioneered by Patrick Wall and Ronald Melzack who ini-
tiated the gate control theory of pain (Melzack and Wall 1965) and Edward Perl who
defined the existence of Aδ and C-fibre “nociceptors” to specific noxious stimulation 
(Burgess and Perl 1967; Bessou and Perl 1969) in the 1960s. The phrase “central
sensitization” was first proposed by Woolf in 1980s and the mechanisms underpin-
ning these events continue to be studied and investigated (Woolf 2007). Later on,
David Julius and colleagues identified TRP channels as key receptors involved in the
nociceptive pathways (Caterina et al. 1997; Caterina et al. 1999; Caterina et al.
2000). Many other ion channels have been actively studied, not least sodium (Nav)
channels which have essential roles in driving pain signalling. Ablation of Nav1.7
and Nav1.8 in nociceptors blocks pain behaviour in the models of inflammatory pain
(Nassar et al. 2004; Abrahamsen et al. 2008) and loss of Nav1.7 results in a congeni-
tal inability to detect painful stimuli (Fertleman et al. 2006). Pain is a broad term and
is primarily divided into four types: nociceptive pain , inflammatory pain, neuropathic
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pain and functional pain (Woolf 2004) . Allodynia and hyperalgesia are clinical terms
to describe painful responses to normally non-noxious stimulation and facilitated re-
sponses to an overt painful stimulusus (Sandkuhler 2009; Jensen and Finnerup
2014).
1.2.2Nociceptors
Nociceptors are a specialized class of primary afferents that respond to intense, nox-
ious (mechanical, thermal and chemical) stimuli (McMahon et al. 2013). Nociceptors
are the free nerve endings that innervate organs or tissues and the axon conducts
electrical signals to the central ending which terminates in the dorsal horn of the spi-
nal cord. (Woolf and Ma 2007; Dubin and Patapoutian 2010). Nociceptors are
broadly classified into Aδ and C fibres depending on their conductance, which is as-
sociated with diameter and myelination (Coutaux et al. 2005; Fein 2012). A fibers
are myelinated and have faster conduction velocity (Aβ fibre: 35-75 m/s and Aδ : 5-
30 m/s) whereas the un-myelinated C-fibres have a slower conductance velocity at
0.5-2 m/s (Purves et al. 2012). Aβ fibres predominantly detect non painful stimuli alt-
hough there is evidence that some of these fibres can also detect painful stimuli.
As a fast conducting efferent fibre, Aδ fibres respond to initial sensations of pain 
(sharp pain) such as cutting and prickling, while C-fibres contribute to the ‘second
pain’ such as burning and gnawing (Giordano 2005). Primary afferent fibre nocicep-
tors have heterogeneous properties and respond to multiple stimulus modalities,
mechanical, thermal and chemical (polymodal) stimuli (McMahon et al. 2013). The
nociceptive input is modulated by multiple mechanisms including, peripheral sensiti-
zation, central sensitization and disinhibition (Woolf 2004).
1.2.3Nociception and peripheral sensitization of pain
Noxious stimuli are detected by polymodal nociceptors C-fibre and Aδ fibre nocicep-
tors which express TRP channels, acid sensing ion channels (ASICs), sodium chan-
nel (Nav1.6-1.9), calcium channels, potassium channels, G protein-coupled receptors
(GPCRs), cytokine receptors and P2X receptors (Mccleskey and Gold 1999; Gold
and Gebhart 2010). The stimulus is transduced by these channels and receptors and
then encoded into electrical signals that initiate action generation in the sensory neu-
rons (Gold and Gebhart 2010) (Fig1.4).
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Peripheral sensitization is a stimulus-evoked increase in response and decreased
threshold of the peripheral ending of the nociceptive neurons (Woolf and Ma 2007).
Peripheral sensitization is mediated by tissue damage and inflammation, which re-
sults in the elevation of a multitude of mediators such as prostaglandins, NGF, cyto-
kines, chemokines, H+ and adenosine triphosphate (ATP) in the receptive field of the
primary sensory neurone and initiates a series of signalling cascades in the nocicep-
tors (Hucho and Levine 2007; Von Hehn et al. 2012). These mediators can act di-
rectly on ion channels or interact with their cognate receptors, which activate the
down-stream signalling pathways such as protein kinase A (PKA), PKC, phospho-
inositide 3-kinase (PI3K) and extracellular-regulated kinases (ERKs) via the second-
ary messengers (cyclic adenosine monophosphate (cAMP) and Ca2+) (Julius and
Basbaum 2001). In turn, these activated kinases can depolarize ion channels (TRP
channels and sodium channels) in the nociceptors (Wang and Woolf 2005) and ele-
vates levels of intracellular Ca2+, which enhances the sensitivity of sensory neurons
Fig 1.4 Transducers including ion channels and receptors are expressed in the termi-
nals of heterogeneous nociceptors. (Figure was modified from Gold and Gebhart
2010)
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to the stimulation by lower intensity stimuli (Fig 1.5) (Levine and Alessandri-Haber
2007).
1.2.4 Central sensitization of pain
Peripheral nociceptive information is conducted to secondary order neurons in the
spinal cord via the primary afferent neurone axon. The primary afferent fibres termi-
nate in specific laminae in the dorsal horn of the spinal cord (Braz et al. 2014). Aβ 
fibres relay non-noxious input and project to the deep laminae (inner lamina II and
lamina V) of the dorsal horn. Aδ fibres project to outer lamina II and lamina V of the 
dorsal horn of the spinal cord. The peptidergic C fibres, defined by release of neuro-
peptides such as calcium gene-related peptide (CGRP) or substance P(SP), project
to the superficial dorsal horn (lamina I and outer lamina II) of spinal cord and non-
peptidergic C fibres project to the inner lamina II of the dorsal horn of the spinal cord
(Fig1.6) (Basbaum et al. 2009).
Fig 1.5 Signal cascades of peripheral sensitization in terminals of primary sensory fibres (nociceptors).
Noxious stimuli and inflammatory mediators act directly on ion channels or interact with receptors,
which activate the down-stream signal ling cascades via cAMP, and Ca2+ to sensitize the peripheral ter-
minals of the nociceptors.Figure was from Levine and Alessandri-Haber (2007).
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Fig 1.6 The projection of primary afferent fibres to the dorsal horn of spinal cord. Figure was from
Basbaum et al (2009).
As the nociceptive signals are processed by the second order neurons in the spinal
cord, responses are subject to modulation by central sensitization and descending
controls from the brainstem. Central sensitization was first described by Woolf (Woolf
2007). Central sensitization is characterized by the decreased threshold or the in-
creased excitability of neurons in the dorsal horn and the enlargement of the periph-
eral receptive fields, which results in pain hypersensitivity (Woolf 2011). Central sen-
sitization has an induction and maintenance phase. The induction of central sensiti-
zation may start from the wind-up of neurons elicited by repeated low frequency
stimulation of C-fibres (Li et al. 1999; Herrero et al. 2000). Maintenance of central
sensitization is associated with changes in neurotransmitter signalling such as glu-
tamate/ N-methyl-D-aspartate (NMDA) receptor mediated sensitization (Woolf and
Thompson 1990), loss of gamma-aminobutyric acid (GABAergic) and glycinergic
control (Sivilotti and Woolf 1994; Malan et al. 2002) and glial-neuronal interaction
(Calvo et al. 2012). In the superficial dorsal horn of the spinal cord, Aδ and C noci-
ceptors release a great number of neurotransmitters such as glutamate, brain de-
rived neurotrophic factor (BDNF), CGRP and SP (Ji et al. 2003). These neurotrans-
21
mitters activate post synaptic neurons via their cognate receptors and the subse-
quent sustained depolarization leads to the activation of the NMDA receptors by glu-
tamate and sustained influxes of Ca2+ (Woolf 2000; Latremoliere and Woolf 2009).
These signals are critical steps to generation of central sensitization as they activate
the downstream signal cascades including calcium/calmodulin-dependent protein
kinase II (CAMKII), cAMP –dependent PKA and Ca2+-dependent PKC, which phos-
phorylate the receptors expressed by the neurons to increase sensitivity and also
activate ERK1/2 and cAMP response element binding protein (CREB ) to drive tran-
scription of c-fos, COX2, NK1 and TrkB (Fig 1.7) (Latremoliere and Woolf 2009). In
addition, inflammation induces phenotype shifts in responses to Aβ fibre input lead-
ing to increases in the excitability of neurons and enhanced synaptic transmission in
the dorsal horn of spinal cord to maintain the central sensitization (Neumann et al.
1996).
Fig 1.7 Signalling cascades involved in the generation of central sensitization. Receptors
expressed by the post-synaptic neurons are activated by their corresponding neurotrans-
mitters; kinases are activated to drive the down-stream signalling cascades leading to the
central sensitization. Figure was from Latremoliere and Woolf (2009).
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Under normal conditions, nociceptive signals are modulated by inhibitory interneu-
rons and descending fibres. It is proposed that disruption of these inhibitory systems
may contribute to the chronic pain. This is what Melzack and Wall described as the
gate control theory of pain (Melzack and Wall 1965). However, disinhibition mecha-
nisms are debated as some suggested the disinhibition results from death of GA-
BAergic interneurons (Ibuki et al. 1997; Moore et al. 2002) while others showed there
was not obvious evidence that the neurons or GABA receptors were lost in neuro-
pathic pain models (Polgar et al. 2004; Polgar et al. 2005; Polgar and Todd 2008).
Some other factors such BDNF and TRPV1 were reported to be involved in the dis-
inhibition of inhibitory neurotransmitters or long-term depression of GABAergic inter-
neurons (Coull et al. 2005; Kim et al. 2012; Chen et al. 2014). Importantly, disinhibi-
tion can  also contribute to alterations in Aβ fibre input as blocking GABAergic and 
glycinergic receptors increased Aβ fibre input to dorsal horn neurons (Torsney and 
Macdermott 2006; Schoffnegger et al. 2008).
The interactions of glial cells (microglia and astrocytes) and neurons have emerged
as an important component of the maintenance of central sensitization and chronic
pain. Under the normal conditions, microglia are quiescent in the gray matter of spi-
nal cord; however, they become activated following damage to peripheral tissues or
the central nervous system. Activated microglia have altered morphology and re-
lease inflammatory mediators such as cytokines (TNFα, IL1β and IL6), BDNF and 
cathepsin S (Mifflin and Kerr 2013). These mediators bind to cognate receptors ex-
pressed by neurons and activate the down-stream signal cascades which increase
the excitability of neurons. In return, neurotransmitters released from neurons bind to
receptors such as P2X receptors, toll-like receptor 4 (TLR4), C-C chemokine recep-
tor type 2 (CCR2) and CX3CR1 expressed by microglia and promote the activation
of microglia (Mcmahon and Malcangio 2009). This interaction between microglia and
neurons contributes to the central sensitization in the dorsal horn of spinal cord.
Studies showed that spinal administration of ATP activated microglia and produced
pronounced tactile allodynia in naïve rats which supports the role of microglia in
chronic pain states (Tsuda et al. 2003; Coull et al. 2005). TLR is another emerging
family of receptors expressed by microglia contribute to central sensitization. TLR4
expressed by microglia was shown to maintain the behavioural hypersensitivity as
genetic deletion of TLR4 and administration of TLR4 antisense oligodeoxynucleotide
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(ODN) attenuated pain behaviour and microglia activation in a neuropathic model
(Tanga et al. 2005). A recent study revealed TLR2 mediated up-regulation of nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase 2 (Nox2) which was critical
for microglia activation after nerved injury and subsequent pain hypersensitivity (Lim
et al. 2013).
Astrocytes are also implicated in pain modulation but their contribution to central
sensitization is less clear. Astrocytes activation (reactive gliosis) is evident at later
stages of models of chronic pain, they can release numerous neurotransmitters such
as glutamate, D-serine or ATP which activate synaptic NMDA receptors on neurons
leading to cross-talk between astrocyte and microglia (Ren and Dubner 2010). In
addition, astrocytes can release inflammatory mediators such as IL1β and CCL2 and 
express TLRs, which sensitize NMDA receptor and contribute to central sensitization
(Liu et al. 2012). The neuroimmune interaction for central sensitization is described
in Fig 1.8.
Fig 1.8 The interaction between glial cells and neurons induce and maintain central sensitization in
the dorsal horn of spinal cord. The primary afferent terminal fibres release neurotransmitters
which activated receptors expressed by neurons in the dorsal horn. The released ATP and chemo-
kines activate glial cells which change morphology and release inflammatory mediators. In turn,
these mediators sensitize neurons in the dorsal horn and contribute to central sensitization. Figure
was from Mcmahon and Malcangio (2009).
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1.2.5 The ascending and descending pain pathways
The nociceptive output from the second-order neurons crosses over the anterior
white commissure of the spinal cord, ascends to the thalamus along the spinotha-
lamic tract and projects to the cingulate and sensory cortex in brain. Nociceptive in-
formation is also sent to the medulla via spinoreticular and spinomesencephalic
tracts. (Almeida et al. 2004; Tracey and Mantyh 2007).
A number of studies have characterized the responses of thalamic neurons to nox-
ious stimulation. Neuronal firing was observed in the ventroposterolateral (VPL) nu-
cleus of the thalamus in naïve rats and chronic constriction injury (CCI) -induced rats
after mechanical stimulation and activity of VPL neurons was blocked by an NMDA-
glycine antagonist, morphine and NMDA channel blocker (Bordi and Quartaroli 2000).
The anterior cingulate cortex (ACC) has been shown to play a major role in pain pro-
cessing. Positron emission tomography revealed that the anterior cingulate cortex
has significantly higher activity following pain-related signals (unpleasant) (Rainville
et al. 1997). Two forms of long-term potential (LTP) have been demonstrated in the
ACC and blocking pre-LTP in ACC prevented allodynia in nerve injury mice com-
pared to saline treated mice (Koga et al. 2015).
In addition to the ascending pathways, pain is also modulated by the descending cir-
cuit which consists of various areas including rostral ACC, amygdala, periaqueduct
gray (PAG) and rostroventral medulla (RVM) (Rainville 2002; Ossipov et al. 2010).
Neurons are excited in amygdala by noxious stimuli to the somatic tissues such as
joint, skin and muscle (Neugebauer and Li 2002). A recent study revealed that the
mGlu1 receptor was associated with the pain-related increase of synaptic transmis-
sion and decrease of inhibitory transmission of neurons in amygdala (Ren and
Neugebauer 2010). Stimulation of the PAG inhibits nociceptive responses of neurons
in the dorsal horn of the spinal cord and this disinhibition of neurons was attributed to
the release of some neurotransmitters such as serotonin (5-HT), norepinephrine
(NE), Gly, and GABA in the spinal cord (Cui et al. 1999). Further study has shown
different subtypes of 5-HT receptors produce differential effects on neuronal excita-
bility in the PAG (Jeong et al. 2013). The RVM receives input from PAG and two
main subpopulations of neurons have been described in the RVM. The ‘on cells’ in-
crease firing and ‘off cells’ decrease firing prior to withdrawal reflex, these cells send
information to the neurons in the dorsal horn of the spinal cord (Fields 2004). There
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is good evidence that this system is involved in chronic pain mechanisms in that ‘on
cells’ and ‘off cells’ in RVM are sensitized by innocuous and noxious stimuli in spinal
nerve ligation (SNL) -induced neuropathic pain (Carlson et al. 2007) and SNL- in-
duced allodynia was reversed by intrathecal injection of lidocaine in RVM (De Felice
et al. 2011). NMDA receptors, serotonin and neurokinin-1 receptors in RVM are im-
plicated in facilitating pain transmission via the descending pain pathway (Zhang and
Hammond 2009; Da Silva et al. 2010; Wei et al. 2010).
Overall, pain is modulated by both ascending and descending pathways between
spinal cord and cerebral cortex via various neurotransmitters and signalling path-
ways.
1.3 Contribution of inflammation to pain
Inflammation is a physiological or pathological process initiated by noxious stimuli
such as infection or tissue injury (Medzhitov 2008). It modulates pain by the release
of multiple inflammatory mediators from immune cells (Moalem and Tracey 2006).
The contribution of pro-inflammatory mediators such as TNFα, IL1β and prostaglan-
dins to pain are well documented in previous studies (Dray 1995; Moalem and
Tracey 2006). Herein, the section has a brief induction to the contribution of key in-
flammatory mediators relevant to pain.
Intra-plantar repeated injection of TNFα, IL1β and IL8 produced persistent mechani-
cal nociceptor hypersensitivity (Cunha et al. 1992; Sachs et al. 2002). Expression of
TNFα, IL1β, IL6 and iNOS was up-regulated in spinal cord glial cells via activation of 
NFκB and mitogen-activated protein kinases (MAPKs) after stimulation with superna-
tant from damaged sensory neurons (Kim et al. 2007). TNFα and IL6 can increase 
neuronal hyperexcitability and inhibit the inhibitory interneurons respectively and
IL1β shows both of the effects (Kawasaki et al. 2008). Moreover, spinal administra-
tion of all these cytokines can produce heat hyperalgesia via phosphorylation of
CREB (Kawasaki et al. 2008).
The contribution of IL1β to thermal hyperalgesia has been demonstrated in a drug 
interventions study in the Complete Freud’s adjuvant (CFA)-induced model (Safieh-
Garabedian et al. 1995) and IL1β produces the inflammatory pain hypersensitivity by 
up-regulation of spinal COX2 and prostaglandin E2 (PGE2) (Samad et al. 2001).
Spinal administration of IL1β and TNFα increases spinal expression of COX2 and 
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produces thermal hyperalgesia (Narita et al. 2008). Moreover, expression of NF-κB is
up-regulated in the spinal cord of CFA model (Narita et al. 2008). Subcutaneous in-
jection of IL1β increases formalin-induced behavioural responses and pERK and p-
p38 in neurons and microglia, indicating IL-1β-induced central sensitization of noci-
ception via MAPK pathway (Yang et al. 2013). Interestingly, IL1β also induces rapid 
LTP of glycinergic synapse, which was shown for the first time in superficial dorsal
horn of the spinal cord (Chirila et al. 2014).
Local sciatic injection of TNFα produces transient thermal hyperalgesia and mechan-
ical allodynia and nerve edema (Wagner and Myers 1996). Intramuscular injection
of TNFα produces muscular hyperalgesia and increased protein level of CGRP, NGF 
and PGE2 (Schäfers et al. 2003). Knock down of TNFα receptor (p55) abolishes 
thermal and mechanical hyperalgesia in a neuropathic injury model (brachial plexus
avulsion) and the mechanical allodynia was reversed by TNFα antibody and TNFα 
synthesis inhibitor (Quintao et al. 2006). TNFα increases expression of BDNF in tri-
geminal ganglion sensory neurons via influx of sodium channel and p38-MAPK
(Balkowiec-Iskra et al. 2011). Treatment of TNFα also has been demonstrated to in-
crease BDNF, TrkB, CGRP and SP in dorsal root ganglia (DRG) neurons, which are
essential neurotransmitters for pain transmission (Lin et al. 2011).
Intradermal injection of PGE2 reduces mechanical threshold of C-fibres (Chen et al.
1998) and direct application of PGE2 to PAG and RVM decreases paw withdrawal
latency, activates ‘on cells’ and inhibits ‘off cells’, which indicates PGE2-induced hy-
peralgesia (Heinricher et al. 2004). PGE2 induces thermal hyperalgesia and inflam-
matory nociception via EP1 receptor and sensitizes TRPV1 (Moriyama et al. 2005).
PGE2 and its analogue were also revealed to increase the expression of IL6 in DRG
neuron via the receptor EP4 and activation of PKA, PKC, ERK, CREB and NFκB in a
neuropathic pain model. (St-Jacques and Ma 2011). EP1 receptor antagonist and
microsomal prostaglandin E synthase-1(mPGES1) knock out reduce the activation of
microglia and PGE2 blocked microglial transmission, indicating a role for PGE2 in
maintenance of pain (Kunori et al. 2011). A recent study reported that PGE2 stimu-
lated externalization of it receptor EP4 in DRG neurons, which further supports PGE2
in nociceptive sensitization and results in inflammatory pain (St-Jacques and Ma
2013).
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NGF is heavily implicated in the sensitization of nociceptors in inflamed tissue
(Koltzenburg et al. 1999). The biological effects that endogenous NGF is associated
with chronic pain were firstly demonstrated by using TrkA-IgG to sequester NGF in
sensory neurons. Infusion of TrkA-IgG to the skin of the lower leg reduces capsaicin
and carrageenan-induced thermal hyperalgesia and decreased CGRP in sensory
neurons (Mcmahon et al. 1995). Intra-plantar injection of NGF produces thermal hy-
peralgesia and recruited neutrophil accumulation and this effects was blocked by 5-
LOX inhibitor (Bennett et al. 1998). Expression of NGF is increased during inflamma-
tion (Woolf et al. 1998). Anti-NGF neutralizing antibody attenuates thermal and me-
chanical hypersensitivity and down regulates levels for SP , CGRP and c-fos in dor-
sal horn neurons, indicating role for NGF in inflammatory pain (Woolf et al. 1998).
Both an anti-NGF antibody and an anti-TrkA antibody reverse inflammatory (forma-
lin-induced and CFA) and neuropathic (CCI and SNL) pain, which indicates the criti-
cal role of NGF in established pain (Ugolini et al. 2007; Wild et al. 2007).
A mountain of studies has investigated the role of pro-inflammatory mediators in pain
induction. On the other hand, there are also some cytokines such as IL10 and IL4,
which have anti-inflammatory and anti-nociceptive roles. IL10 reduces endotoxin and
carrageenan-induced inflammatory pain and CCI-induced neuropathic pain and
down-regulates the expression of IL1β and NGF (Kanaan et al. 1998; Wagner et al. 
1998; Willemen et al. 2014). Naïve IL4 knock out mice show tactile allodynia and
CCI-induced increase of TNFα, IL1β, IL10 and IL13 (Uceyler et al. 2011). Expression 
of IL4 is up-regulated in injured sciatic nerve (Kiguchi et al. 2015). Treatment of IL4
could inhibit partial sciatic nerve ligation-induced expression IL1β and CCL3 in mac-
rophages and attenuate tactile allodynia and thermal hyperalgesia (Kiguchi et al.
2015). IL4-transfected DRG neurons reduces SNL-induced mechanical allodynia and
thermal hyperalgesia and inhibits the expression of c-fos, IL1β, PGE2 and p-p38 
MAPK in the model (Hao et al. 2006).
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1.4 Osteoarthritic pain
1.4.1Peripheral and central mechanisms contribute to OA pain
Pain is the cardinal symptom that drives patients to seek treatment for OA. Osteoar-
thritic pain is studied world-wide in preclinical and clinical aspects which provide a
mountain of evidences that sensitization of pain appears in OA. This sensitization of
pain results from changes in nociceptors in joints and neuropathic components which
transduce pain signals in spinal cord, brain stem, thalamus and cerebral cortex
(Schaible 2012). However, when does pain appear and what causes pain in OA is
still elusive. As cartilage is not -innervated and avascular, the sources of pain must
be due to joint-associated structures such as synovia, bone marrow, meniscus, mus-
cles and ligaments (Konttinen et al. 2012). Activity and aberrant loading of joints may
be the major driving force contributing to initial pain in OA (Felson 2009).
Inflammatory mediators released from chondrocytes, macrophages and fibroblasts in
joints are likely to contribute to OA pain. The mechanical stimulation of joints and in-
flammatory mediators can directly sensitize nerve fibres in the joints by acting on ion
channels or receptors in the nociceptors, which are essential for initiation of OA pain
at peripheral sites (Schaible et al. 2009; Schaible et al. 2011). Pro-inflammatory cy-
tokines such as TNFα, ILβ, IL6 and IL17 can directly activate the nociceptive system 
by binding to their receptors, which induce peripheral sensitization of pain (Schaible
2014).
Intra-articular injection of TNFα increases the sensitization of C-fibre to joint stimula-
tion in a dose-dependent manner and enhances neuronal excitability in isolated DRG
neurons in naïve rats (Richter et al. 2010). Both peripheral and spinal administration
of TNFα increases neuronal hyperexcitability in the spinal cord after joint stimulation 
(Konig et al. 2014). Intra-articular injection of IL1β to temporomandibular joints in-
duces joint pathology and joint pain (Lai et al. 2006). Pathology and pain behaviour
are dependent on spinal expression of IL1β, indicating mechanisms from primary in-
jury site to central nervous system (Fiorentino et al. 2008). Increased expression of
IL1β indicates higher pain scores in symptomatic knee OA (Attur et al. 2011). NGF 
was firstly detected and was shown to be up-regulated in human osteoarthritic chon-
drocytes in 2002, which implicates a role of NGF in OA pathogenesis (Iannone et al.
2002). Later on, the increase in NGF was revealed in the vascular channels of oste-
ochondral junction, which also contained CGRP immunoreactive sensory nerve fi-
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bres, indicating an association of NGF with OA pain (Walsh et al. 2010). Intra-
articular injection of NGF produces weight bearing asymmetry and mechanical allo-
dynia in naïve rats. Moreover, weight bearing asymmetry in OA rats was exacerbat-
ed by intra-articular injection of NGF (Ashraf et al. 2014). In addition, intra-articular
injection of NGF increases joint extension induced neuronal firing and expands the
receptive field of spinal neurons in MIA-induced OA model (Sagar et al. 2015).
TRP channels are a family of ion channels involved in pain transduction and trans-
mission (Julius 2013). Some members of TRP channels have been found in chon-
drocytes and synovial fibroblasts of OA patients (Engler et al. 2007; Gavenis et al.
2009). Expression of TRPV1 was increased in human OA synovia and intra-articular
injection of TRV1 antagonist reverses mechanically evoked firing of joint afferents
and weigh bearing asymmetry in the MIA-induced OA model (Kelly et al. 2013). Oral
dosing of a TRPV1 antagonist (A-889425) attenuated pain behaviour and spontane-
ous firing of spinal wide dynamic range (WDR) and nociceptive specific (NS) neu-
rons in the MIA model (Chu et al. 2011). Systemic administration of a TRPA1 antag-
onist (A-967079) decreased WDR neuronal response in the MIA model after noxious
mechanical stimulation (Mcgaraughty et al. 2010). Sodium channels such as Nav1.8
expressed by small nerve fibres are also implicated, block of Nav1.8 reduced the
neuronal response in joint afferents induced by noxious rotation and attenuates pain
behaviour in the MIA model (Schuelert and Mcdougall 2012) . ASIC3 was up-
regulated in joint afferents and strongly associated with pain behaviour in the MIA
model of OA pain and ASIC3 selective peptide blocker (APETx2) reverses the pain
behaviour via down-regulation of ASIC3 (Lzumi et al. 2012).
There is mounting evidence that peripheral and central sensitization contribute to OA
pain (Arendt-Nielsen et al. 2010). CGRP-immunoreactive and SP-immunoreactive
fibres were shown to increase in soft tissues and synovium in the hip joints of OA pa-
tients, indicating a role for these neuropeptides in OA pain (Saxler et al. 2007). Neu-
ronal responses (Aδ and C fibre) evoked by electrical or natural stimulation  werein-
creased in the dorsal horn of MIA rats compared to saline rats, indicating central
mechanism of OA pain (Harvey and Dickenson 2009). Activation of microglia and
astrocyte were observed in MIA-induced OA and microglia activation was correlated
with distal allodynia, which further supports a role for central sensitization in OA pain
(Sagar et al. 2011). The increase of CGRP, activating transcription factor-3 (ATF3)
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and growth associated protein-43 (GAP43) immunoreactive neurons in DRG cell
bodies and microglia in the dorsal horn suggests there may be neuropathic compo-
nents in the MIA model (Orita et al. 2011). CGRP was up-regulated in the dorsal
horn of spinal cord and blocking CGRP attenuates pain hypersensitivity in the model
(Ogbonna et al. 2013). Descending serotonergic facilitation mediates neuronal re-
sponses in the deep dorsal horn in MIA-induced pain (Rahman et al. 2009), and
milnacipran, a serotonin/noradrenaline reuptake inhibitor, inhibited neuronal re-
sponses in the deep dorsal horn and reversed OA pain via descending serotonergic
and noradrenergic pathways (Burnham and Dickenson 2013). Phosphorylation of
ERK1/2 and p38 MAPK, critical intracellular transduction signals for central sensitiza-
tion, is up-regulated in MIA-induced OA (Lee et al. 2011).
Overall, multiple peripheral and central components contribute to OA pain (Malfait
and Schnitzer 2013) (Fig1.9).
Fig 1.9 The transmission pathway of OA pain from peripheral site (knee joint) to central
nervous system (brain) and its potential analgesic targets. Figure was from Malfait and
Schnitzer (2013). Abbreviations: Amy, amygdala; HP, hippocampus; NAc, nucleus accum-
bens; PAG, peri-aqueductal grey; PG, prostaglandin; RVM, rostral ventromedial medulla;
SNRI, serotonin noradrenaline reuptake inhibitor.
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1.4.2 Inflammatory mediators and pain in osteoarthritis
As described above, inflammation is closely associated with both pathogenesis of
OA (see 1.1.5) and pain (see 1.3) and alteration of inflammatory mediators and es-
tablished pain behaviour have been shown in OA.
Inflammatory cytokines, such as TNFα, TNFβ, IL1β, IL2, IL12, IL17 and interferon-γ 
(IFNγ) were significantly higher and expression of IL10 was significantly lower in the 
synovia of OA patients (Vernal et al. 2008). Expression of TNFα, MMP3 and MMP9 
was significantly higher and IL10 was significantly lower in serum of OA patients. In
the synovia and cartilage, expression of MMP-2, -3, -9 and IL10 was significantly
higher in OA patients (Wassilew et al. 2010). In addition, all the tested cytokines
(TNFα, IL1α, IL8, and IL10), MMP-3, -9, and TIMP-1 were higher in the subchondral 
bone in OA patients (Hulejova et al. 2007). Moreover, TNFα was significantly corre-
lated with MMP1 and MMP3 in synovial tissue (Wassilew et al. 2010). Expression of
COX2, mPGES1, iNOS was increased in OA chondrocytes after treatment with ad-
vanced glycation end products (AGEs)- bovine serum albumin, which has been
shown to involve in tissue stiffness in articular cartilage and signalling pathways for
pro-inflammatory responses via the receptor for AGEs (Loeser et al. 2005; Nah et al.
2008). Expression of TNFα, IL6, RANKL was expressed higher in human OA com-
pared to control (Toncheva et al. 2009). IL6, IL8 and MMP13 expression was in-
creased in osteophytes from OA patients and mechanical stimulation increased ex-
pression of IL6 and IL8 (Sakao et al. 2009). IL18 increased COX2 and PGE2 in syn-
oviocytes, and up-regulated expression of COX2, PGE2 and TNFα in chondrocytes 
in OA patients (Fu et al. 2012). Expression of IL6, IL8, MCP1, vascular endothelial
growth factor (VEGF) was up-regulated in human chondrocytes when stimulated with
OA synovial fluid (Hoff et al. 2013). Expression of IL6 and TNFα were increased in 
the synovial fluid from injury joint of canine OA compared to contralateral joint (Venn
et al. 1993). Expression of TNFα, COX2, iNOS and NF-κB was significantly higher in
the cartilage of MIA-induced OA joint (Kim et al. 2012).
The anti-inflammatory cytokines ( IL4, IL10 and IL13) reduced TNFα-induced COX2 
and PGE2 in synovial fibroblast from human OA (Alaaeddine et al. 1999). IL13 re-
duced expression of TNFα, IL1β and increased IL1Rα in synovial membrane of OA 
(Jovanovic et al. 1998).
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All these studies show that pro-inflammatory mediators greatly contribute to patho-
genesis of OA such as acceleration of cartilage degradation, inhibition of proteogly-
can synthesis and induction of chondrocytes apoptosis and anti-inflammatory cyto-
kines played the converse role (Sutton et al. 2009; Bondeson et al. 2010).
In OA patients, the pressure pain threshold (PPT) was significantly lower than in
healthy volunteers, indicating high pain sensitivity, hyperalgesia and higher disability
scores in the patients (Imamura et al. 2008). OA patients had lower PPTs and higher
heat pain rating. In addition, expression of C-reactive protein (CRP) and IL6 was
higher in OA patients and enhanced pain sensitivity was associated with increased
CRP and IL6, suggesting contribution of inflammation to human OA pain (Lee et al.
2011). Central sensitization has been investigated in OA patients via PPTs and
spreading sensitization. Patients with severe pain had lower PPTs and negative cor-
relation was found between PPTs and visual analogue scale (VAS), indicating cen-
tral sensitization of pain in OA (Arendt-Nielsen et al. 2010).
Various models of OA have been used to investigate OA pain, such as the MIA-
induced model (Guingamp et al. 1997; Combe et al. 2004), MNX model (Bove et al.
2006; Mapp et al. 2010; Mapp et al. 2013) and DMM model (Malfait et al. 2010).
MIA is a glycolysis inhibitor that results in cartilage degeneration and joint damage
(Janusz et al. 2001). Intra-articular injection of MIA induces apoptosis of chondro-
cytes and causes loss of cartilage and lesions of subchondral bone, similar to those
observed in human OA (Dunham et al. 1993; Guzman et al. 2003). Thus, this model
is widely used to investigate the peripheral and central mechanisms of osteoarthritic
pain. Herein, I mainly focus on the contribution of inflammatory mediators to OA pain
in this model.
Pain behaviour and synovial inflammation were observed in the MIA model from day
3 until day 14, indicating a quickly developed pain behaviour and joint pathology in
this model (Beyreuther et al. 2007). Linear regression has shown activity of NFκB
and expression of IL1β and IL6 were correlated with pain-related sensitivity in MIA 
model, indicating an important role of inflammatory signals in OA pain (Bowles et al.
2014). Expression of COX1 and COX2 in the spinal cord and pain behaviour were
enhanced in the MIA model, suggesting essential roles of COXs in OA pain
(Prochazkova et al. 2009). Mechanical allodynia developed in MIA-induced OA from
day 4 until day 28 post-MIA injection, pro-inflammatory cytokines (TNFα,IL6 and 
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NGF) were increased in synovia and capsule from joints in the model and numbers
of activated microglia in the spinal cord and CGRP-immunoreacitve neurons in DRG
were increased in this model, indicating sensory innervated joint of inflammatory pain
to neuropathic pain in the model (Orita et al. 2011). Expression of TNFα, IL1β, neu-
ropeptide Y and galanin increased but CGRP and SP decreased in DRG in the MIA
model, which was similar to SNL neuropathic model. In addition, expression of TNFα, 
IL1α, IL1β, IL13,IL17 ,VEGF and thymus chemokine was increased and expression 
of IL4 and IL10 was decreased in the spinal cord of MIA model (Im et al. 2010). Me-
chanical allodynia developed in MIA model and expression of IL1β, IL6, IL15, iNOS, 
MMP13, and receptor for advanced glycation end product (RAGE) was enhanced in
the model, which was attenuated by coenzyme Q10 (Lee et al. 2013). Pain behav-
iour established and chemokines such as CCL2, CCL 7 and CCL9 were also in-
creased in joints of MIA model (Dawes et al. 2013). In a recent study, expression of
IL1β, IL6, nitrotyrosine and iNOS was increased and pain behaviour was established 
in the MIA model and IL1β induced high expression of MMP3, MMP13 and 
ADAMTS5 in human chondrocytes, which were all attenuated by ursodeoxycholic
acid (Moon et al. 2014). Pain behaviour in the MIA model is associated with activa-
tion of pERK in neurons and p-p38-MAPK in microglia of the spinal cord (Lee et al.
2011) and was maintained by activated microglia and astrocytes (Sagar et al. 2011).
Pain behaviour, joint pathology and expression of ATF3, neuropeptide Y and GAP43
were increased in the MIA model, indicating peripheral fibre regeneration and neu-
ronal injury in this model (Ferreira-Gomes et al. 2012; Thakur et al. 2012). These al-
terations of inflammatory cytokines and neuropeptides in the sensory and spinal neu-
rons further support the critical roles of these mediators in peripheral and central
sensitization of OA pain in the MIA model (Im et al. 2010).
Some other models were also used to investigate OA pain as mentioned above. Pain
behaviour, synovial inflammation and angiogenesis have been demonstrated in the
MNX-induced OA model (Ashraf et al. 2011; Mapp et al. 2013). Moreover, dexame-
thasone, indomethacin and PPI-2458 (angiogenesis inhibitor) reduced synovial in-
flammation and angiogenesis as well as pain behaviour, which suggests a role for-
inflammation in OA pain in the MNX model (Ashraf et al. 2011). Decreased paw
withdrawal threshold has been shown in DMM-induced OA rats compared to sham
control and ADAMTS-5 knock out mice didn’t show the behaviour (Malfait et al.
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2010). RT-PCR assay revealed that expression of MMP3, CCL21, and insulin-like
growth factor (IGF-1) was significantly higher in the DMM mice, compared to sham
mice, and expression of CCR7 and IL33 was higher in young DMM mice (12 weeks
old) (Loeser et al. 2012).
1.4.3Treatments for OA pain
As treatment for OA pain has been detailed in the previous section (see 1.1.6). Here
I just make a brief summary for the treatment of OA pain. Some traditional drugs
such as non-selective NSAIDs (Orita et al. 2011; Balmaceda 2014), COX2 selective-
inhibitors (Stengaard-Pedersen et al. 2004; Laine et al. 2008), cannabinoids agonists
(Richardson et al. 2008; Burston et al. 2013), opioids (Avouac et al. 2007; Vonsy et
al. 2009), corticosteroids (Jones and Doherty 1996; Huebner et al. 2014) and hyalu-
ronic acid (Petrella et al. 2008; Ikeuchi et al. 2014) are used to treat OA pain. How-
ever, some side effects have been demonstrated in these drugs such as gastrointes-
tinal bleeding and renal toxicity with NSAIDs (Murray and Brater 1993; Makris et al.
2010; Sostres et al. 2010) and tolerance for opioids (Dumas and Pollack 2008).
Some potential drugs are under preclinical investigation but finding novel drugs with
high potency and safety are still of great interest to improve life quality of OA patients.
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1.5 Resolvins
1.5.1 Biosynthesis of resolvins from Ω-3 poly-unsaturated fatty acids  
Resolvins are endogenous lipid mediators generated during resolution of inflamma-
tion. They were identified for the first time in the exudates from TNFα-induced in-
flammation in a mouse air-pouch model after treatment with docosahexaenoic acid
(DHA), eicosapentaenoic acid (EPA) and aspirin (Serhan et al. 2000; Serhan et al.
2002). These findings have revealed that resolving inflammation with Ω-3 PUFAs is
an active process producing a number of specialized pro-resolving lipid mediators
(SPMs) such as resolvins, protectins and maresins, and contributes to restoration of
tissue homeostasis and functional recovery (Buckley et al. 2014; Serhan 2014). Re-
solvins are the main products of DHA and EPA and are classified into D-series and
E-series respectively (Serhan and Chiang 2008).
DHA (22:6, n-3) is a long chain Ω-3 PUFA with 22 carbons and 6 double bonds
(Stillwell and Wassall 2003), present in fish oil, brain and retina from mammals and
marine products and is beneficial for health (Horrocks and Yeo 1999; Guesnet and
Alessandri 2011). DHA can be converted into the bioactive compounds including D-
series resolvins, protectinD1 (PD1) / neuroprotectin D1 (NPD1) and maresins via
COX2 / aspirin / 5-LOX or 15-LOX / 5-LOX pathway (Spite et al. 2014).
15-LOX or 5-LOX is a highly structural conserved member of the arachidonate lipox-
ygenases, having two functional domains ( β-barrel domain and the catalytic domain) 
and 5-LOX is involved in leukotriene biosynthesis (Peters-Golden and Brock 2003).
In the 15-LOX / 5-LOX pathway, DHA is firstly converted into 17S-H(p)DHA /17S-
HDHA via 15-LOX and is rapidly metabolized to 7S(8)-epoxy-17S-HDHA and 4S
(5)-epoxy-17S-HDHA or 16S,17S-epoxide- protectin by enzymatic epoxidation (see
fig 1.10B). Finally, those precursors are metabolized into their corresponding bioac-
tive compounds such as RvD1-4 via 5-LOX, RvD 5-6 via peroxidase and PD1 /
NPD1 via 15-LOX and hydrolase (Hong et al. 2003; Sun et al. 2007; Kohli and Levy
2009; Serhan and Petasis 2011).
COX2 is an inducible enzyme expressed at a low level under normal conditions, but
it can be rapidly induced by various stimuli such as inflammatory cytokines, growth
factors and bacterial endotoxins (Smith et al. 1996). COX2 has four functional do-
mains including amino-terminal hydrophobic signal peptide, the dimerization domain,
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the membrane-binding domain and the catalytic domain which is composed of perox-
idase and cyclooxygenase active sites (Chandrasekharan and Simmons 2004). In
the presence of aspirin, COX2 is acetylated at serine 530 within the catalytic site ,
which inhibits the cyclooxygenase activity but has little effects on peroxidase activi-
ty, indicating the seperate function and physical property of the two active sites
(Smith et al. 1996). In addition, COX2 homodimer was asymmetric acetylated by as-
pirin and has various activity on oxygenation of arachidonic acid, EPA and DHA
(Sharma et al. 2010). DHA is converted to 17R-H(p)DHA/ 17R-HDHA ( also named
17(R)HDoHE) via aspirin / COX2 or cytochrome P450, and then produces aspirin
triggered D-series resolvins (AT-RvD1-4) via 5-LOX (Hong et al. 2003; Sun et al.
2007; Kohli and Levy 2009). In addition, DHA is also converted into 13S, 14S-epoxy-
maresin via 12-lipoxygenase (12-LOX) and maresin 1 via a new epoxide hydrolase
in human neutrophils and macrophages (Dalli et al. 2013; Abdulnour et al. 2014).
EPA is the other main Ω-3 poly-unsaturated fatty acid beneficial for fetal develop-
ment, healthy aging, cardiovascular and neurodegenerative diseases (Swanson et al.
2012) and is the precursor for the bio- active E-series resolvins. Similar to DHA, EPA
is converted into 18R-hydroperoxy-EPE (18-HpEPE), the precursor of the E-series
resolvins, via aspirin / COX2 or CYP450 and then biosynthesizes bioactive RvE1-2
via 5-LOX and subsequent enzymatic epoxidation or RvE3 via 12-LOX / 15-LOX. In
addition, EPA could be converted into 18S-RvE1 and 18S-RvE2 via 5-LOX (Serhan
2004; Oh et al. 2011; Serhan and Petasis 2011; Isobe et al. 2012; Buckley et al.
2014). The metabolic pathways for resolvins, protectins and maresin from DHA and
EPA are summarized in Fig 1.10.
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Fig 1.10 Biosynthesis pathways of resolvins, protectins and maresin 1 from EPA and
DHA. E-series resolvins are produced from EPA via various metabolic enzymes (A).
D-series resolvins, PD1/NPD1 and maresin 1 are generated from DHA via respective
metabolic enzymes (B).
B
17S-HDHA
Peroxidase
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1.5.2Resolvin receptor system
The biological functions of resolvins are mediated via their specific receptors, which
belong to the GPCR superfamily (Cash et al. 2014). To date, four resolvin receptors
have been identified, which are ALX and GPR32 for the D-series resolvins
(Krishnamoorthy et al. 2010; Chiang et al. 2012; Dalli et al. 2013) and ChemR23
(Arita et al. 2005) and leukotriene B4 receptor (BLT1) (Arita et al. 2007) for the E-
series resolvins.
ALX is a formyl peptide receptor involved in chemotaxis of PMNs or phagocytes in
bacterial infected tissues or Escherichia coli cultures respectively via binding N-
formyl methionyl peptide (Chiang et al. 2006) and was first identified in promyelocytic
lineages (HL60 cells) and human neutrophils (Fiore et al. 1994). Later on, mouse
ALX was cloned and studied in Chinese hamster ovary (CHO) cells (Takano et al.
1997) and rat ALX was cloned from peripheral leukocytes, which shows 74% and 84%
homology of amino-acid sequences with human and mouse ALX respectively
(Chiang et al. 2003). Currently, human GPR32 has been cloned (Marchese et al.
1998) and related pseudogene has been identified on chromosome 19 by RefSeq.
ALX and GPR32 are expressed in leukocytes (neutrophils, monocytes/macrophages)
(Devchand et al. 2003; Chiang et al. 2005), neurons and glial cells (Serhan et al.
2002; Abdelmoaty et al. 2013). ALX can modulate inflammatory arthritis via lipoxin
A4 (Sodin-Semrl et al. 2000; Fiore et al. 2005). The function of GPR32 is less under-
stood as there are few reports on this receptor.
ChemR23 was first cloned and expressed in human monocyte-derived dendritic cells
and macrophages (Samson et al. 1998). ChemR23 and BLT1 receptors are
expressed by leukocytes (neutrophils, eosinophils, monocytes/macrophages,
dendritic cells) (Yokomizo et al. 1997; Uddin and Levy 2011), neurons (Xu et al.
2010) and glial cells (Croitoru-Lamoury et al. 2003; Connor et al. 2007). ChemR23 is
also expressed by chondrocytes from OA patients and in macrophages and
fibroblast-like synoviocytes in synovia from rheumatoid arthritis (RA) and OA
patients (Berg et al. 2010; Kaneko et al. 2011).
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1.5.3The anti-inflammatory and pro-resolving roles of resolvins
As described above, resolvins and precursors were first discovered in inflammatory
exudates and were shown to inhibit human polymorphonuclear leukocytes (PMNs)
infiltration and microglial cytokine (IL1β) in dermal inflammation and peritonitis 
(Serhan et al. 2000; Serhan et al. 2002). Later on, the anti-inflammatory and pro-
resolving actions of resolvins were reported in a number of studies.
RvD1 can directly bind to ALX and GPR32 to enhance macrophage phagocytosis
(Krishnamoorthy et al. 2010) as well as limit recruitment of human PMNs and reduce
prostaglandins and leukotrienes levels in murine peritonitis (Norling et al. 2012).
Pre-treatment of RvD1 (intraperitoneal injection (i.p.), 1μg/kg, 5μg/kg) and post-
treatment of RvD1 (intravenous, i.v, 5μg/kg) have been shown to reduce lipopoly-
saccharide (LPS)-induced acute lung injury in mice and rats respectively (Wang et al.
2011; Wang et al. 2014). In addition, RvD1 acted to down-regulate the expression of
TNFα, IL6, COX2 and iNOS, and inhibited MAPK and NFκB signalling (Wang et al.
2011) and increased activity of Na, K-ATPase and ALX/cAMP/PI3K signalling (Wang
et al. 2014).  RvD1 reduced LPS-induced TNFα in murine macrophage-like RAW 
264.7 cells via inhibition of NFκB, zymosan-A-induced TNFα in peritonitis (Lee et al. 
2013), and leukocyteinfiltration and outcome of peritonitis (Recchiuti et al. 2014).
RvD1 reduced LPS-induced expression of COX2, PGE2 and PGD2 in lung fibroblasts
(Wu et al. 2013) and attenuated LPS-induced expression of TNFα, IL1β, and iNOS. 
In addition, it inhibited activation of MAPK and NFκB in microglia from rats (Xu et al.
2013) and down-regulated superoxide dismutase-1 (SOD-1)-induced expression of
TNFα and IL6 in spinal microglia from amyotrophic lateral sclerosis (ALS) patients 
(Liu et al. 2012).
Some other related actions of RvD1 have been shown in various models for diseas-
es. RvD1 promoted IL4-induced alternative activation of murine microglia (cell line
BV-2), phosphorylation of signal transducer and activators of transcription 6 (STAT6)
and peroxisome proliferator-activated receptor gamma (PPARγ) activation (Li et al. 
2014), reduces myofibroblasts proliferation in obstructed kidney with unilateral ure-
teric obstruction (UUO) and inhibits pERK1/2 and p-AKT (protein kinase B) (Qu et al.
2012). It also has renoprotective effects on podocytes in adriamycin-induced
nephropathy in a mouse model via improvement of proteinuria, glomerulosclerosis
and tubulointerstitial fibrosis (Zhang et al. 2013). RvD1 is also reported to inhibit
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transforming growth factor beta 1 (TGFβ1)-induced epithelial-mesenchymal-
transition (EMT) in A549 lung cancer cells via ALX and GPR32. Moreover, RvD1 and
RvD2 inhibited TGFβ1-induced invasion and migration of cancer cells (Lee et al. 
2013). RvD1 and RvD2 enhance human macrophage efferocytosis to apoptotic os-
teoblasts (Mccauley et al. 2014) and decrease expression of TNFα, IL1β, IL6 and 
IL12 in adipose tissue from an obese mouse model (Claria et al. 2012).
Similar to RvD1, RvD2 has been shown to decrease neutrophil recruitment in micro-
bial peritonitis, inhibit cytokines (TNFα,IL1β, IL6, IL10, IL17, IL23 MIP2) and  lipid 
mediators (PGE2 and LTB4) in mouse model of microbial sepsis and enhance mac-
rophage phagocytosis (Spite et al. 2009). Different from other D-series resolvins,
RvD3 is produced in the late resolution phase and can inhibit neutrophil infiltration in
peritonitis model and TNFα-induced dermal inflammation at a very low concentration 
(10ng/mouse) (Dalli et al. 2013). RvD3 and AT-RvD3 decrease levels of IL6, MCP1,
PGD2, leukotriene B4 (LTB4) and thromboxane B2 (TxB2), up-regulate IL10 expres-
sion and enhance macrophage phagocytosis (Dalli et al. 2013). In E. coli inoculated
mice, RvD5 enhanced macrophage phagocytosis via GPR32, which promoted bacte-
rial clearance (Chiang et al. 2012).
AT-RvD1 inhibits LPS-induced levels for TNFα, IL6, COX2, MCP1 via ALX in bone 
marrow-derived macrophages (Bento et al. 2011) , decreases expression of IL6 in a
mouse model for surgery-induced cognitive decline and reduces release of TNFα 
and superoxide production in LPS stimulated macrophages (Terrando et al. 2013).
In the mouse lung injury model, AT-RvD1 reduced lung vascular permeability, neu-
trophils, inflammatory cytokines (TNFα, IL6), and chemokines in the bronchoalveolar 
lavage fluid. Moreover, AT-RvD1 inhibited NFκB activation and secretion of TNFα 
and IL6 from immunoglobin (IG) stimulated alveolar macrophages and neutrophils
(Tang et al. 2014). In addition, AT-RvD1 improved astrocytic morphology and pre-
vented surgery-induced synaptic transmission and plasticity (Terrando et al. 2013).
The anti-inflammatory and pro-resolving actions of D-series resolvins are summa-
rized in Table 1.2.
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Table 1.2 The anti-inflammatory and pro-resolving actions of D-series resolvins in various models
Lipid Mediator Species /Model Dose/ route Action(s) Ref
17(R) HDHA    Mouse/colitis       0.1, 0.3, 1μg/mouse (i.v.)        Reduces TNFα, IL1β, MIP2, NFκB               (Bento et al. 2011) 
RvD1 Macrophage 10nM Enhances macrophage phagocytosis (Krishnamoorthy et al. 2010)
via ALX and GPR32
                         Mouse/LPS/lung injury    1μg/kg, 5μg/kg (i.p)       Reduces lung injury                                      (Wang et al. 2011) 
                                                                                                       Inhibits TNFα, IL6, COX2 and iNOS,             
                                                                                                       Inhibits MAPK and NFκB 
                        Rat/LPS/lung injury             5μg/kg (i.v)                 Promotes alveolar fluid clearance                 (Wang et al. 2014) 
Increases Na, K-ATPase activation
via ALX/cAMP/PI3K
                        Macrophages/LPS               50nM                         Reduces TNFα via inhibition of NFκB           (Lee et al. 2013) 
Enhances phagocytosis
                        Mouse/peritonitis              300ng/mouse (i.p)         Reduces TNFα  
                        Microglia/LPS                   10, 100nM                     Reduces TNFα, IL1β, and iNOS                     (Xu et al. 2013) 
                                                                                                       Inhibits MAPK and NFκB  
                        Microglia/SOD1                 26.6nM                         Reduces TNFα, IL6                                        (Liu et al. 2012) 
Microglia 1,10,100nM Increases microglia activation, (Li et al. 2014)
                                                                   100nM                         Enhances STAT6 and PPRγ activation 
Human macrophages 0.1-100nM Enhances macrophage efferocytosis (Mccauley et al. 2014)
of apoptotic osteoblasts
Mouse/peritonitis 1-100ng (oral) Reduces leukocytes infiltration (Recchiuti et al. 2014)
0.1-100nM Limits recruitment of human PMNs (Norling et al. 2012)
via ALX and GPR32
Mouse/peritonitis 0.1-10ng (i.v) Decreases prostaglandin and
leukotrienes via ALX
Mouse/UUO 4ng/g(i.v) Inhibits fibroblast proliferation (Qu et al. 2012)
Mouse/nephropathy 4ng/g(i.p) Renoprotective on podocytes (Zhang et al. 2013)
                      Cancer cells/TGF1β           1,10,100,200 n M          Inhibits EMT via ALX and GPR32                    (Lee et al. 2013)     
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Continued
Inhibits cell invasion and migration
Fibroblasts/LPS 10, 50,100nM Decreases COX2, PGE2 and PGD2 (Wu et al. 2013)
                     Mouse/high-fat model              10nM                        Reduces TNFα, IL1β, IL6 and IL12                    (Claria et al. 2012) 
RvD2           Mouse/colitis                0.1, 0.3, 1μg/mouse (i.v.)     Reduces TNFa, IL1β, MIP2, NFκB                    (Bento et al. 2011) 
Human macrophage 0.1-100nM Enhances macrophage efferocytosis (Mccauley et al. 2014)
of apoptotic osteoblasts
Mouse/ peritonitis 10-10000pg/mouse Reduces leukocytes infiltration (Spite et al. 2009)
                    Mouse/microbial sepsis        100ng/mouse (i.v)         Decreases TNFα, IL1β, IL6, IL10,  
IL17, IL23, MIP2, PGE2 and LTB4
Enhances macrophage phagocytosis
                    Cancer cell/TGF1β            1,10,100,200 n M             Inhibits cell invasion and migration                       (Lee et al. 2013) 
                    Mouse/high-fat model              10nM                         Reduces TNFα, IL1β,IL6 and IL12                      (Claria et al. 2012) 
RvD3 Mouse/peritonitis 10ng/mouse (i.v) Inhibits neutrophil infiltration (Dalli et al. 2013)
Enhances macrophage phagocytosis
Decreases IL6, MCP1, PGD2, LTB4, TxB2
RvD5 Mouse/bacterial infection 0.01-100nM Increases macrophage phagocytosis (Chiang et al. 2012)
AT-RvD1     Macrophage/LPS                 300μM                           Reduces TNFα, IL6, COX2, MCP1 via ALX        (Bento et al. 2011)          
                    Mouse/colitis             0.1, 0.3, 1μg/mice (i.v.)            Reduces TNFα, IL1β, MIP2, NFκB                   
Mouse/lung injury 500ng/mouse (i.v) Reduces lung injury (Tang et al. 2014)
                                                                                                       Decrease TNFα, IL6, and NFκB activation                        
Mouse/surgical model 100ng/mouse (i.p) Reduces release of IL6 (Terrando et al. 2013)
Macrophage/LPS                  50nM                            Decreases release of TNFα
                    Mouse/high-fat model           10nM                            Reduces TNFα, IL1β, IL6 and IL12                     (Claria et al. 2012) 
AT-RvD3 Mouse/peritonitis 10ng/mouse (i.v) Inhibits neutrophil infiltration (Dalli et al. 2013)
Enhances macrophage phagocytosis
Decreases IL6, MCP1, PGD2, LTB4 and TxB2
Table 1.2 Anti-inflammatory and pro-resolving roles of D-series resolvins in various models and cell types. Abbreviation: 17(R)HDHA:
17(R)-hydroxy docosahexaenoic acid; RvD1-3,5: resolvin D 1-3,5; AT-RvD1,3: aspirin-triggered RvD1,3. i.p : intraperitoneal , i.v: intra-
venous.
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RvE1 has been reported to enhance macrophage phagocytosis in peritonitis and
limits leukocyte recruitment in the TNFα-induced inflammatory air-pouch model, peri-
tonitis model and 2,4,6-trinitrobenzene sulfonic acid (TNBS) induce colitis (Arita et al.
2005; Arita et al. 2005; Arita et al. 2006; Schwab et al. 2007). RvE1 increases phos-
phorylation of MAPK in human blood leukocytes, down-regulates expression of IL12
in dendritic cells , inhibits NFκB activation in HEK-chemR23 cells via ChemR23 (Arita
et al. 2005), inhibits expression of TNFα, IL12, COX2 and iNOS in colitis (Arita et al. 
2005) and reduces TNFα expression in peritonitis (Arita et al. 2006). It has been re-
ported that RvE1 reduces PMN infiltration in a BLT1-dependent manner (Arita et al.
2007), promotes macrophage phagocytosis and reduces neutrophil infiltration and
pro-inflammatory cytokines (TNFα,IL1β and IL6) in peritonitis (Oh et al. 2011). In a 
rabbit periodontitis model, RvE1 protects inflammation (ligation and gingivalis)-
induced bone loss and tissue damage (Hasturk et al. 2006). RvE1 reduces L-selectin
and CD18 expression on both PMNs and monocytes which are critical for early leu-
kocyte activation and transmigration of neutrophils respectively, and inhibits ADP
and thromboxane receptor-stimulated platelet aggregation (Dona et al. 2008). In the
asthma, RvE1 attenuates airway hyperresponsiveness, inhibits asthmatic inflamma-
tion and down-regulates IL13 expression (Aoki et al. 2008). RvE1 reduces myofibro-
blasts proliferation and macrophage infiltration in the obstructed kidney of mouse
model and primary renal fibroblasts and these effects are mediated by ChemR23
(Qu et al. 2012). RvE1 was also reported to modulate bone resorption and bone for-
mation (see 4.1.2).
Similar to RvE1, RvE2 is generated from 18-HEPE via 5-LOX in human neutrophils
and is revealed to inhibit PMNs infiltration in peritonitis (Tjonahen et al. 2006). RvE2
also prevents chemotaxis of neutrophils, enhances macrophage phagocytosis and
IL10 and interacts with BLT1 and ChemR23 in human leukocytes (Oh et al. 2012).
RvE3 was identified recently in eosinophils and was biosynthesized via 12/15-LOX
and was shown to inhibit neutrophil infiltration in peritonitis and chemotaxis of PMNs
from murine bone marrow (Isobe et al. 2012). The anti-inflammatory and pro-
resolving actions of E-series resolvins are summarized in Table 1.3.
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Table 1.3 The anti-inflammatory and pro-resolving actions of E-series resolvins in various models
Lipid Mediator Species /Model Dose/ route Action(s) Ref
RvE1 Mouse/peritonitis/air pouch 100ng/mouse (i.v) Limits leukocytes recruitment (Arita et al. 2005)
                          Dendritic cells                             1μg/ml                   Decreases IL12 
Lukocytes/HEK cells 100nM Inhibits NFκB and increases MAPK
Mouse/peritonitis/colitis         1μg/mouse (i.p)          Prevents leukocytes infiltration      (Arita et al. 2005)
                          Mouse/colitis                          1μg/mouse (i.p)          Decreases TNFα, IL12, COX2 and iNOS 
                          Mouse/peritonitis                    100ng/mouse (i.v)      Inhibits PMNs infiltration and TNFα                (Arita et al. 2006) 
                          Rabbit/periodontitis                    4μg/topical              Attenuates tissue damage and bone loss   (Hasturk et al. 2006)
                          Mouse/peritonitis                    1μg/mouse (i.p)          Inhibits leukocytes infiltration                       (Schwab et al. 2007) 
Enhances macrophage phagocytosis
                          Mouse/peritonitis                    100ng,1μg (i.v)           Reduces PMNs infiltration via BLT1                (Arita et al. 2007) 
Human blood samples 30nM Decreases L-selectin and CD18 (Dona et al. 2008)
Human blood samples 100nM Inhibits platelet aggregation
                          Mouse/asthma                         1μg/mouse (i.p)        Attenuates airway hyperresponsiveness         (Aoki et al. 2008) 
Inhibits airway inflammation and IL13
Mouse/peritonitis/air pouch 20,100ng(i.v) Decreases PMNs infiltration (Oh et al. 2011)
Human macrophages 1,10nM Increases macrophage phagocytosis
                                                                                                            Reduces TNFα,IL1β and IL6                                  
Mouse/UUO, 4ng/g(i.v) Inhibits fibroblast proliferation (Qu et al. 2012)
Renal fibroblasts 0.25-10ng/ml Inhibits fibroblast proliferation via ChemR23
18S-RvE1 Mouse/peritonitis/air pouch 20ng,100ng (i.v) Decreases PMNs infiltration (Oh et al. 2011)
Human macrophages 1,10nM Increases macrophage phagocytosis
RvE2 Mouse/peritonitis 1, 10,100ng (i.v) Reduces PMNs infiltration (Tjonahen et al. 2006)
Human leukocytes 10nM Prevents neutrophil chemotaxis (Oh et al. 2012)
Human macrophage 1, 10,100nM Enhances macrophage phagocytosis and IL10
Human whole blood 30nM Decreases CD18 in leukocytes (integrin)
RvE3 Mouse/peritonitis 10ng (i.v) Inhibits neutrophil infiltration (Isobe et al. 2012)
PMNs 10nM Prevents PMNs chemotaxis
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1.5.4Actions of resolvins and other anti-inflammatory mediators on pain modulation
In addition to anti-inflammatory roles, anti-nociceptive and anti-hyperalgesic actions
of resolvins are emerging and have been investigated in various pain models (Ji et al.
2011).
Pre-treatment with 17(R)HDoHE (i.p.), aspirin-triggered resolvin D precursor, attenu-
ates both mechanical and thermal hyperalgesia in adjuvant-induced arthritis (AIA).
Post-treatment with 17(R)HDoHE ( i.p.) reduced mechanical hyperalgesia, inhibited
activation of NF-kB and COX-2 in the DRG and the spinal cord and decreased
mRNA level of COX2 in spinal cord (Lima-Garcia et al. 2011). Single dosing of 17(R)
HDoHE (i.p) only decreased mechanical hyperalgesia at day 14 and didn’t attenuate
pain behaviour at day 35. Repeated administration of 17(R)HDoHE (i.p.) (once a day
for 5 days or AT-RvD1 (i.p.) for 3 days) attenuated joint stiffness and mechanical hy-
peralgesia and down-regulated expression of TNFα and IL1β in the hindpaw (Lima-
Garcia et al. 2011).
Intradermal pre-treatment with RvD1 attenuated TRP-mediated and formalin-induced
pain (hind paw licking/flicking or flinching), prevented mechanical and thermal pain in
CFA model and inhibited responses to TRPA1, TRPV3 and TRPV4 in (human em-
bryonic kidney) HEK293T cells and DRG neurons (Bang et al. 2010). Spinal pre-
treatment or post-treatment with RvD1 reduced the mechanical allodynia in the inci-
sion surgery model and skin/muscle incision and retraction (SMIR) model (Huang et
al. 2011). RvD1 was reported to attenuate mechanical allodynia in chronic pancreati-
tis (CP) and inhibit expression of pNR1 (subunit of NMDA receptor), pNR2B, TNFα, 
IL1β and IL-6 in the spinal cord (Feng et al. 2012). AT-RvD1 attenuated TRPV3-
mediated pain behaviour and reversed thermal hypersensitivity in the CFA model
and farnesyl pyrophosphate (FPP)-induced model (Bang et al. 2012). Intrathecal in-
jection of AT-RvD1 reduced mechanical hypersensitivity in carrageenan model and
TNFα release in cerebrospinal fluid (CSF) from the model or cultured astrocytes 
(Abdelmoaty et al. 2013). Single or repeated administration of AT-RvD1 and RvD2
decreased mechanical allodynia and thermal hypersensitivity in reserpine-induced
fibromyalgia-like model with these effects associated with increased levels of dopa-
mine in the cortex and 5-HT in the thalamus (Klein et al. 2014). Spinal administration
of RvD2 inhibited capsaicin and formalin-induced spontaneous pain and reduced
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heat hyperalgesia and mechanical allodynia in carrageenan and CFA-induced mod-
els (Park et al. 2011). RvD2 was reported to block TRPV1/A1 agonist-induced cur-
rents in DRG neurons and reversed C-fibre-induced LTP in the spinal cord after elec-
trical stimulation of sciatic nerve (Park et al. 2011).
Xu and colleagues conducted a series of experiments investigating anti-hyperalgesic
effects of RvE1 on inflammatory, post-operative and neuropathic pain. They revealed
intrathecal pre-treatment with RvE1 reduced formalin-induced second phase of pain
behaviour via ChemR23 and post-treatment with RvE1 attenuated heat hyperalgesia
in CFA and carrageenan models (Xu et al. 2010). Intraplantar or spinal administra-
tion of RvE1 attenuated formalin-induced and capsaicin-induced spontaneous pain
and SNL-induced neuropathic pain. RvE1 reduced paw edema, neutrophil infiltration
and expression of TNFα, IL1β, IL6, MCP1 and MIP1α in the hindpaws from a carra-
geenan model. Further experiments showed RvE1 attenuated inflammatory pain by
blocking TRPV1, TNFα and ERK phosphorylation (Xu et al. 2010). In the same study, 
RvD1 was reported to attenuate inflammatory pain in carrageenan and CFA models
and incision-induced post-operative pain by intrathecal and intraplantar administra-
tion (Xu et al. 2010). Pre-treatment with RvE1 (i.t) attenuated nerve injury-induced
mechanical allodynia and inhibited microglia activation and TNFα expression in the 
spinal cord in the CCI model. Post-treatment with RvE1 reversed mechanical allo-
dynia and thermal hyperalgesia in the SNL model. RvE also reversed LPS-induced
microgliosis in a dose-dependent manner and TNFα release in cultured microglia (Xu 
et al. 2012).
Some other lipid mediators from Ω-3 PUFAs such as NPD1 (Park et al. 2011; Xu et
al. 2013) and maresin1 (Serhan et al. 2012) or arachidonic acid derived lipoxins (Hu
et al. 2012; Wang et al. 2014) also show potential anti-nociceptive and anti-
hyperalgesic effects on pain modulation. The anti-nociceptive and anti-hyperalgesic
actions of resolvins are summarized in Table 1.4.
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Table 1.4 The anti-nociceptive and anti-hyperalgesic actions of resolvins in various models
Lipid Mediator Species /Model Dose/ route Action(s) Ref
17(R)HDoHE Rat/AIA 300ng (i.p) Attenuates mechanical and (Lima-Garcia et al. 2011)
thermal hyperagesia
Day 3, single 300ng (i.p) Attenuates mechanical hyperalgesia
Inhibits activation of NFκB and COX2 in spinal cord and DRG
Decreases m RNA level of COX2 in spinal cord
Day 14, single 600,900 (i.p) Attenuates mechanical hyperalgesia
Day 3, repeat 300ng (i.p) Attenuates joint stiffness and mechanical hyperalgesia
                                                                                                       Decreases TNFα and IL1β in the hindpaw 
AT-RvD1 Day 3, repeat 100ng (i.p) Attenuates joint stiffness and (Lima-Garcia et al. 2011)
mechanical hyperalgesia
                                                                                                       Decreases TNFα and IL1β in the hindpaw 
                             Mouse/CFA/FPP            30μM (i.d)                   Inhibits thermal hypersensitivity                        (Bang et al. 2012) 
                             Keratinocytes                     3μm                        Inhibits TRPV3 activity 
Rat/carrageenan 3,300ng (i.t) Reverse mechanical allodynia (Abdelmoaty et al. 2013)
                                                                      300ng (i.t)                 Decrease TNFα in CSF 
                             Astrocytes/LPS/INFγ        500nM                      Reduces TNFα release 
                            hAstrocytes/TNFα            265nM                       Inhibits ERK activation 
Mouse/fibromyalgia 300ng (i.v) Inhibits mechanical allodynia (Klein et al. 2014)
Attenuates thermal hyperalgesia
Mouse/fibromyalgia 80ng (i.t) Inhibits mechanical allodynia and thermal hyperalgesia
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Lipid Mediator Species /Model Dose/ route Action(s) Ref
RvD1 Mouse/carrageenan/CFA 20ng (i.t) Inhibits Inflammatory pain (Xu et al. 2010)
Mouse/incision 20ng (i.pl.) Attenuates post-operative pain
Mouse/ TRP-mediated 20ng (i.d) Attenuates licking/flicking or flinching (Bang et al. 2010)
Mouse/formalin 20ng (i.d) Attenuates licking/flicking or flinching
Mouse/CFA 20ng (i.d) Attenuates mechanical and thermal pain
HEK293T/neurons 100-1000nM Inhibits TRPA1, TRPV3 and TRPV4 channels
Rat/ incision surgery 20ng (i.t) Attenuates mechanical allodynia (Huang et al. 2011)
and hyperalgesia
Rat/SMIR 40ng (i.t) Attenuates mechanical allodynia and hyperalgesia
Rat/CP 100ng/kg (i.t) Inhibits mechanical allodynia (Feng et al. 2012)
10, 500ng (i.t) Reduces phosphorylation of NMDA receptor subunits
                                                                      10, 500ng (i.t)              Down-regulates TNFα, IL1β and IL6 
RvD2 Mouse/capsaicin/mustard oil 10ng (i.pl) Attenuates spontaneous pain (Park et al. 2011)
Mouse/formalin 0.01, 0.1, 1ng (i.t) Inhibits the second phase pain
Mouse/carrageenan/CFA 10ng (i.t) Attenuates heat hyperalgesia and mechanical allodynia
Mouse/Capsaicin/ AITC 0.05,0.1ng/ml Inhibits TRPA1/TRPV1 currents in DRG neurons
Mouse/sciatic never 10ng (i.t) Reverse C-fibre-induced LTP
Mouse/fibromyalgia 300ng (i.v) Inhibits mechanical allodynia (Klein et al. 2014)
Attenuates thermal hyperalgesia
Mouse/fibromyalgia 40ng (i.t) Inhibits mechanical allodynia
Attenuates thermal hyperalgesia
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Lipid Mediator Species /Model Dose/ route Action(s) Ref
RvE1 Mouse/ formalin 1ng (i.t) Reduces inflammatory pain via ChemR23 (Xu et al. 2010)
Mouse/carrageenan 20ng (i.pl.) Attenuates heat hyperalgesia
Reduces paw edema and neutrophil infiltration
                                                                                                          Down-regulates TNFα, IL1β, IL6, MCP1 and MIP1α. 
Mouse/CFA 1,3,10 ng (i.t) Attenuates heat hyperalgesia
10, 30,100 ng (i.t) Inhibits mechanical allodynia
Mouse/formalin/capsaicin 20ng (i.pl.) Reduces spontaneous pain
                                                                                                         Blocks TRPV1 and TNFα signalling 
                            TNFα-induced allodynia          10ng (i.t)               Inhibits ERK phosphorylation 
Mouse/SNL 10ng (i.t) Decreases neuropathic pain
Mouse/CCI 100ng (i.t) Reduces mechanical allodynia (Xu et al. 2012)
                                                                                                         Inhibits microglia activation and TNFα expression 
Mouse/SNL 100ng (i.t) Attenuates mechanical allodynia and thermal hyepralgesia
                            Microliga/LPS                        1, 10,100ng            Prevents microgliosis and TNFα release 
Table 1.4 The anti-nociceptive and anti-hyperalgesic roles of resolvins in various models. Abbreviation: 17(R)HDoHE: 17(R)-hydroxy
docosahexaenoic acid; RvD1-2: resolvin D 1-2; AT-RvD1: aspirin-triggered RvD1. i.p : intraperitoneal , i.v: intravenous, i.d: intradermal,
i.pl: intraplantar
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1.6 Hypotheses and aims
The anti-nociceptive and anti-hyperalgesic actions of resolvins have been studied in
various pain models; however, the potential analgesic effects of resolvins in models
of OA pain have yet to be described. This thesis aims to investigate the therapeutic
potential of 17(R)HDoHE to treat OA pain in two pre-clinical models and to investi-
gate the underlying mechanisms of action.
The hypotheses tested are:
 The MIA procedure and MNX surgery can produce established pain behaviour
and joint histopathology reminiscent of clinical OA.
 Resolvin receptors (ChemR23 and ALX) are expressed by the key structures
in the knee joint likely to contribute to OA pain (synovia and bone) and levels
of expression are altered in models of OA. Expression of the resolvin recep-
tors is associated with expression of inflammatory cytokines and metabolic
enzymes in the knee joint in these two OA models.
 Systemic administration of 17(R)HDoHE can block OA pain in these two
models and the analgesic effects of 17(R)HDoHE on OA pain are mediated by
effects on inflammatory cytokines and/or metabolic enzymes.
 The resolvin receptors and the key metabolic enzymes are expressed in hu-
man synovia and bone from OA sufferers and expression levels of the recep-
tors are related to levels of inflammatory cytokines and the metabolic en-
zymes.
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2 Materials and methods
2.1 Introduction
The animal experiments were performed on male Sprague-Dawley rats (130-150g)
purchased from Charles River (Margate, Kent, UK) under the guidance of the
Animals (Scientific Procedures) Act 1986 and guiding principles for behavioural
laboratory animal science (Home Office, UK). Research on human samples was
approved by generic ethics for the University Hospitals Nottingham (UHN) Trust Bio-
bank, Research & Innovation (RSCH448). Human synovia and bone from joints
were collected from OA patients undergoing total knee replacement (TKR) at the City
Hospital, Nottingham and femoral heads were collected from trauma patients at UHN,
Queen’s Medical Centre campus.
2.2 Animal models of OA pain
Two models of OA, MIA (a chemical which induces chondrocyte death and cartilage
degeneration, see 1.4.2) and MNX model (a surgery with transection of medial me-
niscus) were used in this study.
2.2.1 Anaesthesia and procedure preparation
Animals were anaesthetized by inhalation of isoflurane (3% for induction and 2.5%
for maintenance) delivered in 1L/min O2 (Abbott, Kent, UK) before MIA injection or
MNX induction. Isoflurane was maintained at 2.5% once the rat was areflexic which
was confirmed by pinching the toe of the hind paw and no response was seen. The
rat was laid in the supine position and both hind legs were shaved from the ankle to
groin and diameters of both knees were measured. The entire left hind-leg was
cleaned using cotton wool soaked in 4% chlorhexidine solution (Ecolab, Leeds, UK).
EMLA Cream (provided by BSU, University of Nottingham) was used as a local an-
aesthetic for MNX or sham surgery. Rats then either underwent MIA injection or
MNX surgery.
2.2.2 Intra-articular injection of MIA to the knee joint of rats
The procedure for intra-articular injection of MIA is based on Bove’s work on the MIA
model (Bove et al. 2003) and our previous studies (Sagar et al. 2011). MIA solution
(Sigma U.K.) was made with sterile 0.9% saline (20 mg /ml Fannin, Ireland) and 50μl 
of MIA solution was injected (0 .5 ml insulin syringe (VWR international, Leicester,
UK) into the rat’s left knee joint of rat. The rat was anaesthetized (see 2.2.1), and
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placed on autoclaved blue tissue paper on a heating pad. Hands were cleaned with
alcohol to minimise bacterial transfer. The left ankle of the rat was held between the
thumb and middle finger of the left hand and was extended away from the body to
increase the space between the femoral and tibial bone. The groove between the
femur and tibial was found and was pressed with the edge of a needle to make a
mark for injection. A syringe with MIA (1mg/50μl) or saline (50μl) was placed per-
pendicular to the knee and injected to the joint cavity (1/3-1/2 of the needle was in-
serted into the space to avoid injecting through the cavity and loss of solution). The
needle was gently removed from the joint and blood (if any) was cleaned with cotton
wool. After injection, the rat was weighed and moved to a new cage on a heating
pad for recovery. Rats were checked at 1, 2 and 4 hours after the procedure and
then transferred back to the holding room or were kept overnight in the recovery
room. Health assessments were conducted for 3 consecutive days post MIA-
injection; these included body weight, joint swelling, limping, movement, hydration
and evidence of pain/suffering.
2.2.3Medial meniscus transection of knee joint of rats
The MNX surgery was performed by my colleagues based on the method previously
described (Janusz et al. 2002; Mapp et al. 2008; Mapp et al. 2013). All instruments
were autoclaved before surgery. Rats were anaesthetized (see 2.2.1) and trans-
ferred to a surgical working station in a supine position. Animals were covered by a
Buster Op-Cover (Buster, Germany) with a suitable hole to expose the left knee joint.
The skin of the medial knee joint was cut using small scissors and the superficial
connective tissue layer was cauterised with a cauterizer. The medial collateral liga-
ment was then located and removed with iris scissors. The meniscus was then tran-
sected, also with iris scissors. After the meniscus was removed, the superficial layer
of connective tissue was sutured with Ethicon coated 8/0 Vicryl (Johnson &Johnson,
Diegem, Belgium) and closed with interrupted stitches using Ethicon coated 4/0
Vicryl (Johnson &Johnson, Diegem, Belgium) or closed with skin clips (9mm, Cell
Point Scientific, Gathersburg, USA). The suture knots were buried under the skin to
minimize the risk of the rats opening their wound.
Sham surgery was performed with the same protocol as MNX surgery but without
transection of the meniscus.
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After surgery, rats were weighed and moved to a new cage and placed on a heating
pad for recovery. They were checked at 1, 2 and 4 hours post-surgery and moved
back to the holding room. Health assessments were conducted for 3 consecutive
days post-surgery with regard to body weight, joint swelling, surgical wounds, limping
and general behaviour. The diagram of the surgery is summarized in Fig 2.1.
2.3 Pain behaviour testing
Weight bearing (WB) and paw withdrawal thresholds (PWT) of hindpaws were tested
to measure pain behaviour in the MIA and MNX models of osteoarthritis. Rats were
habituated to the apparatus for WB and PWT a day before model induction. The
baseline behaviour was tested on the day before MIA injection or MNX surgery.
Pain behaviour was then tested from day 3 post-model induction until the end of the
study. All pain behaviour testing was performed in the morning and rats were habitu-
ated to the room for 30 min prior to behavioural assessment to minimize stress and
circadian variations.
2.3.1 Weight bearing and paw withdrawal threshold
Weight bearing was tested as previously described using an Incapacitance Tester
(LintonInstrumentation, Norfolk, UK) (Pomonis et al. 2005; Sagar et al. 2011). Rats
were placed in a perspex chamber (Medical Engineering Unit, University of Notting-
ham) with their two hindpaws on transducer pads and their two forepaws on the
slanted wall of the chamber, as shown in Fig2.2 A. Three readings, which recorded
weight applied each pad for 3s, were made. One or two more recordings were made
if there were large differences in the first three readings. The mean of weight bearing
differences (injured vs non-injured limb) was used for data analysis.
Paw withdrawal thresholds were tested using vonFrey hair (Linton Instrumentation,
Norfolk, UK) stimulation with different forces (in grams) of filaments. Rats were
Anaesthetize
the rat
Open skin Cauterize the
connective tissue
Remove ligament
and/or meniscus
Suture the collec-
tive tissue and skin
Recovery
Fig 2.1 The diagram of simplified procedure for MNX or sham surgery.
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placed in a plexiglass chamber with 5 compartments and a wire mesh floor (Fig2.2 B)
and were habituated for 5-10 minutes after weight bearing testing. After the rats had
acclimatised to the chamber (as indicated by sitting still and no longer engaging in
exploratory behaviour) , vonFrey hairs were applied to the central plantar surface of
the hindpaw. The testing force of stimulation was 1, 1.4, 2, 4, 6, 8, 10, 15 and 26g.
Briefly, stimulation started at 4g and 3 different sites of the central plantar surface of
the hindpaw were stimulated at 3s interval between each stimulation. A stimulation
force was then increased to 6g or decreased to 2g depending on whether there was
a withdrawal response to the 4g hair. The lowest force which elicited a paw with-
drawal was recorded as threshold. If no response were observed up to 26g, it was
recorded as > 26g; higher forces were not used in order to prevent tissue damage.
All the instruments and the chamber were cleaned with 20% ethanol after behav-
ioural testing.
A B
Fig 2.2 Pain behavioural testing for OA. Weight bearing was measured by an incapcitance
tester (A) and paw withdrawal threshold was tested in a plexiglass chamber by vonFrey mon-
ofilaments (B).
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2.3.2 Intraperitoneal drug administration
17(R)HDoHE is a oxygenated derivative from DHA via aspirin / COX2 and is the
precursor of AT-RvD (Serhan et al. 2002). The drug was bought from Cayman
Chemical, USA and the structure is shown in Fig 2.3:
17(R) HDoHE was made up from the stock (100μg / 1ml in ethanol) by diluting in 
normal sterile saline to give a concentration of 1ng per μl, 300 μl of which was then 
intra-peritoneally injected. Vehicle injection consisted of a 1% ethanol solution in sa-
line. To minimise potential subjective bias, drugs were administered in a blinded
fashion. Rats were habituated to i.p injection every other day for two weeks by injec-
tion of 300μl of 0.9% saline with a 1ml syringe (25G needle, BD microlance, Louth,
Ireland). The drug or vehicle was administered by intra-peritoneal (i.p) injection on
day 14 post-MIA injection or MNX surgery.
2.3.3 Data analysis
The behaviour data were analysed by GraphPad Prism Version 5/6 (GraphPad
Software Inc., USA) and presented as mean±S.E.M (standard error of mean). Pain
behavioural data in different groups were analysed by two-way ANOVA with Bonfer-
roni’s post-hoc test with p<0.05 indicating statistical significance.
Fig 2.3 The structure of 17(R) HDoHE.
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2.4 Tissue collection
Tissues were collected at the end of each study. Spinal cords, DRGs, synovia and
blood were freshly collected and knee joints were fixed in 10% neutral-buffered for-
malin.
2.4.1 Reagents
Heparin sodium
Liquid nitrogen,
10% neutral buffered formalin:
100ml methanal
900ml double distilled water
4g NaH2PO4
6.5g Na2HPO4
2.4.2 Euthanasia
Rats were sacrificed by a Schedule 1 technique after pain behaviour testing at the
end of the study. Rats were placed in an acrylic chamber and carbon dioxide deliv-
ered at 2L/min for 6 min or until respiration ceased (Coenen et al. 1995; Smith and
Harrap 1997). Death was confirmed by checking the corneal reflex.
2.4.3 Blood, synovia and femorotibial joints
Blood (approximately 4ml) was collected in a container with 50μl (50 units) of heparin 
sodium and was gently shaken up and down to mix blood and heparin and then was
immediately transferred onto wet ice to minimize the coagulation and post-mortem
changes. After tissue collection, each container of blood was divided into two 2 ml
polypropylene tubes and centrifuged (at 4°C) for 10 min at 10000 g to separate
plasma from blood cells. The supernatant layer was transferred to new 2ml polypro-
pylene tubes and stored at -80°C.
The skin over the knee joint was opened with a scalpel, the synovium with patella
and infra-fat pad was gently removed from the femorotibial joint and then the patella
was cut. The synovium was isolated from the infra-fat pad, placed in a cryo-vial and
immediately snap frozen in liquid nitrogen. The femorotibial knee joint was cut with a
bone clipper and the muscles were trimmed from the joint to minimize the soft tissue
which could slow fixation. Each joint was fixed in a tube containing about 20 ml of 10%
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neutral-buffered formalin for 48 h and decalcified with diamonoethanetetra-acetic ac-
id disodium salt dehydrate (EDTA, Fisher scientific, UK) solution for 4-6 weeks for
joint histology (see 2.5). Both ipsilateral and contralateral synovia and knee joints
were taken.
2.4.4 Spinal cord and DRG
The spinal cord was taken immediately after blood collection based on previous
studies (Woodhams et al. 2012) but was split into four parts (ipsi-dorsal, ipsi-ventral,
contra-dorsal and contra-ventral side). Rats were placed in the prone position and
the skin was opened from the midline of the back with a scalpel. Muscles covering
the spine and spinous processes were removed with rongeurs. The vertebral lamina
was carefully removed from the caudal (bottom) to rostral (top) terminals and the
bone was trimmed to expose the spinal cord which was excised with small sharp
scissors. The spinal cord was gently lifted away from the column with fine forceps
and the dorsal roots on the two sides were carefully cut. Spinal cord was placed on a
metal plate with dorsal side upward. Dura and vessels around the spinal cord were
removed and the lumber section cord (L3-5) was cut away. The cord was flipped
over to make the ventral side uppermost with the ipsilateral cord on the right-handed
side and contralateral side on the left-handed side. The cord was split into ipsi- and
contra- lateral sides along the midline with a sharp scalpel and then ipsi- and contra-
lateral sides were split into dorsal and ventral parts respectively. The four quadrants
of spinal cord were placed into cryo-vials and immediately snap frozen in liquid nitro-
gen. DRGs (L3-5) were removed under a dissecting microscope immediately after
the spinal cord was taken as described in previous studies (Wood et al. 1988; Sagar
et al. 2005). Briefly, spinal nerves and roots were cleaned under microscope to ex-
pose the DRGs with conjunctival scissors and fine forceps. DRGs were placed in
cryo-vials and snap frozen in liquid nitrogen immediately.
All the fresh tissues were kept at -80°C for long-term storage and were used for
Taqman RT-qPCR (see2.8). Formalin-fixed knee joints were used for joint histology
(see 2.5 - 2.7).
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2.5 Knee joint processing
2.5.1EDTA decalcification and wax embedding
Joint processing was conducted as previously described (Mapp et al. 2013). Knee
joints were fixed in neutral-buffered formalin for 48 h after tissue collection (see
2.4.3). Formalin buffer was replaced with EDTA buffer and tubes were placed on a
shaker to agitate the solution and aid with decalcifying the joints. EDTA buffer was
changed twice a week for 4-6 weeks. The decalcification of joints was confirmed by
splitting the joint into anterior and posterior sections along the lateral collateral liga-
ment but was split in sagittal transection. If joints were fully decalcified, splitting was
easily achieved. Joints were placed in printed plastic cassettes with unique code for
each joint. Joint samples were sent to King’s Mill Hospital, Nottingham, where they
were dehydrated and incubated overnight before paraffin wax embedding.
Briefly, knee joints in cassettes were placed in a warming molten wax module of a
Tissue-Tek® TEC® 5 EME2 Tissue Embedding Console system (Sakura Finetek
Europe, the Netherlands) to incubate the samples and metal moulds were heated in
the other module of the Tissue-Tek to clean them for embedding. The temperature
was controlled at 62°C. The empty mould was filled with melting wax and placed on
a hotplate. Knee joints were placed in the middle of the mould with the flat side fac-
ing down. Joints were cooled down on a cold plate for a few seconds to fix the sam-
ple and then the mould was covered with the lid of the plastic cassette. The whole
block of knee joint was cooled down on the Cryo Module of Tissue-Tek to tightly em-
bed the sample. After the blocks were completely cold, they were taken out from
moulds with a spatula and were kept at room temperature.
2.5.2Sectioning knee joints with a microtome
The joints were cut based on previous studies (Gerwin et al. 2010). Joint sections
from medial and lateral parts were cut in coronal transection. All the medial blocks of
joints were cut on a rotary microtome (Slee cut 4060, Slee Medical GmbH, Mainz,
Germany) based at the Advanced Microscopy Unit (AMU), University of Nottingham.
Briefly, each block was fixed on the rack of the microtome and adjusted to make it
parallel to the edge of blade. Wax was removed from the block until tissue appeared.
The first 500μm of tissue was removed from the top to get a suitable transection of 
the joint. Several consecutive sections were cut and floated on a surface of warm
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water in a paraffin section mounting bath. Sections were mounted on 3-
aminoproplytriethoxysilane (APES)-coated slides and heated on a thermal plate at
40°C. 30 sections were cut from each block at 5 levels with 6 sections per level and
200μm intervals between each level. The slides were kept at room temperature for 
future use.
2.6 Haematoxylin and eosin staining
H&E staining was used to enable morphological assessment of the joint sections.
Haematoxylin stains the nuclei blue and eosin stains the cytoplasm pink because of
their respective affinities for basophilic and eosinophilic structures (Fischer et al.
2008; Cardiff et al. 2014). I selected 4 sections of joint with good quality of structure
from 4 different levels in 30 sections (5 levels, 6 sections per level) from each block
for staining. The staining was performed at AMU.
2.6.1 Haematoxylin&eosin staining
Knee joint slides were placed on a staining rack and sections were dewaxed by xy-
lene (5 min) and a series of descending concentrations of industrial methylated spir-
its (IMS) (100%, 100%, 90%, 70% and 50%, 30s for each concentration) and rehy-
drated in tap water for 30s. Sections were stained by Harris Haematoxylin for 5 min
and the rack was gently lifted up-and-down to ensure full contact with staining solu-
tion. Sections were washed under running tap water until the water was clear. Then
sections were dipped in acid alcohol for 5-10 s to remove excess staining and
washed again with tap water. Sections were placed in Scott’s tap water for 15s and
washed with normal tap water. The sections were viewed under a microscope to
confirm the presence of blue dye. After that, the sections were stained with 1% eosin
for 5min and washed with running tap water until clear. The sections were dehydrat-
ed with a series of ascending concentrations of IMS (50%, 70%, 90%, 100% and
100%, 10s for each concentration) and were placed in fresh xylene twice (2min each)
to remove residual IMS. A drop of dibutyl phthalate in xylene (DPX) was added on a
coverslip and the coverslip was placed on top of section/slide. The slides were
placed in a fume hood for 4-6 hours or overnight to evaporate xylene and dry the
sections.
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2.7 Histological scoring for H&E stained knee joint sections
The scoring was blinded and performed under an upright microscope (Leica
DB4000B, Germany) with 25 and 100 magnifications at AMU.
2.7.1Histological scoring system
As described above (2.6), I selected and scored 4 sections from each stained sam-
ple. The chondropathy, synovial inflammation, chondrocyte appearance (proliferation,
nuclear cloning and loss of chondrocyte) and osteochondral junction integrity (vascu-
lar channels/mm length of medial tibial plateau) for each section were scored. The
chondropathy of medial tibial plateau, which indicates cartilage damage in the joint
was assessed by the Janusz scoring system (Janusz 2002). Briefly, cartilage dam-
age of the medial tibial plateau was scored on a 0 to 5 scale as follows:
0 = Cartilage of normal appearance
1 = Minimal fibrillation in superficial zone only
2 = Mild, extends into the upper middle zone
3 = Moderate, well into the middle zone
4 = Marked, into the deep zone but not to the tidemark
5 = Severe, full thickness degeneration to the tidemark
The proportion of involved damage of the tibial plate was assessed by 1/3, 2/3 or 3/3,
so the total chondropathy score was cartilage score multiplied by the length of in-
volvement of the tibial plate (1, 2 or 3).
Synovial inflammation, chondrocytes appearance and ostechondral junction integrity
were scored based on previous studies (Mapp et al. 2008; Mapp et al. 2013). Briefly,
synovial inflammation was evaluated by the thickness of cellular layers of synovia
and was scored on a scale of 0 to 3 as follows:
0 Lining cell layer 1-2 cells thick
1 Lining cell layer 3-5 cells thick
2 Lining cell layer 6-8 cells thick and/or mild increase in cellularity.
3 Lining cell layer > 9 cells thick and/or severe increase in cellularity.
Chondrocytes appearance was scored on cloning and death of chondrocytes in the
cartilage as follows:
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0 = No chondrocyte cloning observed (normal appearance and density)
1 = Diffuse hypercellularity of chondrocytes.
2 = Chondrocyte cloning (2 instances of single cloned chondrocyte with 4 nuclei)
3 = Chondrocyte hypocellularity.
Integrity of the osteochondral junction was quantifying by counting the number of
vascular channels breaching the osteochondral junction (the interface between carti-
lage and subchondral bone) and dividing the length of the medial tibial plateau. Im-
ages were taken under a microscope at different magnifications after the scoring.
The simplified procedure for knee joint processing is shown in Fig 2.4.
Knee joints Fxied knee joints
10% neutral-buffered
formalin Decalcification
4-6 w
Decalcified knee joints
Paraffin
embedding
Paraffin embedded block
Splitting into medial
and lateral parts
Knee joint sections
Microtome
5μm
Stained sections
H&E staining
Fig 2.4 The key procedures for histopathological assessment of ipsilateral knee joints. Knee
joints were fixed in 10% neutral-buffered formalin and decalcified for 4-6 weeks. After the
decalcification, knee joints were split in to medial and lateral parts and embedded in paraf-
fin. Medial tibial plateau of ipsilateral knee joints were cut by microtome, stained with H&E
and scored under the microscope.
Knee joint scoring
Microscope
63
2.7.2Data analysis
Data were analysed by Graphpad Prism 6 and are presented as mean±S.E.M.
Histological scoring for different groups was analysed by one-way ANOVA with
Bonfferoni’s post-hoc test and p<0.05 was considered statistically significant.
2.8 Gene expression quantified by Taqman quantitative Real-Time Polymerase
Chain Reaction (RT-qPCR)
2.8.1Principles of Taqman quantitative RT-qPCR
RT-PCR is a complex reaction system involving RNA extraction, biosynthesis of
cDNA and amplification of cDNA and the reaction system includes essential com-
ponents such as dNTP, primers; probes, DNA polymerase, reverse transcriptase and
RNA inhibitor (see details in 2.8.3-2.8.9) (Ohan and Heikkila 1993). There are differ-
ent fluorescent based systems available, such as SYBR®Green (Carl T. Wittwer et
al. 1997), TaqMan® (Pamelam. Holland et al. 1991), Scorpions (Whitcombe et al.
1999) and Molecular Beacon (Sanjay Tyagi and Kramer 1996), which can detect
production of DNA, cDNA or RNA in real time.
Thermus aquaticus (Taq) DNA polymerase is a thermostable enzyme which has 5´ -
3´ exonuclease activity and can cleave probes into small fragments (Pamelam. Hol-
land et al. 1991). The Taqman probe is a specific sequence of nucleotides which has
a fluorescent reporter dye (6-carboxyfluorescein, FAM) at the 5’ end and quencher
dye (6-carboxytetramethylrhodamine, TAMRA) at the 3’ end and can hybridize with
its target. The primer and probe bind with the target sequence when annealing. Taq
DNA polymerase is activated and binds to the primer to extend the template of the
target sequence. When the complex attaches to the probe, the polymerase cleaves
the probe which allows the extension to continue to the end and release the fluores-
cent reporter from the probe. In this way, the fluorescent signals accumulate and can
be detected at a cycle threshold (CT value) (Fig 2.5). As PCR cycles continue, the
number of copies of target sequence exponentially increase after the PCR product is
first detected and finally the PCR reaction reaches a plateau stage when the assay
components are limiting (Arya et al. 2005).
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3’
2.8.2Design of primers and probes
Expression levels of resolvin receptors (ChemR23 and ALX), inflammatory cytokines,
and their metabolic enzymes were quantified by Taqman RT-qPCR in synovia and
spinal cords from rats and synovia, tibial plate, femoral condyles and femoral heads
from human subjects. The design of primers and probes was based on published
mRNA sequences (found at NCBI) and Primer Express® software v 3.0. As the ge-
nome consists of coding and non-coding sequences, designed sequences of primers
and probes were generated from the coding sequences spanning over exon-exon
junctions. Minor groove binding (MGB) probes were employed when the regular
probes could not be designed. The MGB probes, which can bind with complemen-
tary DNA at an enhanced melting temperature (Kutyavin et al. 2000), are more spe-
cific, shorter and more efficient sequences than regular designed probes. Primers
and probes were designed according to some general rules such as appropriate
length of bases (18-30 bp), optimal melting temperatures for primers (58-60°C) and
probes (69-70°C), percentage of GC content (30-80%) and avoiding primer-dimer
5’
cDNA (template strand)
5’
cDNA (template strand)
Taq DNA polymerase
Annealing
Extension
Reporter Quencher
Primer Probe
Fig 2.5 Principle of Taqman RT-qPCR. Both the primer and probe anneal to the target se-
quence but no fluorescence is detected when the probe is intact. Then Taq DNA polymer-
ase binds to the primer and start to extend the template. When the polymerase attaches
to the probe, the 5' →3' exonuclease cleaves the reporter from the probe and releases the 
signal fragment. As PCR cycles continue, the intensity of the fluorescent signals is accumu-
lated and can be detected at a threshold cycle. The reaction reaches a plateau stage and
fluorescent signals are not increased.
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formation. When designing the primers and probe of a target gene, the mRNA se-
quence from NCBI was copied into Primer Express3 software, and exon-exon junc-
tions were found in the sequence. After the primers and probes were designed, the
sequences were “blasted” at NCBI to confirm that they were 100% specific to the
target genes. The primers and regular probes were synthesized by Eurofins MWG
Operon (Germany). MGB probes were synthesized by Applied Biosystems (Cheshire,
UK). The specific sequences of primers and probes for rat (Table 2.1) and human
(Table 2.2) are shown below:
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Target gene Forward Primer Sequence Reverse Primer Sequence Probe sequence
β-actin CGTCCACACCCGCCG CACAGCCTGGATGGCTACGT TGAGACCTTCAACACCCCAGCCATG
ChemR23* AGGACCTACCCTCGAGTTCTATTCT CGTAGATGCTGGAGTCGTTGTAA TCCAAAGAGATGGAGTACGA
ALX CTTGGACCGCTGCATTTGT CCTTCCTAGCCAGGCTCACA CAGTCTGGGCTCAGAACCACCGC
TNFα GCAGGAGAAAGTCAGCCTCCT TACTACCAGGGCTTGAGCTCA AGAGCCCTTGCCCTAAGGACACCCCT
IL1β CACCTCTCAAGCAGAGCACAG GGGTTCCATGGTGAAGTCAAC TGTCCCGACCATTGCTGTTTCCTAGG
IL6* CAGAGCAATACTGAAACCCTAGTTCA CCATTAGGAGAGCATTGGAAGTTG TTCAAACAAGAGATAAAAGACTC
IL10 GAAGCTGAAGACCCTCTGGATACA CCTTTGTCTTGGAGCTTATTAAAATCA CGCTGTCATCGATTTCTCCCCTGTGA
5-LOX* TGGTGTCTGAGGTGTTCGGTAT GGCAATGGTGAACCTCACATG CCCTTTTCAAGCTGCTG
FLAP CCCCACTTTCCTTGTGGTACTC TGCCTCACGAACAGATACATCAG AGCCAAGTCCCCGCCGCCT
15-LOX TGATGCCTGATGGACAACTCTT CCGAGGGCGTGAAAATAGG CCATAGCCATCCAGCTTGAACTTCCCA
COX2 GCACAAATATGATGTTCGCA CCTCGCTTCTGATCTGTCTTGA TCTTTGCCCAGCACTTCACTCATCAGTTT
EPHX2 GCCAGTTTGAACACTCCATTAATG TTGAAAACTGGGATCGATCTGA CACCAAATCCTGAGGTGTCCCCCA
CYP2J2 GCAATGGATACCACTTTGAATGG CCCTGTGCAGTGCAGTTAGGT CCACCTGCCAAAGGGTACCATGGTTCT
mPGES1 GCGAACTGGGCCAGAACA GGCCTACCTGGGCAAAATG CCCCGGAGCGAATGCGTGG
iNOS CCCAGAGTCTCTAGACCTCAACAAA GCCCTCGAAGGTGAGTTGAA AAGTCCAGCCGCACCACCCTCC
GFAP TGGCCACCAGTAACATGCAA CAGTTGGCGGCGATAGTCAT CAGACGTTGCTTCCCGCAACGC
TRPV1 TCAAAGACCCAGAGACAGGAAAG CTGTCTTCCGGGCAACGT AAAAGCCATGCTCAATCTGCACAATGG
Table 2.1 Primer and probe sequences of target genes from rat were designed for Taqman RT-PCR by Primer Express 3. The se-
quences for primer and regular probe were synthesized by Eurofins MWG Operon. MGB probes were synthesized by Applied Bio-
systems. The probes with”*” are MGB probes. EPHX2: soluble epoxide hydrolase 2, CYP2J2: cytochrome P450, family 2, subfamily
J, polypeptide 2
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Target gene Forward Primer Sequence Reverse Primer Sequence Probe sequence
hβ-actin CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT ATCAAGATCATTGCTCCTCCTGAGCGC
hChemR23 CATGCCTGGCTCTGTCTTCA TGCAGCTGTTGGCAATGG TTGCCCCTGGCCACTGCCCT
hALX ACGAGCTCCCTGGCCTTCT GGAGGTCTTGGCCCACAAAG CAACAGCTGCCTCAACCCCATGC
hTNFα CCCAGGGACCTCTCTCTAATCA GGTTTGCTACAACATGGGCTACA CTCTGGCCCAGGCAGTCAGATCATCT
hIL6 CTGCAGAAAAAGGCAAAGAATCTAG CGTCAGCAGGCTGGCATT TGCAATAACCACCCCTGACCCAACC
h5-LOX GAGAGCAAAGAAGACATCCCCTACT GGCCGTGAACGTCCTGAT TTCTACCGGGACGACGGGCTCC
h15-LOX1 GGCAAGGAGACAGAACTCAAGGT GAACCAGGCGTCGTCCTTAA TGTGAAACTGCGCAAACGGCACC
h15-LOX2 CACCTGCTGCACTCACATCTG CGATGCCTGTGGACTTGAAGA CACCCTGGCTACCCTGCGTCAGC
hCOX2 GCCCTTCCTCCTGTGCC AATCAGGAAGCTGCTTTTTAC ATGATTGCCCGACTCCCTTGGGGTGT
Table 2.2 Primer and probe sequences of human target genes were designed for Taqman RT-PCR using Primer Express 3
software and were biosynthesized by Eurofins MWG Operon.
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2.8.3Reagents
RNA extraction: Trizol (TRI) reagent (Sigma, UK), 1% sodium dodecylsulfate (Fisher
Scientific, UK), liquid nitrogen, bromo-3-chloropropane (BCP, Sigma, UK), isopropa-
nol (Fisher Scientific, UK), sodium acetate (2M, pH=4), ethanol absolute (Sigma, UK),
HPLC water (Fisher Scientific, UK), RNeasy Mini Kit (Qiagen, Netherlands).
Reverse transcription: Random Primers, 500μg/ml, 20μg (Promega, USA), deoxyri-
bonucleotide triphosphate (dNTPs) mix (100mM each of dATP, dCTP, dGTP, dTTP,
Promega, USA), AfintyScript MultipleTemperature Reverse Transcriptase 200 μl, 
100mM dithiothreithol (DTT, 800μl),10xAffinityscript RT buffer 1ml (Agilent Technol-
ogy, USA), RNaseOUTTM Recombinant Ribonuclease inhibitor, 5000 Units 40U/μl 
(Invitrogen, Life Technology, USA).
Pre-amplification: 20xTris-EDTA buffer (200mM Tris-Cl, 20mM EDTA, pH 7.5, Invi-
trogen, US). Primers (see Table 2.1 and 2.2). Taqman®Fast Universal PCR Master
Mix (2x) (Applied Biosystems by Life Technology, USA)
RT-qPCR: Primers and probes (see Table 2.1 and 2.2), Taqman®Fast Universal
PCR Master Mix (2x), HPLC water, cDNA samples.
2.8.4Total RNA extraction for rat synovia and spinal cord
Total RNA was extracted from samples with TRI reagent which is a monophasic lysis
reagent that dissolves the biological material and denatures protein (Rio et al. 2010).
I followed the manufacturer’s instructions modified on the basis of previous studies
conducted within the group (Burston et al. 2013). Frozen tissue (synovium or spinal
cord) was homogenized in cold TRI reagent (1ml for synovia and 2ml for spinal cord)
and incubated at room temperature for 5 min to fully digest the nucleoprotein mixture.
BCP (0.2 ml for each 1 ml of TRI reagent) was added to isolate RNA from DNA and
protein. The samples were mixed by vigorous vortexing and centrifuged at 10000g
for 15 min at 4°C. After centrifuging, the solution was separated into three phases
with the aqueous phase containing RNA on the top, DNA at the interface and protein
in the lower organic phase. The supernatant layer containing RNA was transferred in
to fresh collection tubes and 0.25 NaAC (2M, pH4) and 0.7ml isopropanol were add-
ed and mixed thoroughly. The mixed solution containing RNA was precipitated at -
20°C for at least 30 min. Protein in the organic phase was stored at -80°C for future
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use. Precipitated RNA was pelleted by centrifugation at 17000g for 15min at 4°C.
Pellets were washed twice with 70% ethanol and centrifuged again for 10 min at
10000g. Ethanol was removed by pipetting and the remaining residues of ethanol
were evaporated under the filament lamp. Pellets were solubilized in 50μl of HPLC 
water or RNase-free water. The extracted RNA samples were heated at 65°C for 5
min to aid solubilizaiton. RNA samples were kept at -80°C for long-term storage (Fig
2.6). The concentration and purity of RNA samples were measured using
Nanodrop™ 2000 spectrophotometer (Thermo Scientific, UK). The normal spectral
absorbance ratio of 260/280 for RNA is 1.8-2.0 and ratio of 260/230 is 1.8-2.2. The
higher and lower ratios indicate protein or chemical contamination. RNA samples
were purified with an RNeasy Mini Kit if the purity of samples was outside the normal
ranges mentioned above.
Homogenize
BCP, vortex
Centrifuge Precipitate
Centrifuge
Elution
Fig 2.6 Procedure of RNA extraction from tissues. Samples were homogenized in cold TRI
reagent, vortexed with BCP and centrifuged at 10000g for 15 min at 4°C. The mixed solution
was subsequently separated into three layers with RNA, DNA and protein from top to bot-
tom. RNA was precipitated in sodium acetate and isopropanol at -20°C for at least 30min
and centrifuged at 17000g for 15 min at 4°C. Pellets were collected in 50μl of HPLC water 
after washing twice with 70% ethanol and stored at -80°C for long-term storage.
Sample
Homogenized
sample
RNA, DNA, protein
layers
RNA
pellet
RNA
stock
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2.8.5RNA purification
RNA samples were cleaned with RNeasy Mini Kit, performed according to the manu-
facturer’s instruction.  Briefly, sample volume was adjusted to 100μl with RNase-free 
water. RNeasy Lysis Buffer (RLT, 350 μl per sample, β-mercaptoethanol 10μl/ml of 
β-ME was added before using) and 250 μl of ethanol (96%-100%) was added to the 
diluted RNA and mixed thoroughly. The RNA solution (700μl) was cleaned up and 
RNA was collected in 50μl RNase-free water following the instructions. The concen-
tration and purity of RNA samples were measured by Nanodrop™ 2000 spectropho-
tometer.
2.8.6Reverse transcription with AffinityScript Reverse Transcriptase
RNA samples were reverse transcribed with AffinityScript Reverse Transcriptase fol-
lowing the manufacturer’s instructions with slight modification. Random primer and
dNTP were diluted to 0.1μg/μl and 10mM respectively as working solution. 500 ng of 
RNA was used for reverse transcription. 19.5 μl of solution for reverse transcript re-
action was made (1μl of random primer, 1μl dNTP, 500 ng RNA and appropriate 
volumes of HPLC water) to anneal primer to RNA at 65°C for 5 min and cool on ice
for 1min.  25.5 μl of solution was used to synthesize cDNA (3μl of 10xAffinityscript 
RT buffer, 1 μl DTT, 1μl AffintyScript MultipleTemperature Reverse Transcriptase, 
1μl RNaseOUT and 19.5 μl mixed RNA solution).  cDNA synthesis was conducted  
as follows: 25°C for 10min to extend primers, 50°C for 60 min to synthesize cDNA
and 70°C for 15 min to terminate the reaction. cDNA samples were centrifuged for
seconds at 4°C to clean the drops on the wall of tubes and stored at -20°C or used
directly for Taqman RT-qPCR analysis. The scheme for cDNA synthesis is shown
below (Fig 2.7):
60 min
15 min
10 min
Extending
primer
Terminating
Denatured mRNA
samples at 25°C
mRNA samples
at 50°C
cDNA
samples at 70°C
cDNA
samples at 4°C
Fig 2.7 cDNA synthesis. Primer was annealed to mRNA samples and extended at 25°C for
10min. cDNA samples were synthesized at 50°C for 60 min. The reaction was terminated at
70°C for 15 min and cDNA samples were kept at 4°C after termination of the reaction.
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2.8.7cDNA pre-amplification
Synthesized cDNA was pre-amplified because expression levels of some of target
genes were very low. Briefly, working solutions of forward primers and reverse pri-
mers from each gene were diluted 1 in 50 inTris-EDTA buffer (10mM Tris-Cl, 1mM
EDTA) to make a primer pool. 5μl of cDNA sample was added to 5μl of primer mix-
ture and 10μl of Taqman® Fast Universal PCR Master Mix. Samples were pre-
amplified for 3 or 8 cycles and the reaction sequence was as below:
1) 95°C 10 min to activate Hot-start Taq DNA polymerase
2) 95°C 15 s for denaturation of cDNA
3) 60°C 4 min for extension of template
4) Step 2 and 3 repeated for 3 or 8 cycles
5) 4°C holding after the reaction was stopped.
Pre-amplified cDNA was stored at -20°C.
2.8.8qRT-PCR for gene expression
2.8.8.1 Standard curve and sample preparation
As the cDNA template amplifies in an exponential way, the quantity of PCR produc-
tion could be calculated by log10 transformation as the template is based on 10-fold
serial dilutions to generate a linear plot. Standard curves were used to determine the
initial starting amount of unknown sample and the efficiency of PCR by diluting in
sequential concentrations. The CT value of unknown sample was compared with the
standard curve to determine the relative quantity of the sample. The slope of the
standard curve reflects the efficiency of PCR reaction and the correlation co-efficient
(R2) measures how the standard curve fits the data. A PCR efficiency of 100% cor-
responds to a slope of –3.32, as determined by the following equation: Efficiency =
10(-1/slope)–1(Ginzinger 2002). A slope of the standard curve between -3.2~ -3.6 and
R2 >0.95 were considered as acceptable criteria for data analysis.
The stock for the standard curve was made from a mixture of each cDNA sample
(5μl) to a common pool and vortexing. The standard curve was made from the su-
perneat and diluted in 5 sequential concentrations of points to neat, 1: 3, 1:9, 1:27
and 1:81 with autoclaved HPLC water (Fig 2.8). The standard curve and sam-
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ple/unknown cDNA were normally freshly made up and freeze-thawed no more than
twice to avoid degradation of cDNA.
2.8.9RT-qPCR Assay
RT-qPCR of cDNA samples was performed in a sealed 96-well optical plate using
the Applied Biosystem StepOnePlus Real-Time PCR system (Applied Biosystems,
US) . Each cDNA sample was run in triplicate and each of PCR reaction well con-
tained 6.5 μl of Fast Master Mix, 0.375μl of each forward and reverse primer, 0.25 μl 
of probe, 2.5 μl of HPLC water and 3 μl of test sample. 10μl Fast Master Mix and 3μl 
of cDNA sample were added into each well of 96-well plate. The plate was sealed
with optical film and spun with a mini plate spinner (Labnet international, Inc, USA) to
collect any drops of sample on the well wall. The PCR reaction was started at 95°C
for 20s to activate hot-start Taq DNA polymerase and 40 cycles of 95°C for 1s and
60°C for 20s to denature, anneal and extend cDNA template. A flow diagram of the
PCR reaction scheme is shown in Fig 2.9.
slope -3.403533395
intercept 21.07608158
r2 -0.998081885
Fig 2.8 Standard curve of β-actin expression in synovia of saline-treated rats. The slope of the
curve is -3.40 and R2 is -0.998 which indicates high efficiency and fidelity of PCR amplification.
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2.8.10 Data analysis
Data were analysed by GraphPad Prism Version 6 and presented as mean± S.E.M.
Gene expression levels in multiple groups were analysed by one-way ANOVA with
Bonferroni’s multiple comparison post-hoc testing for parametric data and with a
Kruskal-Wallis test with Dunn’s multiple comparison post-hoc testing for non-
parametric data. Data for two groups were analysed by unpaired t-test for paramet-
ric data and Mann-Whitney test for non-parametric data. To investigate correlation
between expression levels of target genes or pain behaviour with resolvin receptors
(ChemR23 and ALX), XY analysis was used. Gene expression level and weight
bearing difference are continuous variables and paw withdrawal threshold is discrete
variable. To investigate how close the correlation between the variables would be,
we expected that the expression levels of resolvin receptors (ChemR23 and ALX)
will have a linear correlation with pain behaviour and target genes, so linear regres-
sion has been used for the correlation analysis. Pearson correlation analysis is sen-
sitive to linear correlation between two variables and the co-efficient indicates
strength of the correlation, therefore, was used for parametric data with normal dis-
tribution. Spearman correlation was used for non-parametric data to measure the ex-
tent of tendency between resolvin receptors and other genes or pain behaviour. p <
0.05 was taken as statistically significant.
20
s
20 s
DNA polymerase
activated at 95°C
cDNA denatured
at 95°C
Template annealed
and extended at
60°C
Amplification
finished
1 s
Fig 2.9 PCR reaction. Taqman DNA polymerase was activated at 95°C for 20s. 40 cycles of
PCR reaction was performed at 95°C for 1s to denature cDNA templates and 60°C for 20s to
extend the templates. The amplification finished after 40 cycles.
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2.9 Human tissue samples
2.9.1 Sample collection
The research project on clinical samples was approved by generic ethics for the
Trust Biobank, Research & Innovation, University of Nottingham. A letter of support
was issued to allow access to operating theatres in NHS hospitals for fresh tissue
collection (ASCH 448, see Appendices). Human synovia, femoral condyles and tibial
plateau were taken from OA patients undergoing total knee replacement (TKR) at
the City Hospital. Femoral heads from trauma patients were harvested at the
Queen’s Medical Centre campus. Human samples were immediately placed on dry
ice and were stored at -80°C in the Bio-bank. Sample details were registered in the
Bio-bank database with individual barcodes for tracking. Samples were transported
to the laboratory on dry ice for experiments.
2.9.2 Tissue homogenizing
Human synovia were taken on dry ice and placed in a 5 ml container containing 3ml
of TRI Reagent. Synovia were roughly homogenized with a large Ultra Turrax probe
and finely homogenized with a small probe in 4 ml of TRI reagent. Samples were
then incubated at room temperature for 5min.  800μl of BCP was added to each con-
tainer and mixed by vortexing. Samples were centrifuged at 10000g for 15min at 4°C.
and the following steps of RNA extraction and RT-PCR were conducted as previous-
ly described (see 2.8.4-2.8.9).
For bone tissue, the middle part of the medial tibial plateau from OA patients was
taken to investigate expression levels of genes of interest as OA damage is more
frequently observed in that compartment (Miyazaki et al. 2002; Mundermann et al.
2005). Bone fractions of femoral heads from trauma patients were used as controls
for OA patient. As bone is a highly dense connective tissue and it is much more dif-
ficult to homogenize directly than synovium or spinal cord, a slightly modified proce-
dure was employed (C. Reno et al. 1997). Bone tissue (medial tibial plateau or femo-
ral head) was placed on dry ice and tissue from the middle part of medial tibial plat-
eau or bone fractions from femoral head (about 200 mg per sample) were removed
using a bone clipper. Frozen tissue was pulverized in a mortar containing liquid ni-
trogen and transferred to a 5 ml container. 3 ml of TRI Reagent was added to the
container and the tissue was homogenized as described above. The remaining steps
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for RNA extraction and RT-PCR were performed as previously described (section
2.8.4-2.8.9).
2.9.3 Data analysis
Data were analysed by GraphPad Prism Version 6 and presented as mean± S.E.M.
Expression of ChemR23 and ALX were compared by un-paired t-test. Comparisons
of gene expression in OA and trauma patient tissues were compared by un-paired t-
test or Mann-Whitney t-test. Correlations were analysed by XY analysis with the
Pearson correlation for parametric data and Spearman for non-parametric correlation.
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3 MIA-induced and MNX-induced models of osteoarthritis
3.1 Introduction
3.1.1Translational relevance of rodent models of OA pain
Animal models of OA are widely used to mimic the pathology, pathogenesis and clin-
ical symptoms associated with human OA, and to investigate potential therapeutics
for the treatment of OA in pre-clinical studies. The models of OA are either experi-
mentally-induced or spontaneous in various species of animals. The experimentally-
induced models are conducted by surgery or chemical agents while spontaneous
models occur naturally or arise as a result of genetic modification (Bendele 2001;
Lampropoulou-Adamidou et al. 2014). Two osteoarthritic models are widely used to
investigate pathogenesis and mechanisms underlying pain behaviour associated
with OA. Firstly, the MIA-induced model of OA pain. This model is associated with
changes in weight distribution (weight bearing asymmetry) and a lowering of hind-
paw withdrawal threshold; these effects are dose-dependent and last for at least 10
weeks post model induction (Bove et al. 2003; Combe et al. 2004). The types of pain
exhibited in this model mimic the reported pain on standing and changes in pressure
pain thresholds seen in human OA (Kosek and Ordeberg 2000; Hendiani et al. 2003).
Secondly, the MNX-induced model of OA pain, which leads to pathological changes
to the structure and instability of the joint. The MNX model is associated with osteo-
arthritic lesion of medial tibial plateau; the severity and area of cartilage damage in-
creases over time (Janusz et al. 2002). Subchondral and synovial angiogenesis,
synovial inflammation and osteophytes, as well as damage to articular cartilage have
been demonstrated in this model (Mapp et al. 2008). In addition, proteoglycan loss
and cartilage fibrillation have been demonstrated in the MNX model (Mapp et al.
2010), consistent with some of the histological features of human OA (Aigner et al.
2001; Hardy et al. 2002; Fuerst et al. 2009). This model mimics the tears to differ-
ent compartments of medial meniscus and popliteal pain in knee OA patients
(Kamimura et al. 2014). Although the broader histological features of joint damage
are similar in the two models, the MNX model has higher inflammatory and osteo-
phytes scores, compared to the MIA model (Mapp et al. 2013).
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3.1.2Resolvins and resolvin receptor system
As described in 1.5.2, there are two series of the resolvins (D-series and E-series).
D-series resolvins act at ALX and GPR32 receptors whereas E series resolvins act
at ChemR23 and BLT1 receptors (Serhan et al. 2011; Im 2012). These receptors are
GPCR expressed by immune cells (Cash et al. 2014), neurons, glial cells (Ji et al.
2011), chondrocytes (Berg et al. 2010) and synoviocytes (Kaneko et al. 2011). D-
series receptors (ALX and GPR32) were identified using radio-labelled RvD1 binding
and actin polymerization assays (Krishnamoorthy et al. 2010). ChemR23 was identi-
fied using a radio-ligand binding assay and demonstrated high expression in human
monocytes (Arita et al. 2005). The resolvins have receptor-mediated anti-
inflammatory and anti-nociceptive effects, regulating inflammatory cytokines and var-
ious pro-inflammatory signalling pathways (Ji et al. 2011). There has been consider-
able work on the anti-inflammatory properties of the resolvins (Serhan et al. 2008;
Spite and Serhan 2010; Serhan 2014). However, there have been fewer studies of
their analgesic properties.
RvE1 attenuated inflammatory and neuropathic pain and the effects were mediated
by ChemR23 (Xu et al. 2010) . RvD1 reduced pain behaviour in inflammatory models,
however, the receptor mediating this effect was not demonstrated (Xu et al. 2010).
The precursor of the resolvin D-series and aspirin-triggered RvD1 have been shown
to attenuate hyperalgesia in a model of adjuvant-induced arthritis (Lima-Garcia et al.
2011). Mechanisms underlying these effects were suggested to be a reduction in
TNFα and IL1β at peripheral sites and blockade of COX2 and NF-κB signaling at
central sites (Lima-Garcia et al. 2011).
As presented in the general introduction, inflammation is one of the major pathologi-
cal features of OA and multiple mediators are involved in pathogenesis and progres-
sion of OA. Resolvins play broad anti-inflammatory and anti-nociceptive roles by
targeting multiple mechanisms in various inflammatory and neuropathic models of
pain (Sungjae Yoo et al. 2013). To date, the resolvin receptor system has not been
characterized in models of OA and potential effects on pain have yet to be reported.
78
3.1.3Aim
To determine whether the expression of resolvin receptors in synovia and spinal cord
is altered in models of OA pain and whether expression of resolvin receptors is cor-
related with pain behaviour, expression of inflammatory cytokines and metabolic en-
zymes.
3.1.4Objectives
 To confirm the extent of pain behaviour and joint histology in both models of
OA
 To characterize the expression of ChemR23 and ALX in synovial and spinal
cord tissues from the OA models
 To quantify gene expression levels of inflammatory cytokines and metabolic
enzymes relevant to the resolvin system in synovia and spinal cord.
 To investigate potential correlations between the expression of resolvin recep-
tors and pain behaviour, and expression of inflammatory cytokines and their
respective metabolic enzymes in synovia and spinal cord
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3.2 Methods
The induction of models has been discussed in the general methods (2.2-2.3). Spra-
gue Dawley male rats (130-150g) were habituated for environment and equipment
before model induction and behavioural test.
3.2.1Comparison of pain behaviour between two models of osteoarthritis
To compare the pain behaviour between MIA and MNX model, four groups were
used in this study, namely MIA (1mg/50μl) group, saline (50μl) group, MNX surgery 
group and sham surgery group. Two separate studies were undertaken for the work
described in this Chapter. In the first study, 6 rats per group were used to measure
pain behaviour from day 0 until day 28 post model induction and pain behaviour was
tested twice a week. The reason that I chose day 28 as the end point is based on
previous studies. Pain behaviour is maximal at day 28 and there is evidence of spi-
nal sensitization, such as increased glial fibrillary acidic protein (GFAP) immunofluo-
rescence, which indicates activation of astrocytes in the MIA model (Sagar et al.
2010; Sagar et al. 2011). MNX-induced pain behaviour and joint histopathology are
also known to be established, compared to sham control at day 28 (Mapp et al.
2013). Weight bearing asymmetry was tested from day 0 until day 28. At the end of
the study, knee joints were harvested for histological analysis. The protocol is sim-
plified as below (Fig 3.1):
D0D-1
Habituation
Tissue collectionMIA (i.a) or sa-
line/MNX or sham
D3
D7 D14
D10 D18
D22
D26
D28
Behavioural testing
Fig 3.1 Flow-chart of study 1. Baseline values of behaviour (weight bearing and paw
withdrawal threshold) were tested before surgery at day 0 and pain behaviour was test-
ed twice a week from day 3 onwards until day 28. Tissues were collected at day 28 for
joint histology.
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A second study using the MIA and MNX was performed to allow the collection of
fresh synovia and spinal cords (quadrant) for gene expression studies. For practical
reasons in this study, tissues were collected at day 35 using a slightly extended
protocol to that described in Figure 3.1.
3.2.2Assessment of histopathology of knee joint
The general methods have been detailed in Chapter 2 (see 2.5-2.7). Briefly, joints
were fixed in 10% neutral-buffered formalin and decalcified twice a week for 4-6
weeks. Knee joints were embedded in paraffin and cut into 5μm sections. 
To assess joint histopathology in these two OA models, joint sections with clear
structures of femoral condyle and medial tibial plateau qualified for H&E staining.
Furthermore, 4 sections selected from different levels in each block were used for
assessing histological scoring for each rat. Janusz’s scoring system (Janusz et al.
2002) was used to score chondropathy, chondrocyte appearance and osteochondral
junction integrity of medial tibial plateau in the ipsilateral knee joint. Synovial in-
flammation was also scored according to methods described in Chapter 2 (see 2.7.1).
3.2.3Quantification of genes of interest in synovia and spinal cord
The synovia were dissected from the patella and infra-fat pad and were snap frozen
in liquid nitrogen. Ipsilateral synovia were used for the quantification of gene expres-
sion. Spinal cord was split into ipsi-dorsal, ipsi-ventral, contra-dorsal and contra-
ventral quadrants. The ipsi-dorsal part receives sensory inputs from the knee joint
and is the region involved in the integration and modulation of noxious inputs, and
was therefore used for gene expression studies. Tissues were homogenized and
RNA was extracted by TRI reagent lysis buffer. Expression levels for resolvin recep-
tors (ChemR23 and ALX), inflammatory cytokines and metabolic enzymes (see Ta-
ble 2.1) were quantified by Taqman RT-qPCR as described in Chapter 2 (see 2.8).
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3.2.4Data analysis
Data were analysed with Graphpad Prism 6 and are presented as mean±S.E.M.
Pain behavioural data (WB and PWT) were analysed by two-way ANOVA with
Bonferronni’s post-hoc test. Histological scoring was analysed by one-way ANOVA
with Bonferroni’s post-hoc test or Kruskal Wallis with Dunn’s post-hoc test for non-
parametric data. Gene expression levels were analysed by un-paired t-test (para-
metric data) or Mann-Whitney (non-parametric data) test. Correlation of gene
expression of resolvin receptors and pain behaviour or genes of interest was per-
formed with Pearson (parametric data) or Spearman (non-parametric data) test.
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Fig 3.2 Intra-articular injection of MIA (1mg/50μl) increased weight bearing difference (A)  
and decreased paw withdrawal threshold of ipsilateral joint (B) from day 3 post model in-
duction until day 28 in MIA rats, compared to saline treated rats. Medial meniscus transec-
tion (MNX) increased weight bearing difference (A) and reduced paw withdrawal threshold
(B) in the MNX model, compared to sham control from day 7 post model induction until day
28. Data are mean±SEM (n= 6 rats per group) analyzed by two-way ANOVA with Bonferro-
ni’s post-hoc test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.001).
3.3 Results
3.3.1The MIA and MNX-induced models of OA produce comparable pain behaviour
Behavioural assessment revealed that weight bearing asymmetry (Fig 3.2 A) and a
lowering of the hindpaw withdrawal threshold (Fig 3.2 B) started as early as day 3 in
the MIA model and day 7 in the MNX model, compared to their respective controls.
The weight bearing difference increased and paw withdrawal threshold decreased
with time and both measures of pain behaviour were maintained until the end of
study in both models. There was no significant difference between the magnitudes of
the pain behaviour exhibited by the MIA and MNX models.
*
**** ****
***
* * * * ***
**** **** **** ********
*** **** ****
****
**** ****
**** ****
** ***
**** ****
**** **** ****
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3.3.2Histological changes to the knee joint in the MIA and MNX models of OA pain
Histological scores for chondropathy (Fig 3.3 A), synovial inflammation (Fig 3.3 B)
and chondrocyte appearance (Fig 3.3 C) were significantly higher in MIA rats com-
pared to saline treated-rats. Vascular breaching across the osteochondral junction
(Fig 3.3 D) appeared higher in MIA model compared to saline controls, but signifi-
cance was not reached. MNX surgery resulted in significantly higher score for chon-
drocyte appearance compared to sham surgery (Fig 3.3 C) as well as apparently
greater chondropathy (Fig 3.3 A), synovial inflammation (Fig 3.3 B) and vascular
channels (Fig 3.3 D) although significance was not reached. There was no signifi-
cant difference in joint histology between the two models.
Fig 3.3 Histological assessment for knee joints was shown in MIA and MNX rats compared to
the respective controls. Chondropathy score (A), synovial inflammation score (B), chondro-
cytes appearance score (C) and vascular breaching across osteochondral junction (D). Data are
mean±S.E.M (n= 6) analysed with Kruskal-Wallis (A, B, C, non-parametric data) or one-way
ANOVA with Bonferroni’s post-hoc test (D, parametric data) (*p<0.05 vs saline or sham sur-
gery).
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H&E staining revealed intact structures of knee joints for both saline (3.4 A) and
sham surgery (3.4 C) treated rats. Cartilage degeneration and hypocellularity of
chondrocytes were evident in the MIA and MNX models (3.4 B, D).
Saline
Sham MNX
B
MIA
A
D
Fig 3.4 H&E staining revealed chondropathy and hypocellularity of chondrocyte in models of OA
compared to the respective controls. Cartilage damage and hypocellularity of chondrocyte (black
arrows) was present in MIA (B) and MNX (D) rats, compared to their respective controls, saline (A)
and sham(C). Scale bar equals 500μm. 
C
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The synovia from saline (Fig 3.5 A) or sham (Fig 3.5 C) treated rats were only 1-2
cells thick. The synovia from MIA (Fig 3.5 B) or MNX (Fig 3.5 D) rats were com-
posed of many layers of cells (hyperplasia).
Saline
Sham
MIA
MNX
A B
C D
Fig 3.5 Comparison of the extent of synovial inflammation in MIA and MNX rats, versus respective
controls. HE staining revealed a greater number of cells (black arrows) within the synovia in MIA (B)
and MNX (D) compared to, saline (A) and sham (C). Scale bar is 100μm. 
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3.3.3MIA associated behaviour and synovial gene expression
3.3.3.1 Pain behaviour in the MIA model
Similar to the data shown in 3.3.1, intra-articular injection of MIA resulted in robust
pain behaviour (3.6 A, B) until day 35 post model induction.
Fig 3.6 Intra-articular injection of MIA (1mg/50μl) was associated with an increase in 
weight bearing difference up to day 35 (A) and a lowering of the hindpaw withdrawal
threshold (B) compared to saline injected control group. Data are mean ± S.E.M (n= 8),
analyzed by two-way ANOVA with Bonferroni ‘s post-hoc test (****p<0.0001).
********
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3.3.3.2 Expression of resolvin receptors, cytokines and enzymes in the MIA model
of OA pain
The levels of gene expression of ChemR23 and ALX, some key inflammatory cyto-
kines and associated metabolic enzymes were quantified in synovia from the models.
As showed in Fig 3.7, the expression level of ChemR23 was significantly lower in
synovia from MIA treated rats, compared to saline treated-rats (Fig 3.7A) Expression
of ALX was comparable between the two groups of rats (Fig 3.7B).
There was no significant difference in the gene expression of the cytokines studied in
MIA and saline treated rats (Fig 3.8). With regards to the enzymes, expression of
15-LOX was significantly lower in synovia from MIA-treated rats compared, to saline-
treated rats (Fig 3.9B). There were no other differences in the expression of the oth-
er enzymes studied (Fig 3.9).
Fig 3.7 Gene expression of ChemR23 (A) was significantly lower in the MIA synovia,
compared to control (saline) at 35 days following model induction. There was no
difference in ALX (B) expression between synovia from MIA and saline treated rats.
Data areindividual data points as a scatterplot, with mean ± S.E.M indicated by the
bars, analysed with an unpaired t-test, (**p<0.01).
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Fig 3.8 Gene expression of selected cytokines (TNFα, IL1β, IL6 and IL10) in the synovia
of MIA rats at day 35 following model induction compared to saline treated rats. Data
are individual data points as a scatter plot, with mean±S.E.M (n= 7) analysed with un-
paired t-test or Mann-Whitney t-test.
*
Fig 3.9 Expression levels of enzymes in synovia from the MIA model at day 35 post model
induction compared to saline controls. 5-LOX(A),15-LOX (B) , COX2(C), EPHX2(D), CYP2J2(E),
iNOS(F) and m PGES1 (G). Data are individual data points as a scatter plot, with mean±S.E.M
analysed with an unpaired t-test or Mann-Whitney t-test (*p<0.05).
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Fig 3.10 Medial meniscus transection (MNX) significantly increased weight bearing differ-
ence (A) compared to sham control from day 18 until day 35 post model induction. Data are
mean±S.E.M analyzed by two-way ANOVA with Bonferroni ‘s post-hoc test (*p<0.05,
**p<0.01).
3.3.4MNX associated behaviour and synovial gene expression
3.3.4.1 Pain behaviour in the MNX model
The development of pain behaviour in the MNX rats, compared to sham controls was
studied up to day 35 post-surgery. Significant weight bearing difference was evident
at day 18 post MNX surgery and lasted until the end of the study (Fig3.10A). The
paw withdrawal threshold appeared lower in the MNX model, but was not significant
compared to sham controls (Fig3.10B). Some of the sham surgical rats also showed
pain behaviour over the time-course of the study.
*
**
* *
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Fig 3.11 Gene expression of ChemR23 (A) and ALX (B) in the synovia from MNX rats at
35 days following model induction compared to sham controls. Data are individual
data points as a scatter plot, with mean ± S.E.M, analysed with an unpaired t-test
(*p<0.05, **p<0.01).
3.3.4.2 Expression of resolvin receptors, cytokines and key enzymes in the synovia
of MNX model
The expression of mRNA encoding ChemR23 and ALX, inflammatory cytokines and
associated metabolic enzymes was quantified in synovia of MNX rats. Gene expres-
sion was normalized to the geometric mean of β-actin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in the MNX model and sham control as β-actin 
was not consistent across the two groups based on data analysis for β-actin. There 
was no significant difference in the expression of ChemR23 (Fig 3.11A) between the
two groups.
Expression of ALX was significantly lower in MNX rats compared to sham surgical
rats (Fig 3.11B). TNFα and IL1β expression was significantly lower in MNX  
synovia (Fig 3.12A, Fig3.12B), compared to sham control. Gene expression of
COX2, EPHX2 and mPGES1 was also significantly lower in MNX synovia, compared
to sham control. There were no significant differences in the other genes studied
(Fig 3.13).
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Fig 3.12 Gene expression of cytokines (TNFα, IL1β, IL6 and IL10) in synovia from MNX
rats at day 35 post model induction compared to sham controls. TNFα (A), IL1β (B), IL6 
(C) and IL10 (D). Data are individual data points as a scatter plot, with mean±S.E.M (n=
5- 8) analysed with unpaired t-test or Mann-Whitney t-test. (*p<0.05, **p<0.01).
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Fig 3.13 Gene expression of enzymes in synovia from MNX rats at day 35 post model
Induction compared to sham controls. 5-LOX(A),15-LOX (B) , COX2(C), EPHX2(D),
CYP2J2(E), iNOS(F) and m PGES1 (G). Data are individual data points as a scatter plot,
with mean±S.E.M (n= 6-8) analysed with unpaired t-test or Mann-Whitney t-test.
(**p<0.01, ***p<0.001).
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3.3.5The relative expression of ChemR23 and ALX in synovia of the two models
To obtain a clearer picture of the relative contribution of the resolvin receptors in
synovia in the models of OA pain, expression levels of these two receptors were
compared for each condition (Fig3.14). It was evident that the relative expression of
the two receptors in synovia was comparable for all treatments, apart from the sham
surgery group which had a significantly higher expression of ALX compared to
ChemR23 (Fig3.14C).
A B
C D
Fig 3.14 Comparison of gene expression for ChemR23 and ALX in the models of OA and
control groups at day 35. Data are presented as individual data points as a scatter plot,
with mean ± S.E.M, analysed with unpaired t-test (*p<0.05).
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Table 3.1 Correlation of ChemR23 and ALX expression with inflammatory cytokines (TNFα, IL1β, IL6 and IL10) and associated
metabolic enzymes (5-LOX, 15-LOX, COX2, EPHX2, CYP2J2, iNOS and mPGES1) in the synovia from the MIA model and saline control.
Data were analysed with Pearson or Spearman correlation (n=7, r is the co-efficient of correlation, *p<0.05).
3.3.6Correlation of resolvin receptors with genes of interest in synovia from the two models of OA
To investigate whether the expression pattern of the two resolvin receptors in synovia is associated with expression of
inflammatory cytokines and their respective metabolic enzymes, correlation analysis was undertaken in MIA (Table 3.1) and
MNX (Table 3.2) rats. Expression of ChemR23 in the synovia was not correlated with the expression of any of the genes of
interest in the synovia from MIA or saline treated rats. There was a significantly positive correlation of ALX expression with
TNFα, IL1β and COX2 in MIA-treated rats and ALX with IL1β and COX2 expression in saline-treated rats. There was a signifi-
cantly negative correlation of ALX and 5-LOX expression in MIA rats. Gene expression of ChemR23 in the synovia was not
correlated with the expression of any genes of interest in the synovia from MNX or sham surgical rats. There was a significant-
ly positive correlation of expression of ALX with TNFα, IL1β, COX2, EPHX2 and mPGES1 in synovia of both MNX and sham 
surgical controls.
Treatment Genes TNFα IL1β IL6 IL10 5-LOX 15-LOX COX2 EPHX2 CYP2J2 iNOS mPGES1 
Saline
ChemR23
r=0.09
p=0.84
r=-0.22
p=0.63
r=0.46
p=0.30
r=-0.04
p=0.96
r=0.60
p=0.17
r=-0.27
p=0.56
r=0.02
p=0.97
r=0.21
p=0.66
r=0.60
p=0.17
r=0.36
p=0.42
r=0.38
p=0.10
ALX
r=0.43
p=0.33
r=0.83
p=0.02*
r=0.07
p=0.89
r=0.50
p=0.23
r=-0.14
p=0.78
r=0.00
p=0.99
r=0.77
p=0.04*
r=0.68
p=0.11
r=0.68
p=0.11
r=0.39
p=0.39
r=0.49
p=0.27
MIA
ChemR23
r=0.35
p=0.44
r=0.19
p=0.71
r=0.68
p=0.11
r=0.42
p=0.40
r=0.17
p=0.71
r=0.20
p=0.67
r=0.55
p=0.25
r=0.26
p=0.61
r=-0.07
p=0.88
r=0.30
p=0.52
r=0.71
p=0.07
ALX
r=0.88
p=0.01*
r=0.82
p=0.03*
r=0.25
p=0.59
r=0.65
p=0.12
r=-0.79
p=0.04*
r=-0.21
p=0.65
r=0.84
p=0.04*
r=0.72
p=0.11
r=-0.09
p=0.84
r=0.60
p=0.15
r=0.60
p=0.15
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Table 3.2 Correlation of ChemR23 and ALX expression with inflammatory cytokines (TNFα, IL1β, IL6 and IL10) and associated
metabolic enzymes (5-LOX, 15-LOX, COX2, EPHX2, CYP2J2, iNOS and mPGES1) in the synovia from the MNX model and sham
control. Data were analyzed with Pearson or Spearman correlation (n=7, r is the co-efficient of correlation, *p<0.05).
Groups Genes TNFα IL1β IL6 IL10 5-LOX 15-LOX COX2 EPHX2 CYP2J2 mPGES1
Sham
ChemR23
r=0.55
p=0.25
r=0.34
p=0.51
r=0.47
p=0.35
r=-0.77
p=0.13
r=0.63
p=0.18
r=0.29
p=0.57
r=0.34
p=0.50
r=-0.02
p=0.98
r=-0.19
p=0.72
r=0.44
p=0.39
ALX
r=0.86
p=0.03*
r=0.94
p=0.02*
r=0.30
p=0.56
r=0.09
p=0.88
r=-0.13
p=0.81
r=-0.19
p=0.71
r=0.99
p=0.02
x10-2*
r=0.81
p=0.05*
r=-0.12
p=0.82
r=0.90
p=0.01*
MNX
ChemR23
r=0.56
p=0.15
r=0.33
p=0.43
r=0.57
p=0.15
r=0.10
p=0.84
r=0.52
p=0.19
r=0.56
p=0.15
r=0.02
p=0.97
r=0.21
p=0.63
r=0.15
p=0.73
r=0.72
p=0.05*
ALX
r=0.84
p=0.01*
r=0.95
p=0.04
x10-2*
r=0.12
p=0.79
r=-0.12
p=0.79
r=0.43
p=0.29
r=0.52
p=0.19
r=0.96
p=0.02
x10-2*
r=0.91
p=0.15
x10-2*
r=-0.25
p=0.56
r=0.73
p=0.04*
95
3.3.7Correlation of ChemR23 and ALX with pain behaviour in models of OA
Correlation of the synovial expression of ChemR23 and ALX with pain behaviour
(WB and PWT) in the MIA model (day14 and day 35) and MNX model (Day 35) was
determined.
Expression of ChemR23 in the synovia was negatively correlated with weight bearing
difference at both 14 days (Fig3.15A) and 35 days (Fig3.16A) following MIA induction.
In parallel, expression of ChemR23 in the synovia was positively correlated with paw
withdrawal thresholds at both time-points (Fig3.15B, Fig3.16B) in the MIA model. These
data demonstrate that less weight bearing difference and higher paw withdrawal
threshold (less pain) are associated with higher expression of ChemR23 in the syno-
via from the MIA model at both day 14 and day 35. There was no correlation of ALX
expression in the synovia with pain behaviour at either time-point in the MIA model
(Fig3.15C, D and Fig3.16C, D).
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C D
Fig 3.15 The correlation of mRNA level of ChemR23/ALX with weight bearing (A/C) and paw with-
drawal threshold (B/D) in the synovia in the MIA model and saline control at day 14. The maximal
force for von Frey hair was 26g. Data were analysed with Spearman
MIA Day 14
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C D
Fig 3.16 The correlation of mRNA level of ChemR23/ALX with weight bearing (A/C) and paw
withdrawal threshold (B/D) in the synovia in the MIA model and saline control at day 35. The
maximal force for von Frey hair was 26g. Data were analysed by Spearman correlation.
MIA Day 35
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In the MNX model, expression levels of ChemR23 in the synovia were negatively
correlated with paw withdrawal threshold (Fig 3.17B) but not correlated with weight
bearing difference (Fig 3.17A). There was no correlation between the expression of
ALX in the synovia and either measure of pain behaviour.
MNX Day 35
A B
C D
Fig 3.17 The correlation of mRNA level of ChemR23/ALX with weight bearing (A/C) and paw
withdrawal threshold (B/D) in the synovia in the MNX model and sham control at day 35. The
maximal force for von Frey hair was 26g. Data were analysed by Pearson or Spearman correla-
tion.
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Fig 3.18 Gene expression of ChemR23 (A) and ALX (B) in the ipsilateral dorsal quadrant
of the spinal cord from MIA or saline-treated rats at 35 days following model induc-
tion. Data are individual data points as a scatterplot, with mean ± S.E.M, analysed
with Mann-Whitney test (A) and unpaired t-test (B) (**p<0.01)
3.3.8Expression levels of target genes in spinal cord from the MIA model
Gene expression of ChemR23 and ALX, inflammatory cytokines and associated
metabolic enzymes was quantified in the ipsilateral dorsal horn quadrant of the spinal
cord from MIA rats at day 35 post model induction. As showed in Fig 3.18, expres-
sion level of ChemR23 in the ipsilateral dorsal horn quadrant was significantly higher
in MIA rats, compared to saline treated-rats (Fig 3.18A) Expression levels of ALX in
the ipsilateral dorsal horn quadrant of MIA rats were comparable to levels in saline
treated rats (Fig 3.18B).
**
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Fig 3.19 Gene expression of selected cytokines in the ipsilateral dorsal of the spinal
cord from MIA rats at day 35 post model induction. TNFα (A), Ilβ (B) and IL6 (C).  Data 
are individual data points as a scatterplot, with mean±S.E.M (n= 7-8) analysed with un-
paired t-test.
There was no significant difference in the expression of selected cytokines in the
ipsilateral dorsal horn quadrant between MIA and saline treated rats (Fig 3.19).
Expression of 15-LOX had a trend towards a decrease in the ipsilateral dorsal horn
quadrant of MIA-treated rats, compared to saline controls (Fig 3.20C). There was a
trend towards an increase in the expression of COX2 (Fig 3.20D) in the ipsilateral
dorsal horn quadrant of MIA rats, compared to saline controls.
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Fig 3.20 Gene expression of enzymes in the ipsilateral dorsal quadrant of the spinal cord from
MIA rats at day 35 post model induction. 5-LOX (A), FALP (B), 15-LOX (C), COX2 (D), m PGES1 (E),
iNOS (F) and GFAP (G). Data are individual data points as a scatterplot, with mean±S.E.M ana-
lysed with unpaired t-test or Mann-Whitney t-test. (*p<0.05)
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Fig 3.21 Gene expression of ChemR23 (A) and ALX (B) in the spinal cord from MNX and
sham-operated rats at 35 days following model induction. Data are individual data
points as a scatterplot, with mean ± S.E.M, analysed with unpaired t-test.
3.3.9Expression levels of target genes in spinal cord from the MNX model
Gene expression of ChemR23 and ALX, inflammatory cytokines and associated
metabolic enzymes was quantified in ipsilateral dorsal horn quadrant of the spinal
cord in MNX rats and sham controls. There was no significant difference in the spinal
expression of ChemR23 or ALX between the two groups (Fig 3.21A, Fig 3.21B).
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Fig 3.22 Gene expression of cytokines in spinal cord from MNX or sham-operated
rats at day 35 post model induction.  TNFα (A), Ilβ (B), IL6 (C) and IL10 (D).  Data are 
individual data points as a scatterplot, with mean±S.E.M (n= 6-8) analysed with un-
paired t-test or Mann-Whitney t-test.
For the majority of the genes of interest, there was no difference in the levels of
cytokines between the two groups (Fig 3.22A, B, and C). Expression of IL10 was
higher in the ipsilateral quadrant of the dorsal horn of the spinal cord in MNX rats,
compared to sham controls (Fig 3.22D). Gene expression of FLAP was significantly
higher in the ipsilateral dorsal quadrant of the spinal cord in MNX rats,
compared to sham controls (Fig3.23B).
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Fig 3.23 Gene expression of selected enzymes in spinal cord from MNX or sham-operated rats at
day 35 post model induction, compared to controls. 5-LOX (A), FALP (B), 15-LOX (C), COX2 (D), m
PGES1 (E), iNOS (F) and GFAP (G). Data are individual data points as a scatterplot, with
mean±S.E.M (n= 7-8) analysed with unpaired t-test or Mann-Whitney t-test (*p<0.05, **p<0.01).
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3.3.10 The relative expression of ChemR23 and ALX in spinal cord of the two models
To obtain a clearer picture of the relative contribution of the resolvin receptors in
spinal cord in the models of OA pain, expression levels of these two receptors were
compared for each condition (Fig3.24). It was evident ALX expression was
significantly higher in saline rats (Fig3.24A) but lower in MIA rats (Fig3.24B), com-
pared to ChemR23. There was no difference in the expression of the two receptors
in the MNX model and sham control.
A B
C D
Fig 3.24 Comparison of ChemR23 and ALX in ipsilateral dorsal quadrant of the spinal cord
in the models of OA and control groups at day 35. Saline (A), MIA (B), Sham (C) and MNX
(D). Data are individual data points as a scatterplot, with mean ± S.E.M, analysed with
unpaired t-test (A, C, D) or Mann-Whitney test (B). (*p<0.05)
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Table 3.3 Correlation of ChemR23 and ALX expression with inflammatory cytokines (TNFα, IL1β and IL6) and associated meta-
bolic enzymes (5-LOX, FLAP, 15-LOX, COX2, iNOS, mPGES1 and GFAP) in the ipsi-dorsal spinal cord from the MIA model and
saline control. Data were analysed with Pearson or Spearman correlation (n=7-8, r is the co-efficient of correlation, *p<0.05).
3.3.11 Correlation of resolvin receptors with genes of interest in the spinal cord from the two models of OA
To investigate whether there is an association between the expression pattern of the two resolvin receptors in the spinal cord
and the expression of inflammatory cytokines and their respective metabolic enzymes, a correlation analysis was undertaken
in MIA (Table 3.3) and MNX (Table 3.4) rats. There was no correlation of ChemR23 expression with in flammatory cytokines
and metabolic enzymes in the spinal cord of the MIA model. There was a negative correlation of ALX with IL6 and a week
negative correlation with COX2 but a weak positive correlation between the ALX and 15-LOX in the spinal cord from MIA-
treated rats which were not shown in saline treated rats. Gene expression of ChemR23 in the spinal cord of sham rats was
negatively correlated with 5-LOX but positively correlated with COX2. Expression of ALX was positively correlated with IL1β 
and 5-LOX. There was no correlation between ChemR23 expression with other genes in the spinal cord of the MNX model
while ALX expression was positively correlated with IL1β. 
Treatment Genes TNFα IL1β IL6 5-LOX FLAP 15-LOX COX2 iNOS mPGES1 GFAP
Saline
ChemR23
r=0.03
p=0.94
r=0.16
p=0.71
r=0.03
p=0.94
r=0.35
p=0.39
r=0.50
p=0.21
r=0.67
p=0.08
r=-0.02
p=0.96
r=-0.21
p=0.62
r=-0.18
p=0.67
r=-0.03
p=0.94
ALX
r=0.88
p=0.41
x10-2*
r=0.52
p=0.18
r=0.59
p=0.12
r=-0.16
p=0.71
r=-0.29
p=0.48
r=-0.14
p=0.75
r=0.43
p=0.28
r=-0.26
p=0.53
r=0.32
p=0.45
r=-0.22
p=0.60
MIA
ChemR23
r=0.14
p=0.78
r=0.71
p=0.09
r=0.43
p=0.35
r=0.21
p=0.66
r=-0.18
p=0.72
r=0.29
p=0.56
r=0.14
p=0.78
r=0.14
p=0.78
r=0.18
p=0.71
r=-0.43
p=0.35
ALX
r=-0.43
p=0.35
r=0.36
p=0.43
r=-0.87
p=0.01*
r=-0.27
p=0.57
r=-0.08
p=0.89
r=0.70
p=0.08
r=-0.66
p=0.10
r=0.04
p=0.94
r=-0.14
p=0.77
r=-0.54
p=0.21
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Table 3.4 Correlation of ChemR23 and ALX expression with inflammatory cytokines (TNFα, IL1β and IL6) and associated meta-
bolic enzymes (5-LOX, FLAP, 15-LOX, COX2, iNOS, mPGES1, GFAP and TRPV1) in the ipsi-dorsal spinal cord from the MNX model
and sham control. Data were analyzed with Pearson or Spearman correlation (n=7-8, r is the co-efficient of correlation,
*p<0.05).
Groups Genes TNFα IL1β IL6 IL10 5-LOX 15-LOX COX2 mPGES1 GFAP TRPV1
Sham
ChemR23
r=0.03
p=0.95
r=0.06
p=0.89
r=0.28
p=0.50
r=0.11
p=0.82
r=-0.77
p=0.02*
r=0.10
p=0.84
r=0.76
p=0.03*
r=-0.09
p=0.84
r=-0.66
p=0.07
r=0.10
p=0.84
ALX
r=0.39
p=0.34
r=0.72
p=0.04*
r=0.46
p=0.25
r=0.62
p=0.14
r=0.75
p=0.03
r=-0.19
p=0.66
r=0.02
p=0.97
r=0.33
p=0.43
r=0.58
p=0.13
r=0.60
p=0.13
MNX
ChemR23
r=0.32
p=0.44
r=0.34
p=0.41
r=0.27
p=0.51
r=0.48
p=0.28
r=0.21
p=0.63
r=0.48
p=0.22
r=0.63
p=0.09
r=0.10
p=0.81
r=-0.29
p=0.49
r=0.17
p=0.69
ALX
r=0.57
p=0.14
r=0.91
p=0.20
x10-2*
r=0.42
p=0.30
r=-0.25
p=0.60
r=-0.39
p=0.34
r=-0.13
p=0.76
r=0.44
p=0.27
r=0.58
p=0.13
r=0.15
p=0.73
r=0.04
p=0.93
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3.3.12 Correlation of ChemR23 and ALX with pain behaviour in models of OA
Correlation of the expression of ChemR23 and ALX in the ipsilateral dorsal quadrant
of the spinal cord with pain behaviour (WB and PWT) in the MIA model (day14 and
day 35) and MNX model (Day 35) was determined. There was no correlation
between ChemR23 expression with pain behaviour at day 14 post MIA induction
(Fig3.25A; Fig3.25B). Expression of ALX was positively correlated with WB
(Fig3.25C) and negatively correlated with PWT (Fig3.25D) at day 14 MIA model.
At the later time-point (day 35), expression of ChemR23 in the spinal cord was
positively correlated with WB difference (Fig3.26A) and negatively correlated with
PWT (Fig3.26B). Expression of ALX was positively correlated with PWT (Fig3.26D)
but not WB difference (Fig3.26.C) at day 35 in the MIA model. These data suggest
that more pain was associated with higher ALX expression at early time-point (day
14) but lower ALX expression at late time-point (day 35) in the spinal cord from MIA
model. Furthermore, greater pain behaviour was associated with higher ChemR23
expression at late time point (day 35) in the spinal cord from MIA model.
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Fig 3.25 The correlation of mRNA level of ChemR23/ALX with weight bearing (A/C) and paw with-
drawal threshold (B/D) in the ipsi-dorsal spinal cord in the MIA model and saline control at day 14.
The maximal force for von Frey hair was 26g. Data were analysed with Spearman correlation.
MIA Day 14
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Fig 3.26 The correlation of mRNA level of ChemR23/ALX with weight bearing (A/C) and paw
withdrawal threshold (B/D) in the ipsi-dorsal spinal cord in the MIA model and saline control at
day 35. The maximal force for von Frey hair was 26g. Data were analysed by Spearman correla-
tion.
MIA Day 35
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In the MNX model, there was no correlation between the expression of ChemR23 or
ALX with either WB or PWT at day 35 in the ipsilateral dorsal quadrant of spinal cord
from the MNX model (Fig3.27).
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Fig 3.27 The correlation of mRNA level of ChemR23/ALX with weight bearing (A/C) and paw
withdrawal threshold (B/D) in the ipsi-dorsal spinal cord in the MNX model and sham control
at day 35. The maximal force for von Frey hair was 26g. Data were analysed by Spearman’s
correlation.
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3.3.13 Summary of results
 Pain behaviour was established and joint damage developed in both MIA and
MNX-induced models of OA.
 Expression of ChemR23 and 15-LOX were significantly lower in synovia from
the MIA model, at a time-point of established pain behaviour, compared to
controls.
 Expression of ALX, TNFα, IL1β COX2, EPHX2 and mPGES1 were  
significantly lower in synovia from the MNX model compared to sham control.
 There was no significant difference between ChemR23 and ALX expression in
synovia from the MIA and MNX models.
 There was no correlation of expression of ChemR23 with genes of interest in
synovia from either the MIA or MNX model.
 Expression of ALX was positively correlated with expression of TNFα and 
negatively correlated with expression of 5-LOX in the synovia from MIA-
treated rats but not saline-treated rats. ALX expression was positively corre-
lated with TNFα, IL1β, COX2, EPHX2 and mPGES1 in synovia from both 
sham and MNX rats.
 Higher synovial expression of ChemR23 was correlated with lower pain be-
haviours in the MIA model at both early (day 14) and late (day 35) time-points;
this was not the case for the MNX model. There was no correlation between
the expression of ALX in the synovia and pain behaviour in either model.
 Gene expression of ChemR23 was increased but 15-LOX was decreased in
the ipsilateral dorsal horn quadrant of the spinal cord in MIA rats, compared to
saline treated rats. These effects were not seen in the MNX model. However,
FLAP expression was significantly higher in the ipsilateral dorsal horn quad-
rant of the spinal cord from the MNX model, compared to sham control.
 Expression level of ALX was modestly higher than ChemR23 in the ipsilateral
spinal cord of saline treated rats but modestly lower in MIA-treated rats.
These differences were not evident in the MNX model.
 Greater levels of pain behaviour were associated with higher spinal cord ALX
expression at day 14 in the MIA model, but the converse was true at day 35.
 Greater levels of pain behaviour were associated with higher spinal cord
ChemR23 expression at day 35 in the MIA model.
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 There were no correlations between spinal expression of resolvin receptors
and pain behaviour in the MNX model.
 There was a negative correlation of ALX with IL6 and a week negative corre-
lation with COX2 but a weak positive correlation between the ALX and 15-
LOX in the spinal cord from MIA-treated rats which were not shown in saline
treated rats. These correlations were not shown in saline treated rats. It is
noteworthy that these correlations were not seen in the MNX rats.
 There was a positive correlation between ALX expression in the spinal cord
with IL1β in both the MNX model and sham control.  
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3.4 Discussion
3.4.1 Pain behaviour was established and joint pathology was shown in both the MIA
and MNX models.
Comparison of the MIA and MNX models showed pain behaviour (WB and PWT)
was established in both models and joint histology was comparable. However, the
progression of pain behaviour and pathology of OA were slightly different between
these two models. Pain behaviour was evident at very early time point ( day 3) in the
MIA studies presented in this thesis, which is consistent with previous studies
(Beyreuther et al. 2007). The behavioural as well as the histopathological data pre-
sented in this Chapter are also consistent with earlier studies using this model (Bove
et al. 2003; Sagar et al. 2010; Stevenson et al. 2011). Whereas, pain behaviour de-
veloped at later time points in the MNX model, compared to the MIA model. In the
first MNX study, both weight bearing asymmetry and lower paw withdrawal thresh-
olds were evident at day 7 and were maintained until the end of study at day 28.
However, in the second MNX study, weight bearing asymmetry was observed at day
18 and no significant change in paw withdraw thresholds were evident compared to
sham controls. This variable extent of pain behaviour exhibited by the MNX model
was also reported in previous studies (Janusz et al. 2002; Mapp et al. 2008; Mapp et
al. 2010; Mapp et al. 2013), which seems to be related to the extent of pain behav-
iour exhibited by the sham control. Indeed, the sham control underwent surgery that
removed medial collateral ligament from the joint, which may change the microenvi-
ronment and stability of joint (Jung et al. 2009; Guilak 2011). In addition, the surgery
itself can produce various levels of nerve damage, which could contribute to the
post-operative pain evident in the sham control (Bove et al. 2006). These factors
need to be taken into consideration when interpreting the gene expression studies
reported in the synovia from this model.
The development of joint pathology including chondropathy, synovial inflammation,
chondrocyte appearance and vascular channel breaching was comparable between
the two models of OA pain. Chondropathy score, synovial inflammation and chon-
drocyte appearance were significantly higher in MIA treated rats, compared to saline
controls. In the MNX model, only chondrocyte appearance was shown to be signifi-
cantly higher compared to sham control. The non-significant joint histopathology for
chondropathy score, inflammation score and vascular breaching osteochondral junc-
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tion in the MNX rats may mainly be masked by joint damage in the sham control as
the medial collateral ligament was removed. The number of rats per group may lead
to an under powered study resulting in non- significant results. This was also shown
in a previous study which indicated the higher chondropathy score and vascular
breaching in both MIA and MNX models but significance was not reached, compared
to their respective controls (Mapp et al. 2013). The variation between MIA and MNX
models may indicate different phenotypes and mechanisms in initiation and patho-
genesis of OA.
3.4.2 Resolvin receptors were altered in the two models of OA
Herein, I demonstrated for the first time that the expression of ChemR23 was altered
in both synovia and spinal cord in the MIA model and ALX expression was altered in
the synovia from the MNX model, compared to their respective controls.
The expression of ChemR23 was significantly lower in the synovia and higher in the
spinal cord in the MIA model at Day 35, compared to saline controls. Furthermore,
lower synovial expression of ChemR23 was correlated with higher pain behaviour in
the MIA model at both early (day14) and late (day 35) time-points and this was not
shown in the MNX model. This finding suggests that a loss of ChemR23 in the syno-
via may contribute to pain behaviour in the MIA model, which is consistent with a
previous study that found RvE1 reduced carrageenan-induced pain via ChemR23
and knockdown of ChemR23 in the hindpaw blocked the anti-nociceptive action of
RvE1 (Xu et al. 2010). These findings suggest a protective role of ChemR23 on pain
at the initial injury site. Given the amount of change occurring in the synovia of the
sham control, it isn’t surprising that this was not replicated in the MNX model. Higher
expression of ChemR23 in the spinal cord was associated with more severe pain
behaviour in the MIA model at day 35. This may be attributed to the increased acti-
vation of glial cells and increased neuronal responses that express ChemR23 in
spinal cord (Ji et al. 2011).
The expression of ALX was significantly lower in the synovia and had a trend to be
higher in the spinal cord in the MNX model at Day 35, compared to sham control.
Expression of ALX had a trend to be lower in the spinal cord of MIA rats, compared
to saline treated rats at day 35.
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Moreover, higher spinal expression of ALX was associated with more pain at day 14
and less pain at day 35 in the MIA model. These findings may suggest that different
cell-types express ALX at different time-points in the spinal cord of the MIA model as
microglia are reported to be activated at earlier time-points and astrocytes activated
at a late time-point at day 28 (Sagar et al. 2011). The expression of ALX increased in
the spinal cord at the early time (day 14) as pain developed and loss of ALX in the
spinal cord was associated with more pain at late time-point (day 35) in the MIA
model which may indicate protective role of ALX in this model
There was no correlation between spinal expression of resolvin receptors and pain
behaviour in the MNX model. Maybe this isn’t surprising as this model does not show
clear-cut central sensitization of pain.
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Pain behaviour
A scheme to summarise the expression of ChemR23 and ALX and their correlations
with pain behaviour in the two models is shown in Fig 3.28.
MIA MNX
Synovia Synovia
Osteoarthritis
+ +
ChemR23 ALX
- -
Spinal cord
+
>
Fig 3.28 Gene expression of resolvin receptors in the synovia and spinal cord and their correlation
with pain behaviour were shown in the MIA (magenta arrows) and MNX (blue arrows) models.
The red text shows correlation of resolvin receptors with pain behaviour in the synovia and the
red bold characters show correlation of resolvin receptors with pain behaviour in the spinal cord.
‘+’ /increase, ‘-’ /decrease. PC / positive correlation, NC / negative correlation, ‘>’ / greater
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3.4.3 Inflammatory cytokines and metabolic enzymes in synovia and spinal cord of the
two models of OA
In the current study, we didn’t find a significant difference in inflammatory cytokine
expression in both synovia and spinal cord in the MIA (1mg/50μL) rats compared to 
saline-treated rats. This was also reported in a previous study that no significant dif-
ference in inflammatory cytokines (IL-1β, IL6, MCP1, IL10, etc.) expression was ob-
served in serum of MIA- induced (50μg/5μl) OA (Bowles et al. 2014). In another 
study, only IL15 was up-regulated in early OA and there was no difference in TNFα, 
IL1β, IL2, IL6 and IL21 in synovial fluid between early OA and late OA (Scanzello et 
al. 2009). However, more studies have shown up-regulation of inflammatory cyto-
kines in the OA models and human OA.  Synovial inflammatory cytokines (TNFα, 
IL1β), COX2 and NF-κB were significantly increased in early stage compared to end
stage in OA patients (Benito et al. 2005). Lambert et al. has shown increased IL6,
IL8 and chemokines in the synovial membrane from OA patients (Lambert et al.
2014). Lee et al. has reported the increase of IL1β, IL6, IL15, and iNOS in cartilage 
of OA by intra-articular injection of MIA (3mg/50μl) (Lee et al. 2013). In the MNX 
model, expression of TNFα and IL1β, were significantly lower in the synovia, com-
pared to sham controls. The inconsistent findings may indicate tissue specific and
time-dependent inflammation at different phases of OA. It may also indicate lower
inflammation in these two models of osteoarthritis. In addition, the sham surgery also
induced pain behaviour and inflammation at the joints which may mask the up-
regulation of inflammatory genes expected to be observed in the MNX model. The
limitation for the MNX model is the expression of housekeeping genes (β-actin and 
GAPDH) was lower than sham control in the synovia which may also affect the nor-
malization of target genes.
I further demonstrated that the expression of 15-LOX was significantly lower in the
synovia of the MIA model and lower expression of COX2, mPGES1 and EPHX2 in
the MNX model, compared to respective controls. The findings in the MNX model
were not consistent with previous studies on metabolic enzymes in OA. COX2 was
up-regulated in OA-affected cartilage and meniscus, synovia and osteophytes of os-
teoarthritis by incubation of IL1β (Amin et al. 1997; Hardy et al. 2002). IL1β stimulat-
ed significant increase in COX2, mPGES1 and iNOS expression in cartilage and
synovial tissue of OA (Kojima et al. 2005; Alvarez-Soria et al. 2008). However, the
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up-regulation of these enzymes in OA was induced by exogenous adding IL1β, 
which is slightly different from the current study.
In the spinal cord, I found higher expression of COX2 in the MIA model although sig-
nificance was not reached. This indicates activation of astrocytes and central sensiti-
zation of pain in the model which is consistent with previous studies (Sagar et al.
2011). The expression of 15-LOX was significantly lower in the spinal cord of MIA
rats, compared to saline control, indicating a protective role of 15-LOX in OA as 15-
LOX metabolites inhibit IL1β-induced MMP1 and MMP13 in chondrocytes and type II 
collagen degradation cleavage from OA patients (Chabane et al. 2009).
Spinal expression of FLAP was significantly higher in the MNX model, compared to
sham control. The highly expressed FLAP in the spinal cord of the MNX model may
support the evidence that 5-LOX metabolites are involved in the inflammatory pro-
cess in OA or RA (Bonnet et al. 1995) and that FLAP is also required for the biosyn-
thesis of leukotriene, indicating its pro-inflammatory property (Dixon et al. 1990).
3.4.4 Resolvin receptors (ChemR23 and ALX) were associated with inflammatory cy-
tokines and metabolic enzymes in these two models of OA
There was no correlation between ChemR23 expression and inflammatory cytokines
or metabolic enzymes in both synovia and spinal cord in either MIA-induced or MNX-
induced model. These findings suggest there is dissociation between the relationship
of ChemR23 with pain behaviour versus inflammatory signalling in the MIA model.
Previous studies revealed RvE1 inhibited the inflammatory cytokines such as TNFα, 
IL1β, IL6 and MCP1 in inflammatory models of pain (Xu et al. 2010) or inflammatory 
cytokines and metabolic enzymes in inflammatory diseases or tissues (Arita et al.
2005; Schwab et al. 2007). My data may suggest that RvE1 inhibits pain behaviour
via other signalling pathways such as ion channels or inhibition of ERK mediated glu-
tamate release and activation of NMDA receptor (Xu et al. 2010) as gluta-
mate/NMDA receptor is an essential component on pain transmission and central
sensitization of pain (Latremoliere and Woolf 2009).
Expression of ALX was positively correlated with TNFα, IL1β, and COX2 and nega-
tively correlated with 5-LOX in synovia from MIA rats which was not shown in saline
treated rats. In the MNX model, expression of ALX was significantly positive corre-
lated with TNFα, IL1β, COX2 and mPGES1 in synovia from both MNX model and 
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sham control. These findings indicate that synovial expression of ALX was increased
in association with the inflammatory response, which may reflect the infiltration of
macrophages and fibroblast-like synoviocytes, which express ALX (Fiore et al. 2005).
Spinal expression of ALX was negatively correlated with IL6 and had a weak positive
and negative correlation with 15-LOX and COX2 respectively in the MIA model at
day 35. This may indicate the protective role of ALX in pain behaviour via inhibiting
inflammatory signalling in the spinal cord in this model. This was evident in previous
studies in which RvD1 reduced mechanical allodynia via inhibiting generation of
TNFα, IL1β and IL6 in a model of chronic pancreatitis (Quan et al. 2012) and 
RvD1/RvD2 dampened the inflammatory cytokines in obesity-induced adipose in-
flammation (Claria et al. 2012). There was no correlation of expression of ALX with
other genes in the spinal cord in the MNX model except a positive correlation with
IL1β. The correlation of ChemR23 or ALX expression with inflammatory cytokines 
and metabolic enzymes in the two models are summarized in Fig 3.29
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Fig 3.29 Gene expressionof resolvin receptors, inflammatory cytokines and metabolic enzymes in
the synovia and spinal cord and correlation of the resolvin receptors with these genes were
shown in the MIA (magenta arrows) and MNX (blue arrows) models. ‘+’ / increase, ‘-’ /decrease,
PC /positive correlation, NC /negative correlation.
IL6
MIA MNX
Spinal cord
FLAP
Osteoarthritis
15-LOX
ChemR23 ALX
-
+
+
NC
IL1β
PC
Synovia
TNFα, IL1β, COX2
5-LOX
TNFα, IL1β COX2,
EPHX2 and mPGES1 Synovia
Spinal cord
NC
PC
PC
- -
-
15-LOX
-
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3.5 Conclusion
Pain behaviour and joint pathology were established in both MIA and MNX-induced
models of OA. However, pain behaviour developed much quicker and more severely
in the MIA model than in the MNX model which may indicate two different pheno-
types and pathological signs of OA.
The expression of ChemR23 was altered in synovia and spinal cord in the MIA mod-
el and ALX expression was altered in the synovia from MNX model. Correlation of
ChemR23 and ALX with pain behaviour in the MIA model suggests a potential im-
portant role of resolvin receptors/ligands in OA pain. Furthermore, this correlation
may be associated with various cell types expressing the two receptors and may be
mediated via various molecular signalling pathways.
Lower expression of 15-LOX in both synovia and spinal cord in the MIA model indi-
cates active roles of these metabolic enzymes in modulation of osteoarthritic pain.
Correlation of ALX expression with inflammatory cytokines and associated metabolic
enzymes in the MIA model may suggest the action of ALX on osteoarthritic pain via
interaction with inflammatory signals and metabolic enzymes. However, the specific
mechanisms of resolvins and their receptors on osteoarthritic pain require further in-
vestigation.
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4 Therapeutic effects of a resolvin precursor in the MIA and MNX
model
4.1 Introduction
As shown in Chapter 3, expression of the resolvin receptors (ChemR23 and ALX)
and some associated enzymes were altered in the synovia and spinal cord from the
MIA and MNX models of OA pain. In this Chapter, I have investigated the effects of
exogenously augmenting the resolvin system on OA joint pathology and pain
behaviour in the MIA and MNX-induced models.
4.1.1Anti-inflammatory and pro-resolving roles of resolvins
As presented in the general introduction (Chapter 1.5.3), resolvins play essential
roles in curtailing the inflammation; this section briefly introduces the identification of
resolvins and their anti-inflammatory roles. The structure of RvD1 was identified by
Serhan’s group in 2007, they demonstrated anti-inflammatory properties of RvD1,
such as preventing transmigration and infiltration of neutrophils (Sun et al. 2007).
RvD1 was shown to play anti-inflammatory roles (macrophage phagocytosis and in-
hibition of neutrophil recruitment) and decreased inflammatory mediators (PGD2 and
LBT4) via FPR2 /ALX (Norling et al. 2012). Next, they identified the stereochemical
structure of RvD2 and showed that RvD2 can inhibit neutrophil infiltration, increase
phagocytosis of macrophage and down-regulate inflammatory mediators including
TNFα,IL1β,IL6, IL10, IL17, IL23 and PGE2 in microbial sepsis (Spite et al. 2009).
More recently, the stereochemical assignment of RvD3 was confirmed and similar
anti-inflammatory roles, such as inhibition of neutrophil infiltration, promoting phago-
cytosis of macrophage and modulating inflammatory cytokines (IL6 , MCP1and IL10)
were demonstrated (Dalli et al. 2013). Furthermore, effects of RvD3 on the phagocy-
tosis of macrophage were mediated by GPR32 (Dalli et al. 2013). RvD5 has been
shown to resolve E. coli infections by enhancing macrophage phagocytosis via
GPR32 and down-regulation of NF-kB and TNFα signalling (Chiang et al. 2012). 
E-series resolvins also have established anti-inflammatory and pro-resolving roles in
various inflammatory models. RvE1 was produced in inflammatory exudates after
treatment with Ω-3 PUFA and aspirin via COX2 and 5-LOX pathway, and was shown
to limit transmigration and infiltration of human polymorphonuclear leukocytes (neu-
trophils) but it was not defined as RvE1 at that time (Serhan et al. 2000). RvE1 at-
tenuates 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis by reducing leukocytes
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infiltration and down-regulating some inflammatory mediators such as TNFα, IL12, 
COX2 and iNOS (Arita et al. 2005). RvE2 was identified in human neutrophils, gen-
erated by the 5-LOX pathway during the biosynthesis of RvE1 (Tjonahen et al. 2006)
and can inhibit infiltration of PMNs (neutrophils) in murine peritonitis (Tjonahen et al.
2006). A further study showed RvE2 enhanced phagocytosis of human macrophag-
es and the production of anti-inflammatory cytokines such as IL10 via its GPCRs
(BLT1 and ChemR23) and decreased expression of integrin (CD18) in human PMN
and macrophage (Oh et al. 2012). RvE3 has been identified in eosinophils, rather
than neutrophil or macrophage, generated via 12/15-LOX pathway and can prevent
neutrophil chemotaxis (Isobe et al. 2012). Collectively, these studies have shown
that resolvins play anti-inflammatory or pro-resolving roles. Interestingly, resolvins
have also been shown to have anti-nociceptive roles in various models of pain (see
4.1.2).
4.1.2Analgesic effects of resolvins in models of pain
The analgesic effects of resolvins were first reported in inflammatory models of pain.
Both RvE1 and RvD1 attenuated inflammatory pain in mouse models of inflammato-
ry pain (formalin, carrageenan and CFA models) following intra-plantar and intra-
thecal routes of administration (Xu et al. 2010). RvE1 also reduced capsaicin and
TNFα-induced spontaneous pain and pain hypersensitivity in mice (Xu et al. 2010).  
This study demonstrated a role for ChemR23 in mediating the anti-nociceptive ef-
fects of the resolvins, which results in inactivation of ERK in pre- and post-synaptic
neurons (Xu et al. 2010). Concurrently, the anti-nociceptive effects of RvD1 were
shown to be mediated via actions at TRP channels on sensory nerves (Bang et al.
2010; Bang et al. 2010; Bang et al. 2012). RvD1 attenuated acute pain responses,
as well as mechanical and thermal hypersensitivity and inhibited expression of
TRPA1, TRPV3 and TRPV4 in DRG neurons (Bang et al. 2010). RvD1 was shown to
reduce acute nociceptive processing via an action at TRPV3 (Bang et al. 2012). Pre-
emptive spinal administration of RvD1 reduced post-operative pain (mechanical allo-
dynia and hyperalgesia) in the skin/muscle incision and retraction model, but only at
early stages of the model (Huang et al. 2011). Intrathecal injection of RvD1 attenuat-
ed chronic pancreatitis-induced mechanical allodynia in a dose-dependent manner,
an effect which was associated with inhibition of phosphorylation of NMDA receptors
and inhibition of expression of TNFα,IL1β and IL6 in neurons or microglia in the spi-
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nal dorsal horn (Feng et al. 2012). More recently, spinal administration of RvD1 was
reported to reduce mechanical hypersensitivity in the carrageenan model of inflam-
matory pain, which was associated with the inhibition of  TNFα in spinal astrocytes 
(Abdelmoaty et al. 2013). Intra-plantar injection of RvD2 was also shown to relieve
capsaicin-induced spontaneous pain, formalin, carrageenan and adjuvant-induced
inflammatory pain via inhibition of TRPA1 and TRPV1 (Park et al. 2011). Acute intra-
venous and intrathecal administration of RvD2 and AT-RvD1 decreased the mechan-
ical allodynia and thermal nociception in a model of fibromyalgia (Klein et al. 2014).
Spinal administration of RvE1 partially attenuated nerve injured pain (CCI and SNL)
by inhibiting activation of microglia and expression of TNFα in the spinal dorsal horn 
(Xu et al. 2012).
On top of the anti-inflammatory and anti-nociceptive roles, RvE1 decreases bone
resorption by inhibiting osteoclast growth and differentiation, these effects were me-
diated by the BLT1 receptor and were associated with inhibition of receptor activator
of NF-kB ligand-induced nuclear translocation (Herrera et al. 2008). A further study
showed RvE1 decreased osteoclast formation at the late stage of osteoclast matura-
tion, but not differentiation of early osteoclast precursor (Zhu et al. 2013). In addition,
RvE1 inhibited the fusion of osteoclast precursor, which is a critical step for osteo-
clast differentiation (Zhu et al. 2013). In addition to inhibiting bone resorption, RvE1
enhanced bone formation in a uniform craniotomy and in vitro study of primary oste-
oblasts demonstrated that bone-protective effects of RvE1 were mediated via in-
creased expression of OPG from osteoblasts (Gao et al. 2013).
The ability of the resolvins to modulate pain behaviour and neuronal responses in
models of inflammatory pain, coupled with the known effects on bone resorption,
makes this system an attractive target for the treatment of OA pain.
The major limitation of the resolvin system is that the active molecules are rapidly
metabolized (Serhan and Petasis 2011) and therefore unstable even when given via
a direct route ofadministration, e.g. intraplantar or intrathecal administration. How-
ever, a previous study revealed that systemic administration (intraperitoneal injection)
of the D-series precursor of resolvin, 17(R) HDoHE, reversed the mechanical hyper-
algesia in adjuvant-induced arthritis, following either pre-treatment or post-treatment
(Lima-Garcia et al. 2011). These analgesic effects were associated with an inhibition
of NF-κB and COX2 signalling in the DRG and spinal cord in this model of arthritis
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(Lima-Garcia et al. 2011). Based on this previous study, the aim of the work in this
Chapter was to determine the potential analgesic effects of systemic administration
of 17(R) HDoHE on OA pain behaviour and the mechanisms of action.
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4.1.3Objectives
 To investigate the effects of acute versus chronic administration of
17(R)HDoHE on MIA-induced pain behaviour and joint pathology.
 To determine the effects of 17(R)HDoHE treatment on the expression of
resolvin receptors, inflammatory cytokines and metabolic enzymes in the
synovia and spinal cord in the MIA model.
 To determine whether discontinuation of treatment with 17(R)HDoHE has
long- lasting analgesic effects in the MIA model of OA pain and to effects on
gene expression of resolvin receptors, inflammatory cytokines and metabolic
enzymes in the synovia in the MIA model
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4.2 Methods
The general methods for model induction, joint histological assessment and RT-PCR
have been described in Chapter 2. Sprague-Dawley male rats (130-150g) were ha-
bituated for environment and equipment before model induction and pain behaviour-
al test. They were also habituated for intra-peritoneal injection with sterile saline for 2
weeks before drug administration.
4.2.1Acute drug administration and pain behavioural testing in the MIA model
To investigate the acute effects of 17(R) HDoHE in the model, three groups
(MIA+17(R)HDoHE, MIA+vehicle (1% ethanol in saline) and saline+vehicle (1%
ethanol in saline) were used (n=8 per group). 17(R) HDoHE was administered
systemically at 300ng per rat by intra-peritoneal injection, based on previous pub-
lished work (Lima-Garcia et al. 2011). The working solution of drug was diluted from
the stock (100μg/1ml) into 1ng/1μl with sterile saline (1% ethanol). Baseline  
behaviour (WB and PWT) was tested at day 0, before intra-articular injection of MIA
(1mg/50μl) injection. Pain behaviour was then tested twice a week from day 3 until 
day 14.  17(R)HDoHE (300ng/300μl) or vehicle was injected i.p. on day 14, pain 
behaviour was measured at 1, 2, 4 and 6 hours post drug administration. Tissues
(synovia, quadrant spinal cords, and knee joints) were immediately harvested after
the final behavioural test on day 14 (Fig 4.1)
D0D-1
Habituation
Tissue
collection
MIA (i.a)
or saline
injection
D3
D7 D14
D10 1 h
2h
4h
6h
17(R)HDoHE
(i.p injection)
Fig 4.1 Rats were habituated a day before model induction. Baseline of behaviour (WB and
PWT) was tested before MIA injection on day 0 and pain behaviour was then tested twice a
week. 17(R HDoHE was administrated (i.p.) on day 14 and pain behaviour was measured at
1, 2, 4 and 6 hours post drug administration. Tissues were collected at 6 hours for subse-
quent gene expression studies.
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4.2.2Repeated drug administration and pain behavioural testing in the MIA model
To observe the potential chronic effects of 17(R)HDoHE in MIA and MNX-induced
osteoarthritic pain, the following groups of rats were used ( MIA+17(R)HDoHE,
MIA+vehicle-1% ethanol in saline, (n=6 per group), ( MNX+17(R)HDoHE,
MNX+vehicle, sham+ 17(R)HDoHE and sham+vehicle, n=8 per group).
Baseline pain behaviour (WB and PWT) was tested at day 0 before MIA (1mg/50μl) 
injection or MNX surgery. Pain behaviour was tested twice a week from day 3 -14
17(R) HDoHE (300ng/300μl per rat, i.p. injection) was administrated every other day 
from day 14 until day 28. Pain behaviour was tested every four days until day 28
post-drug administration and tissues were immediately harvested after the final
behavioural test on day 28 (Fig 4.2) :
D0D-1
Habituation
Tissue
collectionMIA or MNX
model induction
D3
D7 D14
D1 D18
D22
D26
D28
17(R)HDoHE
(i.p injection)
Fig 4.2 Rats were habituated before model induction. Baseline behaviour (WB and PWT)
was tested before MIA injection or MNX surgery (day 0) and then twice a week from day
3 - 14. 17(R) HDoHE was administered (i.p. injection) every other day and pain behaviour
was measured every 4 days post drug administration. Tissues were collected at day 28
for joint pathology.
Every other day
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4.2.3Discontinuous drug administration and pain behavioural testing in the MIA
model
To investigated the discontinuous treatment with 17(R)HDoHE in the MIA model,
MIA+17(R)HDoHE, MIA+vehicle and saline+vehicle(n=8 per group) were used. For
these studies, an extended protocol until day 35 was used to ensure adequate time
to determine the potential duration of the effect following treatment cessation. Pain
behavioural testing prior to drug administration was conducted as described in 4.2.2.
17(R) HDoHE (300ng/300μl per rat) was administrated (i.p injection) every other day 
from day 14 – 22. Following treatment on day 22, drug treatment was terminated;
pain behaviour was then tested for a further 2 weeks until day 35. Tissues were im-
mediately harvested after the final behavioural test at day 35.
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4.3 Results
4.3.1Effects of acute administration of 17(R) HDoHE in MIA-induced pain behaviour
and gene expression
Acute injection of 17(R) HDoHE transiently attenuated established MIA-induced pain
behaviour (weight bearing asymmetry (Fig 4.3 A) and lowered hindpaw withdrawal
thresholds (Fig 4.3B)). Inhibitory effects of 17(R) HDoHE were significant at 1 hour
and were maintained until 6 hours post-drug administration.
Fig.4.3 Intra-articular injection of MIA resulted in significant pain behaviour at 14 days post
model induction. Acute administration of 17(R)HDoHE attenuated pain behaviour in the MIA
model, compared to the effect of vehicle. Data are mean ± S.E.M (n= 8) analyzed with two-
way ANOVA and Bonferroni’s post-hoc test (*/#p<0.05, **/
##
p<0.01, ***p<0.001,
****
/####
p<0.001 vs control),’ # ‘MIA+17(R)HDoHE vs saline+vehicle, ‘*’ MIA+17(R)HDoHE vs
MIA+vehicle.
*
**** **** ****
***
## ##
##
####
* *
###
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4.3.1.1 Effects of 17(R) HDoHE on synovial expression of resolvin receptors, inflammatory
cytokines and enzymes in the MIA model
The levels of gene expression of ChemR23 and ALX, some inflammatory cytokines
and associated metabolic enzymes were quantified in synovia from acute vehicle
MIA and acute 17(R) HDoHE MIA rats at day 14. Expression of ChemR23 was sig-
nificantly lower in the synovia from MIA vehicle rats and 17(R) HDoHE treated MIA
rats, compared to saline treated-rats (Fig 4.4A), there was no difference between the
two MIA groups. There was no significant difference in the synovial expression of
ALX between any groups (Fig 4.4B).
Fig. 4.4 Expression levels of resolvin receptors in synovia at day 14 following intra-
articular injection of MIA or saline, and the effect of acute 17(R) HDoHE treatment.
ChemR23 (A) and ALX (B). Data were analyzed by one-way ANOVA with Bonferroni’s
post-hoc, P*< 0.05, P**< 0.05 (n=7-8 per group).
B
*
**A
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Acute administration of 17(R)HDoHE significantly upregulated the expression of IL6
(Fig 4.5C) in the synovia of MIA rats, compared to vehicle. None of the other in-
flammatory genes in the synovium were altered by 17(R)HDoHE (Fig 4.5).
Expression of the enzyme 5-LOX was significantly down-regulated by 17(R) HDoHE,
compared to vehicle (Fig 4.6A), in the MIA model. Acute 17(R) HDoHE did not alter
the expression of any other genes studied (Fig 4.6).
Fig.4.5 Expression levels of cytokines in the synovia at 14 days following intra-articular in-
jection of MIA or saline, and the effect of acute 17(R)HDoHE treatment in the MIA model.
Data were analyzed by one-way ANOVA with Bonferroni’s post-hoc test (n=7-8 per group).
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Fig. 4.6 Expression levels of metabolic enzymes in the synovia at 14 days following intra-
articular injection of MIA or saline, and the effect of acute 17(R) HDoHE treatment. Data
were analyzed by one-way ANOVA with Bonferroni’s post-hoc test (n=7-8 per group).
*
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4.3.1.2 Gene expression of resolvin receptors, inflammatory cytokines and enzymes in
the spinal cord in the MIA model
Gene expression of ChemR23 and ALX, inflammatory cytokines and associated
metabolic enzymes was quantified in ipsilateral quadrants of the spinal cord in rats
that received intra-articular injection of MIA (14 day), saline and MIA rats receiving
acute treatment with 17(R)HDoHE. There was no difference in the expression of
ChemR23 in the ipsilateral dorsal horn of spinal cord between the three groups (Fig
4.7A). By contrast, spinal expression of ALX (Fig 4.7B) appeared higher in the
MIA+vehicle group, compared to saline group, acute 17(R) HDoHE reduced this in-
crease. There was no significant difference in the gene expression of selected cyto-
kines (Fig 4.8) or metabolic enzymes (Fig 4.9) in the spinal cord between the three
groups.
Fig. 4.7 Expression levels of resolvin receptors in quadrants of spinal cord of MIA
vehicle, saline vehicle and MIA 17(R)HDoHE treated rats at day 14. Data were analyzed
by one-way ANOVA with Kruskal-Wallis with Dunn’s post-hoc test (n=6-8 per group).
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Fig.4.8 Expression levels of selected cytokines in quadrants of spinal cord. Data were
analyzed by Kruskal-Wallis with Dunn’s post-hoc test (n=6-8 per group).
Fig.4.9 Expression levels of metabolic enzymes in quadrants of spinal cord. Data were ana-
lyzed by Kruskal-Wallis with Dunn’s post-hoc test (n=6-8 per group).
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4.3.2 Analgesic effects of chronic 17(R) HDoHE administration in the MIA model
Chronic treatment with 17(R)HDoHE (300ng/300μl every other day from day 14 
until day 28 by i.p injection) significantly reversed OA pain behaviour in MIA rats, as
evidenced by a significant inhibition of weight bearing asymmetry (Fig 4.10A) and
lowered of hindpaw withdrawal thresholds (Fig 4.10B), compared to vehicle treat-
ment in MIA rats.
Fig.4.10 Intra-articular injection of MIA resulted in significant increases in weight bearing
difference and lowered hindpaw withdrawal thresholds. Data are mean ± S.E.M, analyzed by
two-way ANOVA with Bonferroni’s post-hoc test, *p<0.05, **p<0.01, ****p<0.001 vs con-
trol.
** * **
*
**** ****
****
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4.3.2.1 Chronic treatment with 17(R)HDoHE did not alter joint pathology in the MIA
model
Histological scores for chondropathy (Fig 4.11 A), synovial inflammation (Fig 4.11B),
chondrocytes appearance (Fig 4.11 C) and vascular channel breaching of the
osteochondral junction (Fig 4.11 D) were significantly higher in MIA rats, compared
to saline treated-rats. Overall, 17(R) HDoHE treatment did not significantly alter the
pathological scores of the joints from MIA rats, (Fig 4.11 A, Fig 4.11 B).
Fig.4.11 Intra-articular injection of MIA resulted in significant joint pathology at 28 days, com-
pared to saline injected rats. Chondropathy score (A), Synovial inflammation (B), Chondro-
cyte appearance (C) and Vascular channels across osteochondral junction (D) in MIA treated
rats. Data are mean ±S .E.M, analysed with One-way ANOVA with Bonferroni’s post-hot test
for parametric data(B and D) or Kruskal-Wallis with Dunn’s post-hoc test for non- parametric
data(A and C) (*p<0.05, **p<0.01).
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H&E staining revealed intact structures of knee joints in saline treated rats (Fig 4.12 A). Cartilage damage was evident in MIA rats
(Fig 4.12B) and 17(R) HDoHE did not attenuate the damage (Fig 4.12C). The synovium was composed of a single cellular layer in
saline treated rat (Fig 4.12D) but numbers of infiltrated cells increased in the synovium of MIA treated rat (Fig 4.12E).
17(R) HDoHE treatment from day 14 until day 28 post model induction did not alter joint pathology.
A Saline B
Saline
C
MIA+Vehicle
D MIA+VehicleE
MIA+17(R)HDoHE
F
Fig 4.12 Joint histology for saline, MIA with vehicle and MIA plus 17(R) HDoHE treated rats at day 28. Cartilage damage: Saline (A), MIA+vehicle(B) and
MIA+17(R)HDoHE (C); synovial inflammation: saline (D), MIA+vehicle (E) and MIA+ 17(R)HDoHE (F). Black arrows indicate chondropathy and synovial
inflammation, scale bar : 500μm, 100μm,150μm for MIA+vehicle.
MIA+17(R)HDoHE
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4.3.3 Effects of 17(R)HDoHE in the surgical medial meniscal transection model
MNX resulted in a significant increase in weight bearing difference (Fig 4.13A). Alt-
hough hindpaw withdrawal thresholds appeared lower in MNX rats changes were not
significant, compared to sham controls. Chronic treatment with 17(R)HDoHE
(300ng/300μl every other day from day 14 until day 28 by i.p injection) significantly 
attenuated weight bearing difference in the MNX model (Fig 4.13A),
Fig 4.13 Medial meniscal transection (MNX) resulted in a significant increase in weight bearing
difference, compared to sham control. Data are mean±S.E.M and were analyzed by two-way
ANOVA with Bonferroni’s post-hoc (*p<0.05, **p<0.01, ***p<0.001, vs sham vehicle, ##p<0.01
vs MNX vehicle, n= 5-8 per group)
** * *
*** ***
##
##
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4.3.3.1 Chronic treatment with 17(R) HDoHE did not alter MNX-induced joint pathology
Histological scores for chondropathy (Fig 4.14 A) and chondrocytes appearance
(Fig 4.14 C) were significantly higher in MNX rats compared to sham rats.
17(R) HDoHE treatment did not significantly alter the MNX-induced chondropathy
score or chondrocyte appearance score.
Fig.4.14 Histopathological assessment for knee joint in the MNX model and sham control and
respective treatment with 17(R)HDoHE day 28. Chondropathy (A), synovial inflammation (B),
chondrocyte appearance (C) and osteochondral junction (D). Data are mean±S.E.M analysed
by one-way ANOVA with Bonferroni’s post-hoc test (parametric data, B) or Kruskal Wallis with
Dunn’s test (non-parametric data, A, C, D) (*p<0.05, **p<0.01 vs controls, n= 7-8 per group).
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H&E staining revealed intact structures of knee joint in sham treated rats (Fig 4.15
A). Cartilage damage was evident in MNX rats (Fig 4.15 C) and 17(R) HDoHE did
not alter this damage (Fig 4.15D).
Sham+vehicle
A B
Sham+ 17(R) HDoHE
MNX+vehicle
C
MNX+ 17(R) HDoHE
D
Fig.4.15 Joint histology for 17(R) HDoHE treated MNX rats and respective controls. Black arrows indicate
the damage and scale bar was 500μm. 
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The synovium was a single cellular layer in the sham vehicle group (Fig 4.16A),
numbers of cells were increased in the synovim of MNX rat, indicative of synovial in-
flammation (Fig 4.16C). 17(R)HDoHE treatment from day 14 until day 28 post model
induction did not alter synovial inflammation (Fig 4.16D).
Sham+vehicle
A B
MNX+vehicle
C D
Fig.4.16 Representative sections of synovial inflammation in 17(R) HDoHE treated MNX rats and re-
spective controls (Sham vehicle (A), sham 17(R) HDoHE (B), MNX vehicle (C) and MNX 17(R)HDoHE
(D). Black arrows indicate synovial inflammation and scale bar was 100μm.  
Sham+ 17(R) HDoHE
MNX+ 17(R) HDoHE
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4.3.4 Analgesic effects of discontinuous 17(R)HDoHE administration in the MIA
model
To investigate the effect of discontinuous analgesic treatment with 17(R)HDoHE,
treatment was given from day 14-22 and MIA-induced pain behaviour was
quantified until day 35. Pain behaviour was established in the model before drug
administration and 17(R) HDoHE attenuated both weight bearing difference (Fig
4.17A) and paw withdrawal threshold (Fig 4.17B) from day 16 to day 22. Once
treatment was ceased, this inhibitory effect gradually wore off. Pain behaviour re-
turned back to the levels in MI vehicle group at day 35 (Fig 4.17).
Fig 4.17 Effects of discontinuous administration of 17(R)HDoHE in the MIA model from day
14 until day 35. Data are mean±S.E.M (n= 8 per group) analyzed by two-way ANOVA with
Bonferroni’s post-hoc test, ## p<0.01, ###p<0.001 compared to saline vehicle and *p<0.05,
**p<0.01, ***p<0.001 compared to MIA vehicle.
****
****
**** *
****
####
########
####
**
**
*
########
####
####
145
4.3.4.1 Gene expression of resolvin receptors, cytokines and enzymes in synovia and effects of discontinuous treatment with 17(R)
HDoHE
At day 35, expression of ChemR23 was significantly lower in the synovia from MIA rats, compared to saline vehicle rats
(Table 4.1). There was no significant difference in levels of gene expression between the MIA + 17(R) HDoHE group and
MIA vehicle group at day 35 after termination of the drug treatment (Table 4.1). 17(R) HDoHE did not modulate expression
level of any of the enzymes studied in the MIA model, compared to the saline group (Table 4.2).
Groups ChemR23 ALX TNFα IL1β IL6 IL10 
Sal veh 1.58±0.13 1.73±0.46 1.00±0.18 1.18±0.28 1.02±0.21 1.06±0.52
MIA veh 1.07±0.06** 2.51±1.03 1.05±0.24 1.87±0.79 1.87±0.66 1.16±0.49
MIA 17(R)HDoHE 1.10±0.10 1.40±0.43 0.78±0.14 1.20±0.35 0.98±0.13 1.17±0.60
.
Groups 5-LOX 15-LOX COX2 EPHX2 CYP2J2 mPGES1 iNOS
Sal veh 1.26±0.33 2.08±0.63 1.09±0.25 1.13±0.13 1.33±0.28 1.06±0.08 1.24±0.32
MIA veh 0.83±0.19 0.65±0.09 1.58±0.66 1.82±0.72 1.00±0.27 1.21±0.15 1.40±0.37
MIA 17(R)HDoHE 0.82±0.19 0.83±0.18 1.51±0.43 1.04±0.17 1.67±0.37 0.98±0.13 1.65±0.41
Table 4.1 Gene expression of resolvin receptors (ChemR23 and ALX) and inflammatory cytokines (TNFα, IL1β, IL6 and IL10) in the syno-
via from saline control, the MIA model and discontinuous treatment with 17(R)HDoHE in the MIA model at day 35.
Table 4.2 Gene expression of metabolic enzymes (5-LOX, 15-LOX, COX2, EPHX2, CYP2J2, mPGES1 and iNOS) in the synovia from saline
control, the MIA model and discontinuous treatment with 17(R)HDoHE in the MIA model at day 35.
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4.3.5Summary of results
 Acute injection of 17(R)HDoHE transiently attenuated pain behaviour in the
MIA model at day 14, compared to the effect of vehicle.
 Expression of ChemR23 in the synovia was significantly lower in MIA rats at
day 14 and day 35, compared to saline controls.
 Acute injection of 17(R)HDoHE was associated with a significant increase in
the expression of IL6 and down-regulation of 5-LOX expression in the synovia
of MIA model at day 14, compared to vehicle control.
 Chronic 17(R) HDoHE produced a sustained attenuation of OA pain behaviour
in the MIA model. Chronic 17(R)HDoHE produced a sustained attenuation of
weight bearing asymmetry in the MNX model.
 Chronic treatment with 17(R)HDoHE did not significantly alter MIA or MNX -
induced joint pathology.
 The effects of 17(R)HDoHE on MIA-induced weight bearing asymmetry were
maintained for up to a week following cessation of treatment, but then pain
behaviour returned to levels comparable to those exhibited in MIA vehicle rats.
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4.4 Discussion
In the current Chapter, I have demonstrated the analgesic effects of a precursor of
resolvin D-series (17(R)HDoHE) in a series of studies on MIA and MNX-induced
OA pain and investigated the underlying mechanisms of the action.
Firstly, I demonstrated 17(R)HDoHE had robust analgesic effects on OA pain behav-
iour in the MIA and MNX-induced models following systemic administration. Acute
administration of 17(R)HDoHE significantly increased the expression of IL6 and
down-regulated the expression of 5-LOX in the synovia of MIA rats, compared to ve-
hicle control. These findings may suggest the acute inhibitory effects of 17(R)HDoHE
on OA pain via a peripheral site of action.
17(R)HDoHE produced a sustained analgesic effect in the MIA model during drug
administration and this effect was maintained for a week after drug cessation, which
may indicate transient effects of the drug to OA pain. The mechanisms of chronic in-
hibitory effects of 17(R)HDoHE to treat OA pain are still unclear as joint pathology
was not significantly improved by the compound.
4.4.1The acute analgesic effects of 17(R)HDoHE in the MIA model
Acute administration of 17(R)HDoHE showed a transient effect to attenuate pain be-
haviour (WB and PWT) in the MIA model. Weight bearing asymmetry was reduced
by 17(R)HDoHE from 1h until 6h post drug administration. Ipsilateral paw withdrawal
threshold was significantly reversed by 17(R)HDoHE at 1h and 6 h in the model. The
acute effects of 17(R)HDoHE showed here in the MIA model are consistent with a
previous study in the AIA model (Lima-Garcia et al. 2011). Concurrently, I found the
up-regulation of IL6 in the synovia after treatment with 17(R)HDoHE, compared to
vehicle control. The enhanced expression of IL6 here may indicate its anti-
inflammatory role in the acute inflammation and OA which has been shown in some
previous studies (Van De Loo et al. 1997; Xing et al. 1998). IL6 can induce the syn-
thesis of TIMP1 in chondrocytes, fibroblasts and synoviocytes (Lotz and Pa 1996)
and was positively correlated with proteoglycan synthesis, but it was also increased
in OA synovial fluid which may also act on chondrocytes (Venn et al. 1993). This
may indicate dual roles of IL6 in the pathogenesis of OA (Venn et al. 1993; Lotz and
Pa 1996; Westacott and Sharif 1996). 17(R)HDoHE also reduced the expression of
5-LOX in the synovia from MIA rats, compared to MIA vehicle rats, suggesting the
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effects of 17(R)HDoHE on pain behaviour may involve the inhibition of 5-LOX, which
is an essential enzyme for the metabolism of arachidonic acid to down-stream pro-
inflammatory lipid mediators such as leukotrienes (Burnett and Levy 2012) and is
over expressed in synovial tissues promoting progress of inflammatory arthritis
(Gheorghe et al. 2009; Lin et al. 2014). No alteration of the inflammatory cytokines
and associated metabolic enzymes was observed in the spinal cord after treatment
with 17(R)HDoHE. This may indicate that the effects of this intervention on pain are
predominantly mediated by peripheral mechanisms at the primary site of injury. It is
possible that the effects are mediated via actions on ion channels, including the TRP
channels (Bang et al. 2010). Nevertheless, it also could be that 17(R)HDoHE re-
duced the pain behaviour via inhibition of central components such as neuronal hy-
perexcitability (Xu et al. 2010) or activation of glial cells (Xu et al. 2012)
4.4.2Aanalgesic effects of chronic 17(R)HDoHE administration in the MIA and MNX
model
My studies further revealed 17(R)HDoHE produced a sustained analgesic effect in
both MIA and MNX models following repeated administration.
17(R)HDoHE reduced weight bearing asymmetry in both the MIA and MNX model.
This may further suggest 17(R)HDoHE attenuated OA pain in peripheral sites and
by peripheral mechanisms as evident in 4.4.1 and some previous studies of the ef-
fects of the resolvin receptor (Xu et al. 2010) on inflammatory signalling (Lima-Garcia
et al. 2011; Feng et al. 2012; Abdelmoaty et al. 2013) and TRP channels (Bang et al.
2010; Bang et al. 2010; Bang et al. 2012). However, the inhibitory effects of
17(R)HDoHE on the ipsilateral hindpaw withdrawal thresholds also indicate an effec-
tive central sensitization of pain at the distal sites in the MIA model but less so in the
MNX model. This observation in the MNX model may be due to the sham surgery
which also had lowered the hindpaw withdrawal threshold, which may mask the an-
algesic effects of the 17(R)HDoHE on this type of pain behaviour in this model.
In the joint histological assessment, repeated administration of 17(R)HDoHE failed to
improve the joint histopathology in both the MIA and MNX models. This may suggest
the analgesic effects of 17(R)HDoHE are not overly involved in bone remodelling in
the joint and may be more contributed by other peripheral and central components.
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4.4.3Effects of 17(R)HDoHE by discontinuous administration in the MIA model
I also investigated the potential maintenance of analgesic effects of 17(R)HDoHE in
the MIA model with a discontinuous treatment protocol. 17(R)HDoHE attenuated the
pain behaviour (WB and PWT) during drug administration, which was consistent with
previous studies in the MIA model. 17(R)HDoHE produced a sustained analgesic ef-
fect for a week after termination of treatment and then pain behaviour returned to
the level of vehicle-treated MIA rats at day 35 (two weeks after cessation of
17(R)HDoHE ). This was different from the traditional analgesic drugs such as opi-
oids which often exhibit anti-nociceptive tolerance after repeated administration
(Collett 1998).
Given that the effects of the intervention had ceased by the time when tissues were
collected, it is not surprising that I observed no effect of this intervention on levels of
inflammatory cytokines and enzymes. Expression of IL6 was decreased in the cur-
rent study but up-regulated in the acute administration of 17(R)HDoHE in the MIA
model. This further demonstrated the dual role of IL6 in inflammation (Kaplanski et al.
2003) with an anti-inflammatory role in acute inflammation (Xing et al. 1998) and
pro-inflammatory properties in the late stage of inflammation (Scheller et al. 2006).
As 17(R)HDoHE failed to show significant improvement of joint pathology in previous
chronic studies and pain behaviour was worn off at the end of this study, joint pa-
thology was not assessed here. This study further demonstrated that the analgesic
effects of 17(R)HDoHE were transient in the MIA model but mechanisms for the in-
hibition of pain behaviour need further investigation.
The limitations of the studies were to demonstrate the specific mechanisms, espe-
cially the central mechanisms on pain control. Some of the mechanisms such as
blocking spinal synaptic plasticity or microglial activity may contribute to the modula-
tion of pain behaviour. As previous studies have shown spinal administration of
RvE1 can block the activity of TRPV1 and TNF-α-evoked NMDA receptor hyperactiv-
ity in the spinal cord (Xu et al. 2010) and prevent neuropathic pain by blocking mi-
croglial singling in the spinal cord (Xu et al. 2012). It may also be possible that 17(R)
HDoHE modulates bone resorption and bone formation to improve OA pain, as RvE1
has been shown to decrease bone resorption by inhibiting osteoclast growth and dif-
ferentiation (Herrera et al. 2008) and decrease osteoclast formation (Zhu et al. 2013).
On the other hand, RvE1 enhanced bone formation and expression of OPG from os-
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teoblasts (Gao et al. 2013). However, understanding of the anti-nociceptive roles of
resolvins on pain still needs further investigation.
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5 Expression levels of target genes in synovia and knee joints of
human OA.
5.1 Introduction
Currently, no investigation of resolvins on OA has been reported. However, the ef-
fects of Ω-3 PUFAs, which are the precursors to resolvins and other lipid mediators, 
on OA or RA have been shown in some previous studies in human samples and an-
imal models. This may help us understand the association of resolvins with human
OA better.
Supplementation with Ω-3 PUFAs decreased IL1-induced release of proteoglycan 
and blocked proteolytic activity of collagenase and aggrecanase in human cartilage
from osteoarthritis (Curtis et al. 2002). In addition, Ω-3 PUFAs inhibited IL1-induced 
mRNA expression of 5-LOX, COX2, FLAP, TNFα, IL1β, MMP3, MMP13, and 
ADAMTS-4 in cultured cartilage from human OA (Curtis et al. 2002). A meta-
analysis revealed supplementation with Ω-3 PUFAs for 3–4 months attenuated joint
pain, stiffness of joint and number of painful joints in RA (Goldberg and Katz 2007).
DHA and EPA, two Ω-3 PUFAs, inhibited IL1β-induced degradation of bovine carti-
lage (Wann et al. 2010). Supplementation of Ω-3 PUFAs also improved histopatho-
logical scores of right tibial plateau, increased pro-MMP9 and decreased MMP2 acti-
vation in guinea pig model of spontaneous OA (Knott et al. 2011). Endogenous Ω-3 
PUFAs were increased in the cartilage of DMM-induced osteoarthritis compared to
sham controls in wild-type mice. In addition, DMM mice transfected with fat-1gene,
which encodes a Ω-3 PUFAs desaturase and converts Ω-6 PUFAs to Ω-3 PUFAs, 
have lower ratio of Ω-6 PUFAs /Ω-3 PUFAs (Huang et al. 2014). Moreover, the en-
dogenously increased Ω-3 PUFAs and decreased Ω-6 PUFAs reduced formation of 
osteophyte and cartilage damage, inhibited expression of MMP-13 and ADAMTS-5
and decreased chondrocytes number in the DMM model (Huang et al. 2014).
Ω-3 PUFAs are beneficial for various diseases such as cardiovascular diseases 
(Lavie et al. 2009), inflammatory diseases including arthritis (Calder 2006) and can-
cer (Rose and Connolly 1999).  Lipid mediators derived from Ω-3 PUFAs were re-
ported in various tissues in both healthy people and patients with RA. A previous
study has identified profiles of pro-resolving and anti-inflammatory lipid mediators
such as lipoxins, resolvins, protectins and maresins in serum and lymphoid tissues
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from 100 healthy volunteers by liquid chromatograph- mass spectrometry (LC-MS).
Furthermore, levels of RvD1, RvD2, RvD3, MaR1, and NPD1/PD1 were quantified
within their bioactive ranges (Colas et al. 2014). In the serum and plasma of healthy
volunteers given Ω-3 PUFAs for 3 weeks, the resolvin precursors, RvD1 and  RvD2 
were identified and quantified and levels of RvD1 and RvD2 were within the biologi-
cal range which showed anti-inflammatory action (Mas et al. 2012). Supplementation
with Ω-3 PUFAs for 7 days significantly increased levels of RvE1, 18R/S-HEPE, 
17R/S-HDHA, and 14R/S-HDHA in the plasma of healthy individuals (Barden et al.
2014). Lipidomic screening by LC-MS identified and quantified the levels of RvD5,
maresin 1 and lipoxin A4 in the synovial fluid from RA patients (Giera et al. 2012).
Hydroxy-derivatives from PUFAs, RvD5, maresin 1 and lipoxinA4 were detected in
synovial fluid of human OA (Giera et al. 2012). In addition, metabolites from other
PUFAs and metabolic enzymes are also involved in human OA. Expression of 15-
LOX1 and 15-LOX2 were firstly identified in the chondrocytes of human OA. 13(S)-
hydroxy octadecadienoic acid (13-HODE) and 15(S) - hydroxyeicosatetraenoic acids
(15-HETE), which were derived from LA and AA via 15-LOX, inhibited TNFα-induced, 
IL-1β-induced and IL17-induced  protein and mRNA levels of MMP-1 and MMP-13 in 
chondrocytes from OA patients (Chabane et al. 2009).
As we have shown robust (sgnificant) analgesic effects of 17(R) HDoHE in a series
of animal experiments on osteoarthritic pain in the MIA model and weight bearing in
the MNX model and investigated the underlying mechanisms (see Chapter 4). Fur-
thermore, expression of ChemR23 was negatively associated with pain behaviour in
the synovia of MIA model, which indicated the possibility of aloss of ChemR23 in-
duced severe pain behaviour. Correlation between expression of ALX and pain be-
haviour was also shown in the spinal cord in the MIA model at different time points
(positive correlation at day 14 and negative correlation at day 35). Expression of
ALX was positively correlated with TNFα and negatively with 5-LOX in the synovia of 
MIA model. In addition, expression of ALX was negatively correlated with expression
of COX2 and IL6 and positively correlated with 15-LOX in the spinal cord in MIA
model. Therefore, it is of interest to see how the resolvin receptor system might be
altered in human OA to seek clinical evidence for the association between resolvins,
resolvin receptors and inflammatory cytokines or their associated metabolic enzymes
in OA patients.
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5.2 Aim and objectives
Aim:
To investigate the expression of the resolvin receptor system in human OA tissues.
Objectives:
 To compare expression levels of ChemR23 and ALX in synovia and medial
tibial plateau from OA patients.
 To identify the potential for correlation between the two resolvin receptors with
inflammatory cytokines and their metabolic enzymes in synovia and medial
tibial plateau OA patients.
 To investigate the potential for correlation between expression of target genes
between synovia and medial tibial plateau from OA patients.
 To compare gene expression of resolvin receptors, inflammatory cytokines
and metabolic enzymes between the medial tibial plateau from human OA
and femoral heads from trauma patients.
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5.3 Methods
In the current study, 16 OA patients with TKR and 5 trauma patients were recruited
(The ethic approval letter and personal research passport are attached in the appen-
dices of the thesis and consenting forms were kept by the bio-bank at the City Hospi-
tal, University of Nottingham). A patient who was diagnosed with spondyloepiphyseal
dysplasia was excluded later. Synovia from 15 OA patients, fresh medial tibial plat-
eau from 14 OA patients and fresh femoral heads from 5 trauma patients were used
to quantify gene expression of resolvin receptors, inflammatory cytokines and asso-
ciated metabolic enzymes. The general methods for sample collection, sample pro-
cessing and quantification of gene expression have been detailed in Chapter 2 (see
2.8 and 2.9).
To make an objective assessment on the correlation between expression of resolvin
receptors (ChemR23 and ALX) and genes of interest, some risk factors for osteoar-
thritis such as body mass index (BMI) and age which may affect expression levels of
target genes were evaluated as well (Manek et al. 2003; Rai et al. 2013; Rai et al.
2014).
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Table 5.2: The basic information for trauma patients investigated in the study. BMI
Categories: Underweight ≤18.5; Normal weight = 18.5–24.9; Overweight = 25–
29.9 and Obesity = 30 or greater. ‘-‘indicates as not available.
Patients’ data are summarized in Table 5.1 and Table 5.2.
Biobank ID Sex Age TKR BMI Collected Date
13/005449 M 66 Left knee 34.7 19/11/2013
13/005465* F 69 Right Knee 32.4 19/11/2013
13/005243 M 55 Left knee 35.8 05/11/2013
13/05469 M 67 Right Knee 24.5 21/11/2013
13/005268 F 79 Right Knee 30.9 03/12/2013
13/003012 F 67 Left knee 40.1 17/12/2013
14/0000349 M 65 Left knee 36.9 28/01/2014
14/000776 F 64 Left knee 37.3 25/02/2014
14/000778 F 68 Right Knee 26.5 25/02/2014
14/000845 F 51 Right Knee 37.7 04/03/2014
14/001134 M 60 Right Knee N/A 25/03/2014
14/001241 F 58 Left knee 37.8 01/04/2014
14/001347 F 72 Left knee 31.1 08/04/2014
14/001354 F 82 Right Knee 25.7 08/04/2014
14/001632 M 70 Left knee 27.5 06/05/2014
14/001638 M 79 Right Knee 36.1 06/05/2014
Biobank ID Sex Age Tissue collected BMI Collected Date
14/001104 F - femoral head 22.3 21/03/2014
14/001165 M - femoral head - 27/03/2014
14/001242 F - femoral head - 01/04/2014
14/001384 F - femoral head 15.8 11/04/2014
14/001423 M - femoral head - 16/04/2014
Table 5.1: The basic information for OA patients investigated in the study. BMI Cat-
egories: Underweight ≤18.5; Normal weight = 18.5–24.9; Overweight = 25–
29.9 and Obesity = 30 or greater. ‘*’indicates the excluded non-OA sample.
M/male, F/female.
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5.4 Results
5.4.1mRNA levels of ChemR23 and ALX in the synovia and medial tibial plateau
from OA patients
Gene expression of ChemR23 was significantly higher than ALX in synovia, but not
in the medial tibial plateau in OA patients (Fig 5.1A, Fig 5.1B).
Fig 5.1 mRNA levels of resolvin receptors in the synovia and medial tibial plateau from OA
patients. Data are mean ± S.E.M, analyzed with Mann-Whitney t-test (****p< 0.0001).
A B
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5.4.2Correlation of resolvin receptors with genes of interest in the synovia of OA patients
5.4.2.1 mRNA levels of genes of interest in the synovia
Gene expression of resolvin receptors, inflammatory cytokines and associated metabolic enzymes in the synovia
from OA patients was summarized in the Table 5.3.
Genes/sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
ChemR23 0.90 0.88 1.25 1.06 1.08 0.85 1.42 1.09 1.03 0.33 0.81 0.75 1.23 0.92 1.16
ALX 0.13 0.21 / 0.27 0.13 0.36 0.17 0.20 0.26 1.24 0.62 0.12 0.87 0.19 0.24
TNFα 0.70 0.85 0.85 0.88 1.56 0.97 1.11 1.50 1.76 1.04 0.88 1.62 0.83 0.93 1.36
IL6 0.45 0.41 2.55 0.90 0.74 2.86 0.55 0.59 0.77 1.98 1.21 0.69 1.15 1.15 0.61
5-LOX 0.81 1.01 1.45 1.34 0.85 0.66 1.10 0.82 1.09 0.33 0.47 0.57 0.86 0.99 1.10
15-LOX1 0.07 0.09 / 0.25 0.02 0.15 0.11 0.10 0.13 0.68 0.28 0.06 0.80 0.05 0.04
15-LOX2 0.68 0.23 0.42 0.77 0.47 0.77 0.23 0.96 1.02 0.60 1.52 / 1.59 0.59
COX2 1.11 0.75 0.91 1.13 1.03 0.91 1.11 1.15 0.90 0.50 0.94 0.94 0.90 0.90 0.92
Table 5.3: mRNA levels of target genes (normalized to β-actin) in the synovia of OA patients. Synovial samples from 15 OA patients
with TKR were used to quantify the expression levels of target genes. ‘/’ was the excluded outlier with Grubb’s test.
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5.4.2.2 Correlation of resolvin receptors with genes of interest in the synovia of OA pa-
tients
There was a positive correlation between gene expression of ChemR23 and 5-LOX
(Fig 5.2D).
Fig 5.2 Correlation of expression of ChemR23 with inflammatory cytokines (TNFα and IL6) and
associated enzymes (COX2, 5-LOX, 15-LOX1 and 15-LOX2) in the synovia from OA patients
(n=14-15).
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Table 5.4: Correlation of BMI/age with expression of resolvin receptors (ChemR23 and ALX), in-
flammatory cytokines (TNFα and IL6) and metabolic enzymes (COX2, 5-LOX, 15-LOX1 and 15-LOX2) 
in the synovia from human OA.
Fig 5.3 Correlation of ALX expression with inflammatory cytokines and enzymes in the synovia
of OA patients (n=14-15).
Expression of ALX was positively correlated with IL6 (Fig 5.3B) and 15-LOX1 (Fig
5.3E).
5.4.2.3 Correlation of BMI and age with genes of interest in the synovia
Correlation analysis of BMI and age with selected target genes is shown in Table 5.4.
There was no correlation of BMI or age with resolvin receptors and any other genes in the synovia in
OA patients
Factors ChemR23 ALX TNFα IL6 COX2 5-LOX 15-LOX1 15-LOX2
BMI
r=-0.45
p=0.11
r=0.06
p=0.85
r=-0.60x10-2
p=0.98
r=-0.12
p=0.68
r=0.01
p=0.98
r=-0.35
p=0.22
r=-0.11
p=0.72
r=0.05
p=0.89
Age
r=0.06
p=0.82
r=-0.20
p=0.49
r=-0.16
p=0.56
r=0.17
p=0.55
r=0.22
p=0.42
r=0.10
p=0.74
r=-0.04
p=0.89
r=0.47
p=0.10
160
5.4.3Correlation of resolvin receptors with genes of interest in the medial tibial plateau of OA patients
5.4.3.1 mRNA levels of genes of interest in the medial tibial plateau
Gene expression of resolvin receptors, inflammatory cytokines and associated metabolic enzymes in the medial tibial plateau from
OA patients was quantified in Table 5.5.
Genes/sample 1 2 3 4 5 6 7 8 9 10 11 12 13 14
ChemR23 2.73 2.37 1.15 1.86 1.35 0.81 1.81 4.42 0.82 1.98 1.22 1.29 1.41 1.00
ALX 2.61 2.20 0.25 0.54 0.79 0.18 1.16 2.90 0.22 2.97 0.33 0.34 0.64 0.20
TNFα 0.46 1.60 1.16 1.13 0.65 0.57 1.28 0.70 0.81 0.44 0.78 1.24 1.02 0.45
IL6 0.08x
10-1
0.09x
10-1
0.09x
10-1
0.08x
10-1
0.06x
10-1
0.07x
10-1
0.13x
10-1
0.27x
10-1
0.03x
10-1
0.21x
10-1
0.07x
10-1
0.24x
10-1
0.05x
10-1
0.05x
10-1
5-LOX 0.40 1.74 0.75 0.86 0.29 0.38 1.14 3.20 0.43 0.46 0.56 1.21 0.90 0.43
15-LOX1 2.26 2.34 0.41 0.50 1.57 0.79 0.95 2.69 0.25 1.20 0.73 0.19 0.46 0.91
15-LOX2 0.18 0.10 0.92 0.40 0.49 0.66 0.69 0.36 2.60 2.31 0.23 0.55 0.94 2.68
COX2 0.11 0.01 0.06 0.04 0.10 0.12 0.02 0.05 0.02 0.03 0.02 0.08 0.02 0.04
Table 5.5: mRNA levels of target genes (normalized to β-actin) in the medial tibial plateau of OA patients. Medial tibial
plateau from 14 OA patients with TKR were used to quantify expression levels of target genes.
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5.4.3.2 Correlation of resolvin receptors with genes of interest in medial tibial plateau
Expression of ChemR23 was positively correlated with IL6 (Fig 5.4B), 5-LOX (Fig
5.4D) and 15-LOX1 (Fig 5.4E) and negatively correlated with 15-LOX2 (Fig 5.3C)
Fig 5.4 Correlation analysis of ChemR23 expression with inflammatory cytokines and enzymes in
the medial tibial plateau of OA patients (n=14).
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Expression of ALX was positively correlated with IL6 (Fig 5.5B) and 15-LOX1 (Fig
5.5E).
5.4.3.3 Correlation of BMI and age with genes of interest in the medial tibial plateau
Correlation analysis of BMI and age with expression of selected target genes in the
medial tibial plateau from OA patient is shown in Table 5.6. BMI was negatively cor-
related with expression of TNFα, 5-LOX and 15-LOX1 but not correlated with resol-
vin receptors and any other genes. Age showed a negative correlation with the ex-
pression of ChemR23 and 15-LOX1 but not with ALX and any other genes.
Factors ChemR23 ALX TNFα IL6 COX2 5-LOX 15-LOX1 15-LOX2
BMI
r=-0.41
p=0.17
r=0.44
p=0.14
r=-0.76
p=0.34x
10-2*
r=-0.24
p=0.43
r=0.31
p=0.31
r=-0.70
p=0.01*
r=-0.75
p=0.42
x10-2*
r=0.22
p=0.47
Age
r=-0.53
p=0.052*
r=-0.43
p=0.12
r=-0.08
p=0.78
r=-0.17
p=0.54
r=0.15
p=0.61
r=-0.43
p=0.12
r=-0.64
p=0.01*
r=0.14
p=0.63
Fig 5.5 Correlation analysis of ALX expression with inflammatory cytokines and enzymes in me-
dial tibial plateau of OA patients (n=14).
Table 5.6 Correlation of BMI/age with expression of resolvin receptors (ChemR23 and ALX), in-
flammatory cytokines (TNFα and IL6) and metabolic enzymes (COX2, 5-LOX, 15-LOX1 and 15-LOX2) 
in the medial tibial plateau from human OA.
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5.4.3.4 Correlation of the expression of target genes between synovia and medial tibial
plateau in human OA
There was no significant correlation of expression of the target genes between the
two tissues with a weak trend of positive correlation for 15-LOX2 (Fig 5.6H).
Fig 5.6 Correlation analysis of gene expression between synovia and tibial plateau in human OA
(n=13-14).
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5.4.4Comparison of gene expression of resolvin receptors and other genes in OA
patients and trauma patients
Expression of ALX (Fig 5.7B), TNFα (Fig 5.7C), IL6 (Fig 5.7D), 5-LOX (Fig 5.7E)
and COX2 (Fig 5.7H) in medial tibial plateau were significantly lower from OA pa-
tients, compared to trauma patients which may indicate more inflammation in trauma
patients.
To sum up, correlation of expression of resolvin receptors with associated metabolic
enzymes (5-LOX, 15-LOX and COX2) and inflammatory cytokine (IL6) has been
demonstrated in the synovia and tibial plateau in OA patients. These findings indi-
cate potential protective roles of resolvins/resolvin receptors and their metabolic en-
zymes in OA, however, specific mechanisms on this need investigation in depth.
Fig 5.7 Expression levels of genes of interest in the medial tibial plateau from OA and femoral
heads from non-OA patients with trauma. Data are presented as mean±S.E.M and analyzed
with Mann-Whitney t-test( *p<0.05, ***p<0.001).
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5.4.5Summary of results
 Resolvin receptors, inflammatory cytokines and metabolic enzymes were
quantified in both synovia and medial tibial plateau from OA patients.
 Expression of ChemR23 was significantly higher than ALX in synovia of OA
patients.
 Expression of ChemR23 was positively correlated with 5-LOX in both synovia
and medial tibial plateau from OA patients. Expression of ChemR23 showed a
positive correlation with IL6 and 15-LOX1 and a negative correlation with 15-
LOX2 in the medial tibial plateau but not in the synovia.
 Expression of ALX was positively correlated with IL6 and 15-LOX1 in both
synovia and medial tibial plateau in OA patients.
 There was no correlation of BMI and age with genes of interest in the synovia.
BMI showed a negative correlation with the expression of TNFα, 5-LOX and 
15-LOX1 and age was negatively correlated with the expression of 15-LOX1
in the medial tibial plateau in OA patients.
 There was no significant correlation of gene expression between synovia and
medial tibial plateau in OA patients.
 Expression of ALX, TNFα, IL6, 5-LOX and COX2 were significantly lower in 
the medial tibial plateau of OA patients, compared to femoral heads from
trauma patients.
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Fig 5.8 Correlation between expression of resolvin receptors and inflammatory cytokines and
metabolic enzymes are shown in synovia (red) and medial tibial plateau (blue) from OA
patients. positive correlation/PC, negative correlation/NC.
5.5 Discussion and conclusion
The correlation between resolvin receptors and inflammatory cytokines and metabol-
ic enzymes are summarized in Fig 5.8.
The expression of ChemR23 shown in the current study is consistent with the ex-
pression in articular chondrocytes from OA patients and synoviocytes in the synovia
from RA and OA patients demonstrated in previous studies (Berg et al. 2010;
Kaneko et al. 2011). Expression of ALX has been shown in synovial fibroblasts from
healthy individuals (Sodin-Semrl et al. 2000) and may modulate joint inflammation
(Fiore et al. 2005). Herein, I reported for the first time the expression of ALX in both
synovia and tibial plateau from OA patients. Expression of ChemR23 was significant-
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ly higher than ALX in both synovia and medial tibial plateau in OA patients, and this
was not evident in synovia from the OA models.
Higher expression of ChemR23 was associated with greater expression of 5-LOX
mRNA in both synovia and medial tibial plateau, but lower expression of 15-LOX2
mRNA in the medial tibial plateau of OA patients. There was a similar trend for
ChemR23, 15-LOX1 and IL6 expression in the tibial plateau. This pattern was true
for ALX as well in both synovia and tibial plateau from OA patients. These findings
suggest an association between bioactive resolvins and these enzymes in OA pa-
tients which is consistent with the evidence that 15-LOX1 and 5-LOX are key meta-
bolic enzymes involved in the generation of resolvins from up-stream precursors
(Recchiuti and Serhan 2012; Spite et al. 2014). In addition, the positive correlation of
ChemR23 and ALX with 15-LOX1 may suggest a protective role of resolvins in hu-
man OA as 15-LOX has chondroprotective effects in cultured chondrocytes from OA
patients (Chabane et al. 2009).
Previous studies have reported higher expression of COX2 in cultured synovia, me-
niscus and osteophytes from OA patients (Hardy et al. 2002) and the COX2 is up-
regulated by TNFα or IL1β in chondrocytes from OA patients (Kojima et al. 2004). 
My study demonstrated that higher expression of ALX was associated with higher
expression of 15-LOX1 and had a trend towards lower expression of COX2 in the
synovia from OA patients. These findings are consistent with ALX and its corre-
sponding ligands (Resolvin D) having anti-inflammatory properties, which have been
demonstrated in previous studies of the effects of resolvins in inflammatory models.
Positive correlation of ChemR23 expression with 5-LOX and this change was asso-
ciated with variable expression of FLAP (activator of 5-LOX) (Maxis et al. 2006). In
addition, the positive correlation of ChemR23 and ALX with IL6 in the tibial plateau
supports the view that IL6 has anti-inflammatory roles in human OA (Van De Loo et
al. 1997; Xing et al. 1998).
There was no correlation between BMI / age and the target genes in the synovia.
BMI was negatively correlated with TNFα, 5-LOX and 15-LOX1 expression and age 
was negatively correlated with 15-LOX1 in the medial tibial plateau expression from
OA patients. Although obesity is associated with pathogenesis of OA (Grotle et al.
2008), BMI alone does not indicate the relevance of obesity to OA or the levels of
adipocytokines that may contribute to OA (Sowers and Karvonen-Gutierrez 2010).
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As no correlation between the expression of resolvin receptors and BMI or age has
been found and resolvin receptors were positively correlated with 5-LOX and 15-
LOX1in expression levels, this may suggest that the correlation between resolvin re-
ceptors and the metabolic enzymes is not affected by BMI or age in human OA
(Blagojevic et al. 2010).
As for previous clinical studies, it was difficult to get control synovial samples. I de-
termined whether the resolvin receptors, inflammatory cytokines and metabolic en-
zymes were altered in medial tibial plateau from human OA and bone fractions from
femoral heads in trauma patients used as controls. There was lower expression of
ALX, TNFα, IL6, 5-LOX and COX2 in the medial tibial plateau from OA patients, 
compared to femoral heads from trauma patients. This finding may suggest elevated
levels of inflammation following bone fracture and suggests that this is not a good
control for these studies of OA tissue as the systemic inflammation and large
amount of immune cells flushing through injured joints in trauma patients
(Giannoudis 2003; Lenz et al. 2007). It may also suggest low inflammation in the
medial tibial plateau (cartilage and subchondral bone) at the late stage of OA pa-
tients (Benito et al. 2005).
To sum up, the findings demonstrated in the clinical samples from OA patients sup-
port the further investigation of the anti-inflammatory and protective roles of resolvin
receptors/ligands in human OA.
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6 Discussion, limitations and future directions
6.1 General discussion
This thesis reported evidence of alterations in the resolvin receptor system
(ChemR23 in the MIA model and ALX in synovia of the MNX model), correlation of
the receptors with pain behaviour in the MIA model and correlation of the ALX with
inflammatory cytokines and metabolic enzymes in the two preclinical models of OA.
Translational studies also provided evidence that the resolvin receptors were associ-
ated with inflammatory cytokines and metabolic enzymes in clinical samples from OA
patients. A series of drug intervention studies demonstrated therapeutic effects of
17(R)HDoHE on OA pain in preclinical models and the underlying mechanisms of
the actions have been studied.
Administration of single dose of 17(R)HDoHE attenuated established pain behaviour
in the MIA model while repeated administration of 17(R)HDoHE reversed pain be-
haviour in both the MIA and MNX models. The analgesic effects of 17(R)HDoHE
were maintained for a week after cessation in the MIA model. These effects of
17(R)HDoHE on pain behaviour may be mediated by actions of the resolvin recep-
tors on inflammatory cytokines or metabolic enzymes. Significant associations be-
tween the expression of the resolvin receptors and expression of inflammatory cyto-
kines and metabolic enzymes were demonstrated in the human OA samples.
Pain is a cardinal symptom in OA that limits the motion of joints and the main reason
for patients to seek treatment (Hunter et al. 2013). Pain behaviour and joint histo-
pathology have been revealed in the MIA (Guingamp et al. 1997), MNX (Bove et al.
2006) and DMM (Malfait et al. 2010) models of OA.
This thesis has demonstrated that pain behaviour and joint histopathology developed
in both MIA and MNX-induced models. In the MIA model, pain behaviour was initiat-
ed at day 3 and maintained until day 28 and day 35 in two separate studies post
model induction, which supports a rapid development pain in this model of OA
(Beyreuther et al. 2007). Histological assessment in this study confirmed joint dam-
age including chondropathy, synovial inflammation, chondrocyte appearance and
osteochondral junction integrity in the model, which is consistent with previous re-
ports (Bove et al. 2003; Sagar et al. 2010; Stevenson et al. 2011). In the MNX model,
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pain behaviour developed at a late time point and joint histology also revealed dam-
age, which has been shown in previous studies (Mapp et al. 2010; Mapp et al. 2013).
Inflammation is an essential component leading to pathogenesis of OA (Scanzello
and Goldring 2012; Sokolove and Lepus 2013) and resolvins shows tremendous ac-
tions on resolving inflammation (Serhan et al. 2008; Serhan and Petasis 2011).
Therefore, determining the potential alteration of resolvin receptors, inflammatory cy-
tokines and the key metabolic enzymes involved in OA is of great interest to eluci-
date inflammatory mechanisms underlying OA and find new drugs to treat OA pain.
My data revealed that expression of ChemR23 and 15-LOX was lower in the synovia
from the MIA model. In addition, synovial expression of ChemR23 was negatively
correlated with pain behaviour at both time points (day 14 and day 35), supporting a
role of ChemR23/15-LOX in the modulation of OA pain behaviour via a peripheral
site of action (Xu et al. 2010). In the spinal cord, ChemR23 expression was higher in
the ipsilateral quadrant of the dorsal horn of the spinal cord in the MIA model. In add-
tion, this increase in expression was positively correlated with pain behaviour, sug-
gesting that increased numbers of activated neurons or glial cells express this recep-
tor in the model of OA pain (Xu et al. 2012). Spinal ALX was positively correlated
with pain behaviour at early time point (day 14) but negatively at later time point (day
35), indicating the potential for a phenotype shift of glial cells, expressing this recep-
tor at different stages of the model (Svensson et al. 2007; Sagar et al. 2011;
Abdelmoaty et al. 2013). Expression of inflammatory cytokines (TNFα, IL1β and IL6) 
was not significantly altered in either the synovia or spinal cord in the MIA model.
However, expression of 15-LOX in the dorsal horn of the spinal cord was lower in the
MIA model, compared to control rats. Moreover, spinal ALX expression was nega-
tively correlated with IL6 in the spinal cord. These data suggest a contribution of
ALX/15-LOX mediated anti-inflammatory effects on pain modulation in the spinal
cord in this model (Svensson et al. 2007).
In the MNX model, ALX, TNFα, IL1β, COX2 and mPGES1 were expressed at a low-
er level in the synovia and FLAP expressed at a higher level in the spinal cord, com-
pared to the sham control group. There was a positive correlation between ALX ex-
pression and these genes in the synovia. Expression of ChemR23 was not altered in
this model. These data suggest that despite the resolving intervention attenuating
pain behaviour in the MNX model, there is limited evidence for associations with the
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pro-inflammatory pathways in this model. Resolvins have been reported to show an-
ti-nociceptive and anti-hyperalgesic actions on pain modulation (Ji et al. 2011;
Sungjae Yoo et al. 2013). I found the robust analgesic effects of 17(R) HDoHE on
pain behaviour by systemic administration in a series of studies in two models of OA
pain.
My data are consistent with a previous study using an inflammatory arthritis model
(Lima-Garcia et al. 2011). In the acute treatment study, 17(R)HDoHE decreased ex-
pression of 5-LOX and up-regulated IL6 expression. There was also a trend towards
down-regulation of pro-inflammatory cytokines and metabolic enzymes. These find-
ings may indicate anti-inflammatory role (s) of 17(R)HDoHE on pain modulation. The
analgesic effects of 17(R)HDoHE were maintained by repeated administration for
two weeks, indicating no obvious tolerance to the effects of the compound, which is
a huge advantage compared to opioids (Dumas and Pollack 2008). As discussed in
4.4.2, 17(R)HDoHE didn’t attenuate mechanical allodynia in the MNX model. How-
ever, the sham control may mask the therapeutic effects of the drug as this type of
pain behaviour was exhibited by the sham rats. Repeated administration of
17(R)HDoHE did not alter joint histopathology in either the MIA or the MNX model,
may be indicating more central components governing the chronic effects of the
compound on OA pain.
I demonstrated the prescence of mRNA for ChemR23 and ALX in both synovia and
medial tibial plateau in OA patients. Expression of ChemR23 was higher than ALX.
Resolvin receptors are expressed by synovial fibroblasts (Kaneko et al. 2011;
Eisinger et al. 2012), chondrocytes (Berg et al. 2010), osteoclasts (Herrera et al.
2008) and osteoblasts (Gao et al. 2013). Key inflammatory enzymes such as COX2,
15-LOX and 5-LOX are also expressed in synovial fibroblasts and chondrocytes in
OA or RA patients (Chabane et al. 2009; Gheorghe et al. 2009; Chen et al. 2010).
Expression of ChemR23 was positively correlated with 5-LOX in both synovia and
tibial plateau, positively correlated with 15-LOX1 and IL6 and negatively correlated
with 15-LOX2 in tibial plateau. These data support that E series resolvins are pro-
duced via the 15LOX1/5-LOX pathway (Isobe et al. 2012; Lee and Surh 2012).
Expression of ALX was positively correlated with 15-LOX1 and IL6 in both synovia
and medial tibial plateau, indicating production of D-series resolvins via 15-LOX/5-
LOX pathway (Kohli and Levy 2009; Spite et al. 2014). mRNA levels for ALX, TNFα, 
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IL6, 5-LOX and COX2 were significantly lower in medial tibial plateau from OA pa-
tients compared to neck of femoral heads from trauma patients. These data suggest
more inflammatory cells infiltrated to injury sites in trauma patients (Giannoudis 2003;
Lenz et al. 2007) and inflammation is lower in the tibial plateau from OA patients.
Samples from trauma patients may not be good controls for OA patients.
6.2 Limitations and future directions
Limitations for the studies in the thesis have been discussed here based on the data
analysis and discussion described in the previous chapters.
Comparison of the two OA models indicated that pain behaviour was more variable
in the MNX model than the MIA model. This may be due to the pain behaviour exhib-
ited by the sham rats as a result of the removal of the anterior lateral ligaments in the
joints. This procedure on rats may mask the effects of MNX surgery on pain behav-
iour. Nevertheless, it is important that the control rats experience the same surgery
procedure as MNX surgery except meniscus transection. In addition, the environ-
ment for behavioural testing, individual tolerance of rats to the surgery and pain be-
haviour itself may also contribute to the variability in this model, which is inevitable. A
way to address this issue is that a naive control group is used to see how pain de-
velops in sham surgery rats. In gene expression studies using the sham and MNX
rats, synovial expression of inflammatory cytokines (TNFα and IL1β) and metabolic 
enzymes (COX2 and mPGES1) was higher in sham rats compared to MNX rats.
These differences may be due to different expression levels of reference genes (β-
actin and GAPDH), which appeared about two fold higher in sham rats compared to
MNX rats although significance was not reached. Even with the geometric mean of
both genes used as reference, it seems that expression of these two genes was not
stable in this surgical model. Other reference genes such as 18S and 28S rRNA
(Vandesompele et al. 2002) may be used or inflammatory markers should be used
as reference gene for inflammatory conditions (Qureshi et al. 2012) in future.
Expression of some of the target genes, such as ALX in the spinal cord of the MIA
and MNX model and COX2 in the spinal cord of the MIA model was close to signifi-
cant differences compared to controls. This suggests that the number of rats per
group was not higher enough for statistical power and needs to be increased in fu-
ture studies.
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For the chronic studies of the effects of 17(R)HDoHE in both the MIA and MNX
model, joint histopathology was not improved. However, the activity of osteoclasts or
osteoblasts in knee joints was not assessed in these two studies. Future studies
should investigate potential effects of the resolvin percursor on activity of osteoclasts
or osteoblasts as resolvins are known to inhibit bone resorption (Herrera et al. 2008;
Zhu et al. 2013) and promote bone formation (Gao et al. 2013). In addition, the spi-
nal mechanisms of the therapeutic effects of resolvin precursor are not established
as well. Therefore, activation of glial cells and neuronal activity could be investigated
in OA pain in future studies.
The anti-nociceptive and anti-hyperalgesic roles of the bio-active resolvins (RvD1,
RvD2, RvE1 and AT-RvD1) have been reported in recent years as described in pre-
vious chapters. However, there is no report on resolvins and other pro-resolving lipid
mediators such as neuropeptide D and maresin to treat OA pain. There is a huge
gap to fill to understand therapeutic effects of these pro-resolving lipid mediators to
treat OA pain and the underlying mechanisms.
From a pharmacodynamic aspect, a series of drug intervention studies could be
conducted to investigate the therapeutic effects of down-stream bioactive mediators
or their analogues on pain behaviour or the effects of compounds on responses of
sensory neurons in the central nerve system in the models of OA pain by peripheral
and spinal administration. At the cellular level, the activities of these ligands and their
cognate receptors (many of them un-identified), the structure of receptors and bind-
ing sites in OA system are unknown. Future studies on these aspects could be con-
ducted with multi-disciplinary cooperation to investigate enzyme-activity, identifica-
tion of cognate receptors and analyze the crystal structure of the receptors with mul-
tiple laboratory techniques. The antagonists for these receptors are few and may al-
so be designed to investigate the supressing actions in OA and OA pain. In addition,
interaction between the pro-resolving lipid mediators and some other receptors or ion
channels, which may contribute to therapeutic effects of the compounds in OA pain,
is also expected to investigate for future studies.
From a pharmacokinetic aspect, how the resolvins and other pro-resolving lipid me-
diators are distributed and metabolized in organs and the specific tissues and the
anti-nociceptive and anti-hyperalgesic roles of these mediators in various pain mod-
els remain unclear. The levels of resolvin precursors, the bio-active resolvins and
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other pro-resolving lipid mediators in serum, synovial fluids, spinal cords or DRGs
from naïve rodents or model-induced rodents could be measured with liquid chro-
matgraphy- mass spectrometry (LC-MS) eventhough the half-lives of these media-
tors are relatively short (Shimizu 2009). The measurement of levels of these media-
tors in naïve and model-induced rodents may suggest tissue-specific biomarkers for
OA, which helps to find novel therapeutic targets for OA treatment. The metabolic
pathways for these mediators have previously been discussed in inflammatory status
(Serhan et al. 2008; Serhan and Petasis 2011), however, the activity and modulation
of the metabolic enzymes such as COX2, 5-LOX and 15-LOX are not well estab-
lished in peripheral tissues and spinal cord. Future studies on the metabolic path-
ways for fatty acids, resolvins and other lipid mediators in OA pain and OA system
are of great interest in future studies.
In a broad view, the specific mechanisms on anti-nociceptive and anti-hyperalgesic
roles of the pro-resolving lipid mediators are yet to be elucidated. At a molecular and
genetic level, genetic tools and bioinformatic methods are novel emerging techiques
and hot-spots applied in the biomedical researches including pain and osteoarthritis.
Transgenic mouse models are widely used to learn the function of specific genes in
dieseases. It is of great interest to manipulate genes encoding the receptors for re-
solvins and other lipid mediators to observe whether the analgesic effects are affect-
ed. Recently, the genome-wide screening for heat nociception in drosophila identi-
fied α2δ3 as a specific gene for transmission of thermal nociceptive signals from 
thalamus to the sensory cortex (Neely et al. 2010) , three loci such as rs2651899,
rs10166942(TRPM8) and rs11172113 (LRP1) for migraine (Chasman et al. 2011)
and rs6976 within the 3ʹUTR of GLT8D1 on chromosome 3 and rs11177 in the third 
exon of GNL3 for osteoarthritis (Consortium and Collaborators 2012). The large-
scale single-cell RNA sequencing of DRG cells has identified different types of sen-
sory neurons such as low-threshold mechnoreceptive, thermosensitive, itch sensitive,
mechnosensitive and nociceptive neurons expressing the specific markers and
genes (Usoskin et al. 2015). Future studies focusing on identification and manipula-
tion of specific genes or markers (receptors, ion channels) that are responsible for
transduction, transmission and modulation of OA pain are fascinating directions to
explore. Optogenetics is currently a novel technique for activating signalling mole-
cules such as GPCRs and receptor tyrosine kinases (Karunarathne et al. 2015) or
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manipulation of neuronal activity that may modulate animal behaviour (Miesenbock
2011). Optogenetic stimulation has been shown to decrease the activity of inhibitory
neurons in anterior cingulate cortex and attenuate formalin induced pain behaviour in
Thy1-ChR2-YFP transgenic mouse model (Gu et al. 2015). It also attenuated me-
chanical and thermal hyperalgesia via control of ChR2-eYFP transfected neurons
pre-frontal cortex in neuropathic pain (Lee et al. 2015). Siuda et al developed a Gi-
coupled, optically sensitive, muopioid-like receptor which mimics mu-opioid signaling
dynamics including t he canonical intracellular G protein signaling mechanisms and
controls opioid signalling and behaviour by photostimulation (Siuda et al. 2015).
Optogenetic tools also have been shown to inhibit the activity of subunits in GPCRs,
thus inhibit G protein signalling and control down–stream cell signalling (O'neill and
Gautam 2014). The optogenetic tools could be applied to manipulate resolvin recep-
tors, other GPCRs for neurotransmitters and lipid mediators and sensory neuronal
activity in OA pain, which is well deserved and highly expected with great advantage
for future studies.
The neuro-immune interaction is another attractive direction for pain study. The im-
mune system play active role in pain processing and modulation (Ren and Dubner
2010) as well as OA (Haseeb and Haqqi 2013), therefore, should be a good direction
to study functions of the system in OA pain. The signalling pathways, functions and
molecular mechanisms for specific neurotransmitters, channels and receptors in var-
ious immune cells, glial cells and neurons are still not well understood. Signalling
pathways for pain transduction, transmission and modulation and the interaction be-
tween immune cells, glial cells and neurons are interesting for future studies.
Furthurmore, neural circuits for pain modulation are much less known as well and
are a big gap to fill in future. In the clinical study, we revealed a negative correlation
for BMI with the expression of TNFα, 5-LOX and 15-LOX1 and age with 15-LOX1 
however, these correlations do not affect correlations between resolvin receptors
with target genes. However, this couldn’t preclude that the correlation between re-
solvin receptors and inflammatory cytokines and metabolic enzymes may be affected
by some other factors such as drug use or case history for individual OA patient. In
fact, 3 OA patients used aspirin before the surgery. A major limitation for this clinical
study was the lack of control synovia from healthy volunteers or patients without OA.
With these controls in future studies, we can determine how the resolvin receptor
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system is altered in human OA. Another limitation for this study is the bone fractions
from femoral heads of trauma patients may not be a good control for OA patients
when studying inflammatory states as trauma may cause great primary and systemic
inflammation as discussed before (see 5.5). Therefore, selecting a better control for
samples from OA patients may be better considered in future studies. In molecular
biology, the limitation of the thesis is that I didn’t measure the alteraltion of protein
levels of resolvin receptors and other target genes. I have tried to confirm the ex-
pression of resolvin receptors in spinal cord with immunofluorescence and I indeed
observed receptor-positive cells in the spinal cord, however, the antibodies for the
receptors didn’t work very well. This work continues to be conducted by our col-
league in the lab.
To sum up, although limitations are exhibited in these studies, this thesis demon-
strated robust analgesic effects of 17(R)HDoHE on treatment of OA pain in a series
of preclinical models and determined the alteration of ChemR23 and correlation of
ALX with pain behaviour in the MIA model and alteration of ALX in the MNX model.
Possible mechanisms of pain modulation by the resolvin D precursor have been
studied and correlation of the resolvin receptors with inflammatory cytokines and
metabolic enzymes were shown in human OA. The findings in this thesis provide ev-
idence to explore resolvins as novel potential therapeutics to treat OA pain.
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8 APPENDICES
Reagents:
10% neutral buffered formalin:
100ml methanal
900ml double distilled water
4g NaH2PO4
6.5g Na2HPO4
Neutral buffered formalin was made by mixing 100ml methanal (formaldehyde solu-
tion, Sigma, UK) with 900ml double distilled water containing 4g NaH2PO4 (Fisher
Scientific, UK) and 6.5g Na2HPO4 (Fisher Scientific, UK).
EDTA solution (10% w/v):
Distilled water (2.5L),
Trizma®Base (3.35g, Sigma life science, UK),
10% w/v EDTA (250g),
NaOH (pellets, 25g, Fisher scientific, UK)
7.5% w/v Poly (vinylpyrrolidinone) (PVP, 187.5g, Sigma, UK). EDTA solution (10%
w/v) was made via the following method: pellets of sodium hydroxide were first add-
ed to distilled water and dissolved using a magnetic stirrer and then the rest of rea-
gents were added until dissolved. The pH was adjusted to 7 and the solution stored
at room temperature.
208
Letter of access for clinical samples and Research Passort
209
210
211
212
213
